

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

Q. And you didn't make any attempt to compare Tyvaso sales only to other orphan drugs, correct?

A. Not specifically to other orphan drugs. That is addressed inherently in paragraph 24 where all of the competing drugs in that paragraph are treatments for PAH. So that is an analysis that takes into account the patient population size, but paragraph 23 is independent of the patient population size.

Q. So just so I am clear, it is your opinion that an orphan drug with potentially less than 200,000 total patients making over 2.5 billion in net sales over a seven-year period is not a commercial success?

A. Could you repeat the question, please.

Q. Well, let me break it down. Earlier we looked at your Attachment B-4. If you can turn to that on page 38 of 45.

A. Okay.

Q. And for Tyvaso from 2009 to 2016 you totaled revenue at 2.515 billion for

1 DEFOREST MCDUFF, Ph.D.

2 Tyvaso, correct?

3 A. That's right --

4 Q. And --

5 A. -- over all years.

6 Q. Yes. And Tyvaso is an orphan
7 drug meaning that it likely has less than
8 200,000 patients, correct?

9 A. I don't know if that's true as
10 of today. There may have been less than
11 200,000 PAH patients in the U.S. at one point
12 in time.

13 Q. So is it your opinion that
14 \$2.5 billion in sales over a seven-year period
15 for an orphan drug is not a commercial success?

16 A. It depends. It's a
17 case-by-case analysis. So I couldn't give you
18 an answer to that in a global way that would
19 apply to every drug with that profile, but I
20 have analyzed Tyvaso, and the magnitude of
21 sales here do not demonstrate commercial
22 success.

23 Q. So in your opinion an orphan
24 drug with 2.5 billion in sales over seven years
25 in this case is not a commercial success?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

A. It sounds like the same question and the same answer.

Q. It's a yes or no question.

A. I've found that Tyvaso sales do not demonstrate commercial success here.

Q. So an orphan drug with 2.5 billion in sales over a seven-year period is not a commercial success in this case, correct?

A. Maybe I am missing the distinction with the previous question, but it sounds like the same question to me.

Q. Do you agree with that statement?

A. Tyvaso sales, as I have analyzed them here, do not demonstrate commercial success.

Q. And those sales --

A. I agree with that as a summary opinion.

Q. And those sales were 2.5 billion over a seven-year period, correct?

A. Yes.

Q. You provided no opinion regarding gross profits for Tyvaso, correct?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

A. That's correct. I am not aware of that information being available.

Q. Did you try to find that information?

A. I don't believe so. I am not aware of it being available.

Q. Did you ask counsel for that information without disclosing any actual conversations with counsel?

A. I don't recall. It's not the kind of information that's typically available in IPRs in my experience.

Q. And you provided no opinion regarding gross margins for Tyvaso, correct?

A. Similar answers as before. I don't recall that information being available here, but I have not analyzed it as I am not aware of it being available.

Q. Did you attempt to find information about it?

A. I don't recall.

Q. So going back to the top two deciles, why did you consider just the top two deciles as being relevant benchmarks for

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

of approved drugs would not achieve commercial success?

A. I wouldn't describe it that way, no.

Q. So is it your opinion when compared against the top two decile drugs, that 80 percent of approved drugs would not achieve commercial success?

A. I would not put it that way, no.

Q. So a drug could be below the second decile and still be a commercial success, correct?

A. It depends. It's a case-by-case basis and analysis.

Q. But you are not saying that commercial success is limited to the top two decile of drugs, correct?

A. I am not, no.

Q. Do you know how many top decile drugs treat pulmonary arterial hypertension?

A. Not sitting here, no. I don't recall, nor am I aware of that information

1 DEFOREST MCDUFF, Ph.D.

2 being available.

3 Q. Well, you calculated the total
4 revenue of drugs that treat pulmonary arterial
5 hypertension and also reported the amount
6 needed to reach the top decile, correct?

7 A. I performed both of those
8 analyses, yes.

9 Q. And none of the drugs that
10 treat pulmonary arterial hypertension are in
11 the top decile, correct?

12 A. Well, comparing the graphs on
13 page 16 and page 17 of my declaration, it
14 appears that Tracleer is either first decile or
15 second decile, and Letairis is possibly second
16 decile, possibly not. I am not exactly sure
17 where the cutoffs are that allow one to make
18 that determination.

19 Q. Are you looking at paragraph
20 24?

21 A. Yes.

22 Q. Well, your previous chart
23 compares the peak annual sales on page 16 shows
24 first decile drugs 3.565 billion, correct?

25 A. Yes, as an average for first

1 DEFOREST MCDUFF, Ph.D.

2 decile drugs. Some are higher. Some are
3 lower.

4 Q. But Tracleer is far below that
5 number, correct?

6 A. Tracleer is between the
7 averages of the first decile and the second
8 decile. So it depends where the cutoff is.
9 The cutoff between the first decile and the
10 second decile is somewhere between 1.3 billion
11 and 3.5 billion as are the sales of Tracleer.
12 So without that additional information, we
13 don't know whether Tracleer will be in the
14 first decile or the second decile. It might be
15 more likely to be in the second decile given
16 that it's closer to the average for second
17 decile, but I can't say for sure.

18 Q. And given that the average
19 second decile according to your analysis is 1.3
20 billion, is it fair to say that the vast
21 majority of the drugs you analyzed for
22 pulmonary arterial hypertension do not meet the
23 top two deciles?

24 A. I would say the majority do
25 not. I think that's sensible in light of 12

1 DEFOREST MCDUFF, Ph.D.

2 drugs being here on -- in paragraph 24 and two
3 out of 12 being near first decile and second
4 decile around 20 percent, 15 to 20 percent. I
5 think that's consistent with the industry,
6 maybe slightly lower.

7 Q. You did not provide an opinion
8 on the profit obtained by UTC on Tyvaso,
9 correct?

10 A. Not here. I am not aware of
11 that information being available or provided by
12 UTC.

13 Q. Did you look for it?

14 A. Not specifically, nor am I
15 aware of that information being available here.
16 It's typically not.

17 Q. Would you be surprised if UTC
18 had a high profit margin on their 2.5 billion
19 in net sales of Tyvaso from 2009 to 2016?

20 A. I don't know. I would
21 evaluate that information if it were available.

22 Q. Do you consider profit margin
23 to be an important factor in analyzing
24 commercial success?

25 A. It depends on the situation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

Sometimes I analyze it if it's available.

Q. So going back to paragraph 23 and your analysis of peak annual sales of Tyvaso compared to first and second decile and average drugs, you rely on a 2002 article by Grabowski as part of your analysis, correct?

A. As part of my analysis as well as the actual Tyvaso sales.

(WHEREUPON, the document was tendered to the witness.)

BY MR. DELAFIELD:

Q. You have been handed what has been marked as Exhibit 1113 which is an article entitled Returns on Research and Development for 1990s New Drug Introductions, and Exhibit 1113 is the same for both cases.

Do you recognize this document?

A. Yes.

Q. And is this the document that you cite in footnote 12?

A. Yes, it is.

Q. Or one of the documents.

Now, this study analyzes drugs

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

launched between 1990 and 1994, correct?

A. Yes.

Q. And then also uses actual sales that those products made through 2000, correct?

A. That sounds right.

Q. So this means that the study only had between seven and 11 years of actual data from 16 years ago, correct?

A. I don't believe that's accurate. This is a paper that's based on a line of research that occurred in the 1970s, 1980s, 1990s, and then 2000s. They use some data on drugs that were launched from 1990 to 1994, and they combined that with older data it's my understanding to get the longer timeframe and project the full sales path.

Q. So instead of relying on actual data, you chose to rely purely on the projections made in the study or some combination of actual sales and projected sales to create your comparison, correct?

MR. MATHAS: Object to the form.

1 DEFOREST MCDUFF, Ph.D.

2 BY THE WITNESS:

3 A. I wouldn't describe it that
4 way, no.

5 BY MR. DELAFIELD:

6 Q. Well, let's look at the sales
7 page 17 which is one of the pages you cite,
8 page 7 of the exhibit, 17 internal page.

9 A. Okay.

10 Q. And at the top Figure 2 shows
11 worldwide sales profiles of 1990 to 1994 new
12 drug introductions.

13 Do you see that?

14 A. Yes.

15 Q. And it goes out to 20 years,
16 right?

17 A. Yes.

18 Q. But this paper was published
19 in 2002, and so many of those years are just
20 projections, correct?

21 A. The later years are
22 projections based on actual historical sales
23 data as I indicated in my previous response.

24 Q. But it says sales profiles of
25 1990 to 1994 new drug introductions, right?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

A. I am not sure I understand the question.

Q. Let me rephrase.

So we can agree some of the data in this chart represents actual sales of drugs launch between 1990 and 1994, correct?

A. Yes.

Q. And some of the data used to generate this are projections of where those sales would go after the time of this paper based on prior sales, correct?

A. I agree with that, yes.

Q. So your reliance on this is using both actual and projected sales, right?

A. It's a combination of those. That's the methodology that's described in this paper. This is among the most widely cited literature in pharmaceutical research and development.

Q. And you will notice it says worldwide sales, right?

A. Yes.

Q. Now, in evaluating commercial success of a U.S. patent, you would agree that

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

it's appropriate to look at only U.S. sales,
correct?

A. I don't agree with that, no.

Q. Well, if it's not protected in
other countries, then the commercial success
isn't relevant because there's no patent
protection, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. I am not seeking to provide a
legal conclusion on this issue of whether sales
outside the U.S. are relevant from a legal
perspective, but from an economic perspective,
evaluating the commercial opportunity it's
common to evaluate sales worldwide.

BY MR. DELAFIELD:

Q. So, for example, if someone
patented a product and sold none of it in the
United States with the patented -- strike that.

So if someone patented a
product in the United States and there were no
sales in the United States but they had a lot
of sales where there was no patent protection,
are you saying that those sales are relevant to

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

the commercial success of the patent?

A. I don't think I can provide a global conclusion on that. It would depend on the circumstances. That's not the circumstance here.

Q. Well, you are providing global sales numbers for a U.S. patent, correct?

A. I wouldn't describe it that way. I am analyzing sales both in and outside the U.S. for these comparisons in order to put Tyvaso sales into context so that we can understand what the magnitude of Tyvaso sales means. I think it's fully appropriate.

Q. And you didn't provide any analysis of U.S. only sales, correct?

A. Not here in my declaration. I am not aware of those being readily available. Companies report their worldwide sales in public filings. They typically do not do so for U.S. sales alone.

Q. Did you attempt to determine U.S. sales for any of the drugs that you list in your analysis?

A. No, I did not view that as

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

necessary for the conclusions I am drawing.

Q. So you don't know how well Tyvaso has performed in terms of U.S. sales only, correct?

A. I know that their U.S. sales are at least at or below their worldwide sales. So I know the sales are if anything lower than the sales I have analyzed in my report.

Q. I'm sorry. Could you repeat that?

A. In other words, the U.S. sales are certainly no greater than the worldwide sales that I have analyzed. So if anything the U.S. sales are lower than what I have analyzed.

Q. But likewise for every drug and even the top decile drug, those would also be lower, correct?

A. If limiting to U.S. sales only, they could be, yes.

Q. So you don't know how much lower either -- strike that.

You don't know how much lower each drug would sell in the U.S. compared to worldwide sales, correct?

1 DEFOREST MCDUFF, Ph.D.

2 A. I haven't provided that
3 specific breakdown in my declaration, nor do I
4 view it as necessary. I think one would draw
5 the same conclusions if one looked at U.S.
6 data.

7 Q. You said one would draw the
8 same conclusions if they looked at U.S. data;
9 is that right?

10 A. It seems likely to me that one
11 would, yes.

12 Q. But you didn't look at U.S.
13 data. So how you would know that someone would
14 draw the same conclusions?

15 A. In my experience doing many
16 cases of this type, typically doing the
17 analysis on a worldwide basis or a U.S. basis
18 provides similar conclusions.

19 Q. But you don't provide any
20 evidence of that, correct?

21 A. Again, that's not something I
22 specifically sought to do in my declaration. I
23 did not view it as necessary to draw the
24 opinions or the conclusions that I am drawing
25 here, but I think it's likely that if one did

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

the analysis with U.S. sales, one would draw --
or I would draw similar conclusions.

Q. So just to clarify, it is your
opinion with respect to analyzing the
commercial success of a U.S. patent, the sales
in the U.S. are no more relevant than sales in
Japan, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. I wouldn't put it that way,
no.

BY MR. DELAFIELD:

Q. Would you agree that sales in
the U.S. are more relevant than sales in other
countries with respect to analyzing the
commercial success of a U.S. patent?

A. I don't think I have a global
opinion or conclusion on that issue. I think
what I have done here by comparing Tyvaso sales
as publicly reported on a worldwide basis is
sufficient for the opinions I have reached.

Q. Are you aware that UTC --
strike that.

Are you aware that United

1 DEFOREST MCDUFF, Ph.D.

2 Therapeutics holds patents in many different
3 countries on Tyvaso and I believe all of their
4 treprostinil products?

5 MR. MATHAS: Object to the form.

6 BY THE WITNESS:

7 A. I am aware that they have some
8 international patents.

9 BY MR. DELAFIELD:

10 Q. Did you analyze what patents
11 are available in what countries with respect to
12 Tyvaso?

13 A. I don't believe I did that
14 specifically, no.

15 Q. So if Tyvaso is patented in
16 the U.S. and Tyvaso is patented in England,
17 would sales in England still be relevant to the
18 commercial success of a U.S. patent or just the
19 patent in England?

20 MR. MATHAS: Object to the form.

21 BY THE WITNESS:

22 A. I don't have a global
23 conclusion or opinion on that. I would
24 evaluate it on a case-by-case basis. I think
25 evaluating Tyvaso sales as I have done here is

1 DEFOREST MCDUFF, Ph.D.

2 appropriate and sufficient for the conclusions
3 I have drawn.

4 BY MR. DELAFIELD:

5 Q. In your career have you ever
6 evaluated commercial success of patents from
7 different countries?

8 A. I don't believe so. I think
9 given that most of my work occurs here in the
10 U.S., all the litigations I have worked on have
11 been for U.S. patents. Of course, sometimes
12 worldwide patents are relevant to the
13 evaluation, but the litigations are
14 specifically about U.S. patents.

15 Q. And so just to clarify, it is
16 your opinion that sales outside the U.S. are
17 directly relevant to the commercial success of
18 a U.S. patent, correct?

19 MR. MATHAS: Object to the form.

20 BY THE WITNESS:

21 A. They can be, yes, from an
22 economic perspective. I understand that's
23 consistent with guidance provided by the U.S.
24 PTO, and it's consistent with what I have done
25 with my work in the past and what other experts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

evaluating commercial success analyze, but it's a case-by-case situation. It depends on what conclusions one is reaching. The worldwide sales that I have analyzed here are sufficient for the conclusions I have drawn.

BY MR. DELAFIELD:

Q. You mentioned guidance from the U.S. PTO. You don't cite any such guidance in your declaration, correct?

A. I don't recall doing so, no.

Q. So looking back at the Grabowski article Exhibit 1113, Figure 2, is -- this is one of the figures you used for your calculations, correct?

A. Which page are you on?

Q. Page 7 of Exhibit 1113, internal page 17.

A. Yes.

Q. Is that a, yes, that was one of the figures you used to base your calculations on?

A. Yes, that's right.

Q. And if you look at page 16 of your report next to that Exhibit 1113, you

1 DEFOREST MCDUFF, Ph.D.

2 report comparisons for first and second decile
3 and mean or average, correct?

4 A. Yes, that's right.

5 Q. And you don't report a
6 comparison of Tyvaso to the median sales of
7 pharmaceuticals, correct?

8 A. That's correct, because I
9 don't view them as a relevant benchmark for
10 commercially successful pharmaceutical
11 products.

12 Q. Why is the median not a
13 benchmark for commercially successful
14 pharmaceutical products?

15 A. As indicated in this
16 literature, median pharmaceutical products tend
17 to lose money. They tend to not be
18 economically profitable. So they are not a
19 benchmark or an example of a commercially
20 successful drug product.

21 Q. So you don't know whether
22 Tyvaso would be above the median sales because
23 you didn't do that analysis, correct?

24 A. I haven't calculated it here
25 for my declaration because I don't view it as

1 DEFOREST MCDUFF, Ph.D.

2 an appropriate benchmark for commercial
3 success.

4 Q. But you included the mean
5 sales, right?

6 A. Yes, because I viewed that as
7 a relevant benchmark for evaluation.

8 Q. But this paper reports both,
9 right?

10 A. That's correct, and they
11 explain the context for each, and the context
12 that's relevant for commercial success is that
13 average drugs tend to be about break even in
14 terms of profitability, and so when thinking
15 about a commercially successful drug product,
16 the fact that Tyvaso is below average indicates
17 that it's likely not profitable. Whereas, a
18 median drug tends to be not economically
19 profitable, and so it's not a relevant
20 benchmark for evaluating commercial success.

21 Q. Now, we talked about the fact
22 that this paper uses sales numbers of drugs
23 from 1990 to 1994, correct?

24 A. Products that were launched
25 over that period, that's right. The sales

1 DEFOREST MCDUFF, Ph.D.

2 occurred over the next seven to 11 years and
3 beyond.

4 Q. And the beyond we discussed
5 that those are all projections, correct?

6 A. Projections based on actual
7 data prior to that time period.

8 Q. So this paper the actual data
9 all occurred prior to 2000, correct?

10 A. I think it's through 2001
11 based on the launch dates and length of time
12 they appear to report data.

13 Q. And so haven't pharmaceuticals
14 changed since pharmaceuticals launched in 1990
15 and sales of those same products in 2001 since
16 that time?

17 A. Not to my knowledge, not in a
18 way that would make these results inapplicable.
19 I followed this literature over time, and there
20 have been more recent publications, but no
21 publications are as complete that provide the
22 kind of drug sales distribution information
23 that this paper provides.

24 For example, these authors who
25 are among the most widely cited authors in

1 DEFOREST MCDUFF, Ph.D.

2 Q. And so if there are more drugs
3 and more patents out there, you don't believe
4 that the trends may have been changed due to
5 that fact?

6 A. Not in a way that would make
7 the results inapplicable.

8 Q. There were no commercially
9 available treatments for pulmonary arterial
10 hypertension as of 2001, correct?

11 A. I think that's right at or
12 around that time they started being released.

13 Q. So in the analysis that
14 Grabowski does, there are no drugs that were
15 used to treat pulmonary arterial hypertension,
16 correct?

17 A. Not in this data set to my
18 knowledge. That's not the intention of using
19 this data set.

20 Q. Are you aware of any
21 criticisms of the DiMasi and Grabowski studies
22 that you relied on for your opinion?

23 A. I am aware of some criticisms
24 from special interest groups. Yet the
25 peer-reviewed literature on the topic is widely

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

accepting of this literature and of this paper specifically.

Q. Do you recall what those criticisms were?

A. Not sitting here. I believe they are methodological or data critiques that people have articulated and have been evaluated and discredited by the academic literature.

Q. When you say discredited by the academic literature, have you seen academic literature that specifically addresses the criticisms of Grabowski and DiMasi?

A. I guess I would say that there are a number of peer-reviewed publications that have evaluated the methodologies in Grabowski and DiMasi and have confirmed their correctness. That's how I could describe that.

Q. But given the criticisms, it's fair to say that not everyone agrees with the analysis that Grabowski and DiMasi provide with respect to trends in pharmaceutical sales, correct?

MR. MATHAS: Object to the form.

1 DEFOREST MCDUFF, Ph.D.

2 BY THE WITNESS:

3 A. Everyone in the world?

4 BY MR. DELAFIELD:

5 Q. Well, is it fair to say that
6 other economists disagree with the analysis
7 provided by DiMasi and Grabowski?

8 A. There may be some who disagree
9 with it, but as I indicated earlier, the
10 majority of the peer-reviewed literature
11 accepts this as the gold standard research on
12 this topic.

13 Q. And you didn't cite any
14 documents that cite it as the gold standard,
15 correct?

16 A. Not here in this declaration,
17 but I am aware of more than a dozen papers over
18 the last decade that evaluate this topic and
19 cite to this paper specifically as
20 foundational, and this is among the most widely
21 cited papers in pharmaceutical economics
22 overall.

23 Q. But you don't cite any
24 evidence of that either in your declaration,
25 correct?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

A. No, but it's true.

Q. How do you know it's the most cited? How would you determine that?

A. I have seen rank lists of paper citations that is something that's tracked in order to evaluate impact of papers, and this paper has shown up at the top of those lists.

Q. Would you agree that it is the overall context rather than the particular market share that defines whether market share are interpreted as persuasive evidence of commercial success?

A. I think that's a fair statement. I think context matters.

Q. You did not provide any opinion regarding Tyvaso's contribution to UTC's overall profitability, correct?

A. No, I don't believe so.

Q. Did you look into that?

A. No, I don't think so. I don't view it as particularly relevant.

Q. So if Tyvaso contributed significantly to UTC's overall profitability,

1 DEFOREST MCDUFF, Ph.D.

2 Therapeutics has been recognized as a valuable
3 and fast growing company since the time of
4 Tyvaso's launch?

5 MR. MATHAS: Object to the form.

6 BY THE WITNESS:

7 A. I don't know. Is that an
8 excerpt you are reading from from one of the
9 documents I have cited?

10 BY MR. DELAFIELD:

11 Q. I am just asking have you
12 looked into the profitability or market share
13 of United Therapeutics since Tyvaso's launch?

14 MR. MATHAS: I am going to object
15 to the form, and I think it would be fair to
16 characterize the question as being in this
17 proceeding because obviously Dr. McDuff has
18 been involved in other proceedings related to
19 Tyvaso.

20 BY MR. DELAFIELD:

21 Q. In this proceeding?

22 A. Would you mind just repeating
23 the question.

24 (WHEREUPON, the record was read
25 by the reporter.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

A. Sitting here, I don't see why it would be particularly relevant.

Q. So if United Therapeutics' market capitalization went up as Tyvaso sales went up, you don't think that would be a relevant factor to consider for commercial success?

A. It depends on what the information looked like. I didn't analyze that information here. I don't have a conclusion on it sitting here.

Q. Now, the DiMasi paper projected sales based on prior sales for I think 20 years. You did not project Tyvaso sales through the expiration date of the patents-in-suit, correct?

A. That's correct, because they have already started to decline. In other words, they have already reached their peak sales in 2015 and have declined in 2016 and 2017.

Q. Even if there is a decline, isn't it possible that their sales could go back up?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

A. It's possible but it's not likely.

Q. So you don't know for sure that they have already reached peak sales, correct?

A. It's very likely that they have. I have seen very few examples of drugs that reach a peak sales, decline, and then grow to beyond what they have already reached. In light of the competition in this market, I don't think it's likely that they will be greater again. It's certainly possible just not likely.

Q. So it is possible?

A. It's certainly possible, but I don't view it as likely.

Q. In past cases where you have offered an opinion on commercial success, did you project sales through patent expiration?

A. It depends on the circumstances. I have in some instances and haven't in others.

Q. Why didn't you here -- strike that.

1 DEFOREST MCDUFF, Ph.D.

2 Is the fact that you believe
3 Tyvaso has already reached peak sales the only
4 reason you did not project sales through patent
5 expiration in this case?

6 A. That's one reason. Another
7 reason is that future sales are inherently less
8 objective evidence of commercial success given
9 that they haven't occurred yet. They may
10 occur. They may not occur. We don't know. So
11 I put less weight on them.

12 And I guess the third reason
13 is I think that I didn't need to project future
14 sales in order to draw the conclusions that I
15 have drawn in this declaration.

16 Q. So you agree that projected
17 sales have less weight than actual sales
18 because you don't know if those would occur,
19 correct?

20 A. I wouldn't describe it as a
21 global conclusion as you have that would apply
22 to every situation. I don't think it applies
23 to every situation, but I think in terms of
24 evaluating commercial success as a secondary
25 consideration based on sales that have already

1 DEFOREST MCDUFF, Ph.D.

2 occurred, I think future sales are less
3 relevant than past sales.

4 Q. But in your analysis of
5 comparing Tyvaso to the top two deciles from
6 the DiMasi paper, the majority of those sales
7 for those deciles were projected sales,
8 correct?

9 A. I don't agree with that.

10 Q. Well, we discussed how some of
11 the sales are actual sales and some of them are
12 projected, correct?

13 A. Yes, but the primary results
14 aren't influenced heavily by the projections.
15 You can see in the Grabowski, DiMasi paper that
16 most of the sales profile has been achieved
17 already by years seven to 11. So the
18 projections don't change the results that much.

19 Q. But there were several years
20 that are just projected sales, correct?

21 A. Well, they are projected based
22 on the actual sales path. So they are doing
23 their best to program over the full life cycle
24 of a product, but the projections aren't
25 impactful on the result. It wouldn't change my

1 DEFOREST MCDUFF, Ph.D.

2 conclusion.

3 Q. Well, aren't all projected
4 sales based on prior sales? That's how you do
5 a projection?

6 A. Yes.

7 Q. And you didn't do that for
8 Tyvaso here, correct?

9 A. I did not, that's correct.

10 Q. And you do not provide an
11 opinion regarding the relationship between
12 United Therapeutics' gross margin and Tyvaso's
13 gross margin, correct?

14 A. I think that's true, yes. I
15 am not aware of that information being provided
16 by UTC.

17 Q. Did you check to see if it was
18 available?

19 A. I don't recall. It's
20 typically not available in IPRs in my
21 experience.

22 Q. So you don't remember checking
23 to see if it's available?

24 A. I don't recall one way or the
25 other.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

Q. You also did not provide an opinion regarding the economic costs for launching Tyvaso, correct?

A. Correct.

Q. But economic costs are an important factor to consider for commercial success, correct?

A. They can be. It depends on the circumstance.

Q. You did not account for preclinical expenses for Tyvaso, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. Not in this declaration, no.

BY MR. DELAFIELD:

Q. Do you agree that a patented invention should be considered a commercial success if it can be shown to have earned or can reasonably be expected to earn a positive net return on invested capital after accounting for all relevant costs associated with development and commercialization?

A. I think that's one factor one could analyze.

1 DEFOREST MCDUFF, Ph.D.

2 Q. Well, do you agree with that
3 statement?

4 A. I don't agree that that's the
5 only factor or that that's a sole
6 consideration, no.

7 Q. But you agree that if a
8 patented invention meets those criteria, it
9 should be considered a commercial success?

10 A. It depends on the
11 circumstance.

12 (WHEREUPON, a certain document
13 was marked McDuff Deposition
14 Exhibit No. 1, for
15 identification, as of 4/6/18.)

16 BY MR. DELAFIELD:

17 Q. You have been handed what's
18 been marked as McDuff Exhibit 1 which is a
19 paper entitled Thinking Economically about
20 Commercial Success.

21 Do you recognize this paper?

22 A. Yes.

23 Q. You are the primary author of
24 this paper, right?

25 A. I am one of three authors.

1 DEFOREST MCDUFF, Ph.D.

2 Q. Do you recall writing this
3 paper?

4 A. Yes, with contributions from
5 my co-authors.

6 Q. So if you turn to page 3 at
7 the top the first full sentence: "Rather,
8 commercial success should inform on whether
9 sales and profits provide objective evidence on
10 whether material economic incentives (i.e.,
11 'market forces') would have incentivized others
12 to bring product to market had the invention
13 been obvious."

14 And then it goes on to say:
15 "Other economists and scholars agree that this
16 is, in essence, the fundamental purpose of
17 commercial success analysis."

18 Do you see that?

19 A. Yes.

20 Q. And then it has an endnote 10
21 for that statement, and you cite a paper by
22 Jesse David and Marion Stewart and quote: "A
23 patented invention should be considered a
24 commercial success if it can be shown to have
25 earned, or can reasonably be expected to earn,

1 DEFOREST MCDUFF, Ph.D.

2 a positive net return on invested capital after
3 accounting for all relevant costs associated
4 with development and commercialization."

5 Do you see that?

6 A. I do.

7 Q. Do you agree with that
8 statement?

9 A. Well, those aren't my words.
10 Those are their words. I think that there's
11 some validity to what they are saying. I don't
12 think it's the only thing one should examine in
13 evaluating commercial success.

14 Q. Well, in your paper in your
15 words where you cite that paper, you say:
16 "This is, in essence, the fundamental purpose
17 of commercial success analysis," and then you
18 cite that quote, correct?

19 A. I think that's a
20 mischaracterization of what I have written
21 here. The full sentence is: "Other economists
22 and scholars agree that this is, in essence,
23 the fundamental purpose of commercial success
24 analysis," and I am describing the previous
25 sentence which are my words about material

1 DEFOREST MCDUFF, Ph.D.

2 economic incentives.

3 Q. So you don't think it's a
4 fundamental purpose of commercial success
5 analysis?

6 A. I don't think what is a
7 fundamental purpose of commercial success?

8 Q. The whether a product has
9 earned or can reasonably be expected to earn a
10 positive net return on invested capital after
11 accounting for all relevant costs associated
12 with development and commercialization?

13 MR. MATHAS: Object to the form.

14 BY THE WITNESS:

15 A. Well, as I have already
16 explained, that's an excerpt from other
17 economists. I think there's some validity to
18 what they are saying, but I would describe it
19 as I have on page 3 of the article.

20 BY MR. DELAFIELD:

21 Q. Would you agree that profit is
22 an important factor to consider in analyzing
23 commercial success?

24 A. It can be. It depends on the
25 circumstance.

1 DEFOREST MCDUFF, Ph.D.

2 Q. Well, according to your paper
3 on page 3 the last sentence of the first
4 paragraph: "Said another way, ideas are
5 brought to market when there is a profit
6 opportunity, not merely when sales or market
7 shares are 'high' or 'substantial' in some
8 abstract sense."

9 Do you agree with that?

10 A. I do. I think that's
11 consistent with what I have evaluated here.

12 Q. And so profit is an important
13 factor to consider for commercial success,
14 right?

15 A. It depends what you mean by
16 that.

17 Q. Well, I am just looking at
18 your paper. You are talking about the
19 importance of a profit opportunity, correct?

20 A. What is your question?

21 Q. Do you agree that profit is an
22 important factor to consider for commercial
23 success?

24 A. I think it can be.
25 Conceptually we are thinking about a market

1 DEFOREST MCDUFF, Ph.D.

2 opportunity, and profit is, of course, an
3 element of that. Does one have to analyze
4 profit specifically? Sometimes, yes.
5 Sometimes, no. It depends on the context, but
6 fundamentally we are thinking about an economic
7 incentive to bring a product to market.

8 Q. Have you ever provided an
9 opinion that a patented product was a
10 commercial success that was not profitable?

11 A. I don't recall.

12 Q. Do you recall providing any
13 opinions on commercial success of a patented
14 product that was not profitable as a factor of
15 why it was not a commercial success?

16 A. Could you read that back or
17 ask it again.

18 (WHEREUPON, the record was read
19 by the reporter.)

20 BY THE WITNESS:

21 A. Yes, I think if a product is
22 unprofitable, that weighs against commercial
23 success.

24 BY MR. DELAFIELD:

25 Q. And in this case you didn't

1 DEFOREST MCDUFF, Ph.D.

2 analyze cost or positive net return for Tyvaso,
3 correct?

4 A. Not specifically. Here for
5 the IPR, there's very limited information. I
6 am not aware of UTC providing profit
7 information for its Tyvaso product. Had they
8 done so, I would have been open to considering
9 it.

10 Q. Did you look for that
11 information?

12 A. I don't recall. It's not
13 typically available, and my understanding is
14 that it's not available here.

15 Q. But you don't know because you
16 didn't look, right?

17 A. I looked at the case
18 information, and I didn't see profit
19 information provided by UTC. Perhaps I
20 overlooked it, but I don't think so. They
21 certainly did not do so in their prosecution
22 history which I did examine.

23 Q. But other than their 10-Ks and
24 prosecution history, you didn't look elsewhere
25 for profits, prices, or costs associated with

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

Tyvaso?

A. I don't know where else I would look. That kind of information is typically confidential and proprietary. UTC would often have that information on a confidential basis but would not make it publicly available.

Q. Do you agree that premium pricing can be an indicator of commercial success?

A. It depends on the circumstance.

Q. In this case if Tyvaso had premium pricing, would that affect your opinion regarding Tyvaso's commercial success?

A. I think having a greater price can be one indicator of some product differentiation, but I don't think it's the only factor that is relevant for evaluation in commercial success.

Q. But it's one factor, correct?

A. It could be.

Q. Have you used that before in your analysis of commercial success of other

1 DEFOREST MCDUFF, Ph.D.

2 products?

3 A. I have analyzed price, yes.

4 Q. You do not provide any
5 analysis of number of prescriptions in your
6 declaration, correct?

7 A. That's correct. I focused on
8 revenues.

9 Q. Did you look into that
10 information?

11 A. I don't recall specifically.

12 Q. Have you ever used IMS data
13 before?

14 A. I have, yes.

15 Q. And they typically provide
16 prescription information?

17 A. That's one type of data you
18 can purchase.

19 Q. So it's publicly available?

20 A. Publicly available but not
21 freely available.

22 Q. And you didn't look at
23 prescriptions for Tyvaso or any of the other
24 drugs for your analysis, correct?

25 A. I did not. I did not view it

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

as necessary to do so. IMS health data is expensive, and it didn't seem necessary given the conclusions that I am drawing based on what I have examined here.

Q. Well, it would be relevant if, for example, Tyvaso's price was much higher than competitor price and sold fewer units compared to sales of other -- strike that.

For example, prescriptions may be relevant if they are not indicative of the sales compared to other drugs?

A. I am not sure what you mean by that.

Q. If more people were prescribed Tyvaso than other drugs, would that influence your decision on commercial success?

A. Sitting here, it doesn't seem likely that it would change my opinions. I would be open to considering it if it were available, but it is not something that I have analyzed here, nor do I view it as necessary to have done so.

Q. But it is available. You just didn't get it, right?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

A. Well, as I explained, it's not freely available. It can be expensive, and given the information that I saw and the conclusions that I have drawn, I don't view it as necessary to have obtained IMS health data or some other prescription metric.

Q. In a commercial success analysis, it's important to consider the fact that commercial and government payers consider the benefits of Tyvaso to be important enough to justify paying for it, correct?

A. Could you repeat the question. (WHEREUPON, the record was read by the reporter.)

BY THE WITNESS:

A. I don't think I have a global opinion on that that would apply to every situation.

BY MR. DELAFIELD:

Q. So, for example, if an insurer or government payer included a very expensive drug in its formulary coverage, then they would have to provide substantial benefits to the user over other drugs in order to be covered,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. Not necessarily. I don't have a global opinion on that that would apply to every situation.

BY MR. DELAFIELD:

Q. Do you agree that would be relevant to commercial success?

A. It depends on the circumstances, I suppose. I didn't see information on -- that would make that relevant here.

Q. Did you look into whether that was the case for Tyvaso?

A. I don't recall.

Q. Are you aware that Tyvaso can only be obtained through specialty pharmacies?

A. That sounds familiar.

Q. Did you consider that in your analysis the availability of Tyvaso compared to the other drugs?

A. It's a factor that's inherently considered when one looks at the

1 DEFOREST MCDUFF, Ph.D.

2 sales data. If one drug is harder to obtain
3 and another drug is easier to obtain, that will
4 show up in sales, but it's not a factor that I
5 focused on.

6 Q. So if a drug is harder to
7 obtain, they might have less sales not because
8 of any patented features, but just because of
9 the availability of the drug, correct?

10 A. There could be lower sales due
11 to lack of availability. I think that
12 represents a smaller commercial opportunity.
13 In other words, a less successful product.

14 Q. Well, you would have to
15 consider it in light of the fact that it can
16 only be provided by specialty pharmacies,
17 correct?

18 A. I don't know what you mean by
19 that.

20 Q. The commercial success of a
21 product in relation to the patented features
22 have nothing to do with availability, but the
23 total sales could have something to do with
24 availability, correct?

25 MR. MATHAS: Object to the form.

1 DEFOREST MCDUFF, Ph.D.

2 BY THE WITNESS:

3 A. Well, there are various
4 attributes of a product. Some that may relate
5 to a patent and some may not relate to a patent
6 could contribute to its availability. All else
7 being equal, more effective drugs are more
8 available.

9 BY MR. DELAFIELD:

10 Q. Did you look into what drugs
11 are only available at specialty pharmacies
12 other than Tyvaso in your list of drugs?

13 A. I don't think I performed that
14 specific analysis, no. I don't view it as
15 particularly relevant here.

16 Q. And you provided no other
17 opinions on any other secondary consideration
18 other than commercial success, correct?

19 A. That's correct in terms of my
20 analysis and conclusions. Although, my
21 declaration may be cited towards other
22 secondary considerations, but I did not draw
23 conclusions on other secondary considerations.

24 Q. So you were only asked to
25 provide opinions on commercial success,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

correct?

A. That's correct, but I don't have the full scope of what my declaration will be used to support or rebut.

Q. So it's your opinion that the '075 patent and the '222 patent are patents that would -- are blocking patents in this case; is that correct?

A. Yes.

THE WITNESS: Maybe if you are shifting gears, we could take a break.

MR. DELAFIELD: Sure.

THE VIDEOGRAPHER: The time is now 3:03 p.m. This is the end of media 3. We are off the record.

(WHEREUPON, a recess was had at 3:03 p.m. until 3:13 p.m.)

THE VIDEOGRAPHER: The time is now 3:13 p.m. This is the beginning of media 4. We are back on the record.

(WHEREUPON, the documents were tendered to the witness.)

BY MR. DELAFIELD:

Q. You have been handed four

1 DEFOREST MCDUFF, Ph.D.

2 documents. The first of which is Exhibit 1019
3 which is U.S. Patent 4,306,075, and it's
4 Exhibit 1019 in both cases.

5 Do recognize that document?

6 A. Yes.

7 Q. The next exhibit is Exhibit
8 1025 which is the same exhibit number for both
9 cases, and is a copy of U.S. Patent 5,153,222.

10 Do you recognize this
11 document?

12 A. Yes.

13 Q. The third document is Exhibit
14 1018 which is labeled 1018 in both cases, and
15 it is a copy of U.S. Patent 6,521,212.

16 Are you familiar with this
17 document?

18 A. Yes.

19 Q. And then finally Exhibit 1057
20 which is the same exhibit number for both cases
21 and is a copy of U.S. Patent 6,756,033.

22 Are you familiar with this
23 document?

24 A. Yes.

25 Q. Have you reviewed all of these

1 DEFOREST MCDUFF, Ph.D.

2 documents in preparing your declaration?

3 A. Yes.

4 Q. So let's start with the '075
5 patent which is Exhibit 1019.

6 A. Okay.

7 Q. Do you know if Watson sought
8 to license this patent from United
9 Therapeutics?

10 A. I don't know one way or the
11 other.

12 Q. Or from the Upjohn Company,
13 the original assignee?

14 A. Did you mean to ask about
15 Watson?

16 Q. Yes.

17 A. I don't know.

18 Q. But it was available to be
19 licensed, correct?

20 MR. MATHAS: Object to the form.

21 BY THE WITNESS:

22 A. I don't know what you mean by
23 that, not as I think of it.

24 BY MR. DELAFIELD:

25 Q. Well, generally all patents

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

are capable of being licensed to someone else, correct?

A. What do you mean by capable of? You can license a patent.

Q. And like that example this patent could be licensed, correct?

A. Without more specifics, I am not sure what you are getting at. Could be licensed to whom, under what circumstances?

Q. Well, this is one of the patents that you designated as a blocking patent; is that correct?

A. Yes.

Q. And a blocking patent, according to your analysis, a patent that effectively blocks others from making, selling, or using the product without the use of the invention claimed in the patent, correct?

A. Yes.

Q. Or put another way, a blocking patent prevents practicing another patent, correct?

A. I am not sure I agree with that last characterization.

1 DEFOREST MCDUFF, Ph.D.

2 Q. So a blocking patent doesn't
3 necessarily prevent practicing another patent?

4 A. A blocking patent doesn't
5 present -- prevent practicing another patent?
6 I am just not sure what you mean.

7 Q. So you have a blocking patent
8 that according to your definition blocks others
9 from making, using, or selling a product
10 without the use of the invention claimed in
11 that patent?

12 A. Yes.

13 Q. So if someone wants to patent
14 something else using that product, would you
15 agree a blocking patent prevents obtaining
16 another patent that uses that technology?

17 MR. MATHAS: Object to the form.

18 BY THE WITNESS:

19 A. No, that's not how I think
20 about it. A blocking patent blocks
21 commercialization and sales activities, and it
22 disincentivizes development of other
23 technologies.

24 BY MR. DELAFIELD:

25 Q. You agree, though, a blocking

1 DEFOREST MCDUFF, Ph.D.

2 patent is one that effectively blocks others
3 from making, selling, or using a product
4 without use of the invention purportedly
5 claimed in that patent, correct?

6 A. Yes, that's a sentence from my
7 declaration.

8 Q. And making or using a product
9 doesn't necessarily mean selling the product,
10 right?

11 A. What do you mean?

12 Q. Well, earlier I asked you if a
13 blocking patent would prevent others from
14 patenting something else that includes the
15 invention that's part of that blocking patent,
16 and you said that's not how you think of it,
17 correct?

18 A. That question is very
19 confusing to me.

20 Q. Is it your opinion that
21 blocking patents would prevent others from
22 patenting similar technology that uses the
23 invention in the blocking patent?

24 A. It would disincentivize
25 development of other technologies because, as I

1 DEFOREST MCDUFF, Ph.D.

2 explain in paragraph 27, other entities would
3 have strong disincentives not to develop
4 technology that they would be blocked from
5 utilizing or implementing in the marketplace.

6 So if I am entity considering
7 developing a technology, if another patent
8 would block me from bringing my technology to
9 market, I am not going to pursue that as an
10 economic incentive.

11 Q. But pursuing another patent on
12 related technology that uses that would be part
13 of making or using the blocking patent,
14 correct?

15 MR. MATHAS: Object to the form.

16 BY THE WITNESS:

17 A. I am just not sure what you
18 mean by that.

19 BY MR. DELAFIELD:

20 Q. Is it your position that the
21 '075 patent is a blocking patent as to the '240
22 and '507 patents?

23 A. Yes, along with the other
24 patents listed in paragraph 28.

25 Q. Now, with respect to the '075

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

patent, it was filed in 1980, correct?

A. Yes.

Q. Do you know when it expired?

A. I believe it was sometime in the late 1990s or around 2000.

Q. And the '240 and '507 patents weren't filed until 2006, correct?

A. Correct.

Q. So this patent had expired and wasn't blocking anything as of 2006, correct?

A. In 2006 the '075 patent wouldn't be a blocking patent, but in the period of time leading up to 2006, it was a blocking patent. Again, it's the collection of patents here that provides the blocking disincentive, not just the '075 patent.

Q. But right now I just talking about the '075 patent.

You would agree that given the '075 patent had expired years before the '507 or '240 patents had even been filed, that it was not a blocking patent for those patents, correct?

MR. MATHAS: Object to the form.

1 DEFOREST MCDUFF, Ph.D.

2 BY THE WITNESS:

3 A. I don't agree with that. I
4 agree that the '075 patent was not a blocking
5 patent in 2006, but it was prior to 2006.

6 BY MR. DELAFIELD:

7 Q. Why does it matter prior to
8 2006?

9 A. Because we are contemplating
10 the idea of an invention potentially being
11 developed sooner in response to market forces
12 had it been obvious, and so sooner means before
13 when it was actually submitted. So prior to
14 2006.

15 Q. So this patent expired I
16 believe in 1999. I could be wrong about that,
17 but assuming it was 1999, it expired a full
18 seven years before either the '240 or '507
19 patent had been filed, correct?

20 A. If it expired in 1999, that's
21 correct.

22 Q. And that's before anybody had
23 thought of -- strike that.

24 Do you know when research on
25 the '240 and '507 patents began?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

Q. So as of the expiration date of the '075 patent, it was not a blocking patent for the '240 or '507 patent, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. Could you read the question back.

(WHEREUPON, the record was read by the reporter.)

BY THE WITNESS:

A. After the '075 patent expired, it would no longer be a blocking patent, but it was a blocking patent for the period up to expiration.

BY MR. DELAFIELD:

Q. So in your analysis of what is and isn't a blocking patent, did you consider whether the patent actually worked?

A. I don't know what you mean by that.

Q. Well, let's look at the '075 patent.

Can you point out what specifically in the '075 patent you consider to

1 DEFOREST MCDUFF, Ph.D.

2 be blocking with respect to Tyvaso?

3 A. My understanding is that the
4 '075 patent covers the compound treprostinil.

5 Q. Can you --

6 A. And that's why it's a blocking
7 patent.

8 Q. Can you point me to where it
9 discloses treprostinil?

10 A. I believe that's what the
11 patent is about. What are you looking for?

12 Q. I am just asking for you to
13 identify the treprostinil disclosure that you
14 are claiming the '075 patent discloses?

15 MR. MATHAS: Object to the form.

16 BY THE WITNESS:

17 A. Well, I am not a chemist. So
18 I wouldn't purport to wade through all of the
19 chemistry explanation here, but my
20 understanding is that the '075 patent covers
21 the treprostinil compound.

22 BY MR. DELAFIELD:

23 Q. Is that based solely on
24 Dr. Donovan's declaration?

25 A. I believe it is, yes.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

Q. Have you ever identified the structure of treprostinil in the '075 patent?

A. What do you mean by that?

Q. Well, you are claiming it's a blocking patent because it discloses treprostinil, and I am just wondering have you ever satisfied yourself that treprostinil is, in fact, disclosed in the '075 patent?

A. That's my understanding based on information from Dr. Donovan. I don't have any reason to question that.

Q. Do you know if the process described in making treprostinil in this patent actually works?

A. What do you mean by actually works?

Q. Well, do you know whether someone following this patent could actually make treprostinil based on this patent?

A. I have not waded into these technical issues for the purposes of my declaration. My understanding is that this patent covers treprostinil. I understand that Dr. Donovan has provided that opinion.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

Q. And so your opinion that this patent discloses treprostinil is solely based on the fact that Dr. Donovan said that it discloses treprostinil, correct?

A. I believe that's correct. It's based on my understanding and discussion with counsel as well.

Q. You would agree with me that the first commercially available form of treprostinil was Remodulin, correct?

A. I believe that's correct, yes.

Q. And that was launched in 2002; is that correct?

A. 2001 or 2002, around then.

Q. And so the '075 patent was filed in 1980. So for 22 years, nobody had commercialized the compound treprostinil, correct?

A. To the best of my recollection, that's true.

Q. But it is your opinion that it is the compound that is responsible for the commercial success or at least in part of Tyvaso -- strike that.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

It's your opinion that it is the compound treprostinil that is responsible for whatever success was obtained by Tyvaso?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. I would point you to paragraph 35 in my report. I think it is stated best there. I write quote: "The vast majority of the clinical benefit of Tyvaso comes from the treprostinil compound itself and the application of that compound to treating PAH" end quote.

My understanding is that that relates to the '075 patent and the '222 patent.

BY MR. DELAFIELD:

Q. So do you have any understanding as to why treprostinil was apparently known since 1980 and yet not commercially available until 2002 if the commercial success is due specifically to the drug itself?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. I think it's consistent with a

1 DEFOREST MCDUFF, Ph.D.

2 limited market opportunity and a small patient
3 population and a lack of commercial incentives
4 for development.

5 BY MR. DELAFIELD:

6 Q. Because the '075 patent
7 expired before any commercial use of
8 treprostinil, it actually was not a blocking
9 patent during -- strike that.

10 It was not a blocking patent
11 at the time that treprostinil was first
12 commercially sold, correct?

13 MR. MATHAS: Object to the form.

14 BY THE WITNESS:

15 A. If you are limiting to 2001
16 onward, which it sounds like you are, I agree
17 that the '075 patent was not a blocking patent
18 for that period of time after it expired. It
19 was a blocking patent before expiration.

20 BY MR. DELAFIELD:

21 Q. So if you would look at
22 Exhibit 1025, and this is patent number
23 5,153,222. Now, can you point out treprostinil
24 in this patent?

25 A. Like with the '075 patent, I

1 DEFOREST MCDUFF, Ph.D.

2 don't have an independent interpretation of the
3 chemistry here, but my understanding is that
4 this patent covers method of treating pulmonary
5 hypertension with treprostinil.

6 Q. And so your understanding that
7 this patent discloses treprostinil is based on
8 Dr. Donovan's declaration that states that this
9 discloses treprostinil, correct?

10 A. Yes, as well as this patent
11 being listed in the FDA Orange Book for Tyvaso
12 which has treprostinil as the active
13 ingredient.

14 Q. So if you look on the first
15 page of the '222 patent, you see that it was
16 filed in 1991.

17 Do you see that?

18 A. Yes.

19 Q. And in references cited, it
20 lists the '075 patent.

21 Do you see that?

22 A. I do.

23 Q. So if you also compare the
24 '075 and the '222 patent, they are different
25 inventors and different assignees, correct?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

A. I see that, yes.

Q. So the '075 patent didn't block Burroughs Wellcome from developing the '222 patent, correct?

A. Well, as we discussed earlier, the notion of a blocking patent doesn't block someone from performing scientific research. Rather it reduces economic incentives for bringing products to market, but this did occur over the time period where the '075 patent had not yet expired.

Q. So even though the '075 patent had not expired, Burroughs Wellcome was able to patent the use of treprostinil for treating pulmonary hypertension, correct?

A. That's my understanding, yes.

Q. And so they were not blocked from making or using treprostinil that was disclosed in the '075 patent, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. Well, as we discussed earlier, the scientific research itself may not be blocked. Had Burroughs Wellcome brought a

1 DEFOREST MCDUFF, Ph.D.

2 product to market, perhaps they would have been
3 sued or prevented from doing so by the owner of
4 the '075 patent.

5 BY MR. DELAFIELD:

6 Q. So you mentioned economic
7 disincentives. It takes a good amount of money
8 to get an issued patent, correct?

9 MR. MATHAS: Object to the form.

10 MR. DELAFIELD: We can ask Steve.

11 BY MR. DELAFIELD:

12 Q. Would you agree that it takes
13 a lot of money to get an issued patent?

14 MR. MATHAS: Same objection.

15 BY THE WITNESS:

16 A. I understand there's a range.
17 Some patents are less expensive than others.

18 BY MR. DELAFIELD:

19 Q. But in order to obtain a
20 patent, there must be some sort of economic
21 incentive to do so, correct?

22 A. I would agree with that. It
23 wouldn't necessarily be a big incentive or one
24 that's shared with the broader market, but
25 there may be some incentives for some

1 DEFOREST MCDUFF, Ph.D.

2 to make and use but not sell certain patented
3 inventions, correct?

4 A. It applies to certain types of
5 scientific research which are permitted even if
6 there's patent protection.

7 Q. So, for example, a generic
8 company can make and use and put into clinical
9 trials a patented drug. They just can't go
10 sell the drug, correct?

11 A. As one example, yes.

12 Q. And if they want to sell the
13 drug, then they can challenge the patent and
14 have a litigation, correct?

15 A. They can, yes.

16 Q. Do you know when the '222
17 patent expired?

18 A. I don't recall the exact year.
19 Although, the '222 patent was listed in the FDA
20 Orange Book for Tyvaso in 2009 or 2010 so after
21 that. Sometime in the early 2010s would be my
22 best guess sitting here.

23 Q. So both of these patents
24 despite the fact they may disclose
25 treprostinil, a company could still have made

1 DEFOREST MCDUFF, Ph.D.

2 and used treprostiniil and not have been blocked
3 from doing so, correct?

4 A. Scientific research may have
5 been permitted under the safe harbor provision
6 as we discussed, but that misses the notion of
7 blocking patents. Blocking patent is about the
8 economic disincentive to perform that research
9 if one would be later prevented from
10 commercializing a product that resulted from
11 that research. So it's about the economic
12 incentive or disincentive to perform research
13 on which one can't later commercialize.

14 Q. But in that analysis, wouldn't
15 part of the analysis be to look at the blocking
16 patents and whether they can be performed and
17 whether they are valid themselves?

18 A. I am not sure what you mean.

19 Q. Well, for the purposes of your
20 declaration, you are assuming that the '222
21 patent and the '075 patent where both valid and
22 enabled or worked for the purpose that it was
23 used, correct?

24 A. I don't believe I have made
25 such an assumption.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

further confirmed by the '222 patent, '212 patent, and '033 patent being listed in the FDA Orange Book for Tyvaso.

Q. If you could look at Exhibit 1018 which is a copy of U.S. Patent 6,521,212, and it's the same exhibit number for both cases.

Are you familiar with this document?

A. Yes, this is the '212 patent referenced in my declaration.

Q. Now, this patent does not claim any device to administer treprostinil, correct?

A. That strikes me as a technical issue. I would defer to others on the exact scope. As a general matter, I understand this patent to be covering methods of treating PAH via inhaled treprostinil.

Q. But the patent doesn't cover any kit or use of a kit, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. That strikes me as a technical

1 DEFOREST MCDUFF, Ph.D.

2 issue. I would defer to others on that.

3 BY MR. DELAFIELD:

4 Q. So you don't know?

5 MR. MATHAS: Object to the form.

6 BY THE WITNESS:

7 A. It is just not something I
8 have evaluated in my role as an economist here.

9 BY MR. DELAFIELD:

10 Q. If you could look at Exhibit
11 1057 which is U.S. Patent 6,756,033, and for
12 both cases, it's Exhibit 1057.

13 The same question. This
14 patent also does not claim a kit or method of
15 using a kit to administer treprostiniil,
16 correct?

17 A. It strikes me as a technical
18 issue and not one that I have drawn a
19 conclusion on. At a general level, my
20 understanding is that this provides methods for
21 treating PAH via inhalation.

22 Q. But it doesn't specify the kit
23 or technology used to administer, correct?

24 A. That's not something I have
25 drawn a conclusion on or sought to.

1 DEFOREST MCDUFF, Ph.D.

2 Q. Well, that's what the
3 patents-in-suit cover, right?

4 A. Well, as we discussed, I
5 provided a summary of the patents-in-suit. I
6 wouldn't want to wade into technical issues of
7 what's covered and what's not covered, but at a
8 general level it describes methods and kits
9 associated with nebulizer delivery with certain
10 limitations and certain aspects and attributes.

11 Q. And -- strike that.

12 So in your investigation of
13 blocking patents, did you look to see if others
14 had patented treprostinil or processes of
15 making treprostinil to see if people were
16 actually being blocked by these patents?

17 A. I don't recall performing that
18 analysis.

19 Q. For example, if several
20 patents were out there to other companies other
21 than United Therapeutics that claimed
22 treprostinil or processes for making it or use
23 of treprostinil with something else, wouldn't
24 that indicate they were not blocked by the
25 patents that you have identified?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. It depends. I am not aware of any of those.

(WHEREUPON, a certain document was marked McDuff Deposition Exhibit No. 2, for identification, as of 4/6/18.)

BY MR. DELAFIELD:

Q. You have been handed what's been marked as Exhibit 2 which is a copy of U.S. Patent 9,550,716.

Have you seen this patent?

A. I don't believe so, no.

Q. If you will notice the title of the patent is Process For Treprostinal Salt Preparation.

Do you see that?

A. I do, yes.

Q. And the assignee is Eon Labs, correct?

A. I see that, yes.

Q. And this has an earliest priority date of 2010.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

Do you see that?

A. I do, yes.

Q. And in the abstract it says:
"Disclosed is a process for preparing a
treprostinil salt," correct?

A. Yes.

Q. So Eon Labs and the inventors
of the '716 patent were not blocked from
developing a patent that provides a way of
making a treprostinil salt, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. Well, we have discussed the
safe harbor provision. So I wouldn't expect
any blocking of scientific research to have
occurred. I don't see any evidence sitting
here, although I have just taken a brief look,
of this being specific to treating pulmonary
arterial hypertension. So I don't know how
related it is to the other patents. It's just
related to the '075 patent and treprostinil
compound that expired in 1999.

BY MR. DELAFIELD:

Q. And the '222 patent expired

1 DEFOREST MCDUFF, Ph.D.

2 after this was filed though, correct?

3 A. That's my understanding, yes.

4 Q. So this patent was filed
5 before the '222 patent had expired. Yet it
6 discloses a process for preparing a
7 treprostiniil salt, correct?

8 MR. MATHAS: Object to the form.

9 BY THE WITNESS:

10 A. I mean, I see that in the
11 title. I wouldn't provide a technical
12 interpretation of what this covers, but the
13 title is Process For Treprostiniil Salt
14 Preparation.

15 BY MR. DELAFIELD:

16 Q. Now, you mentioned scientific
17 research. This is a patent, though, which is
18 designed to prevent others from making or using
19 the idea you came up with, correct?

20 MR. MATHAS: Object to the form.

21 BY THE WITNESS:

22 A. It's a patent. It provides
23 the right to exclude.

24 BY MR. DELAFIELD:

25 Q. And so Eon Labs had at least

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

some commercial incentive to patent this technology, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. They had some reason for doing so. I don't know what commercial incentive that would be.

BY MR. DELAFIELD:

Q. Wasn't there at least some commercial incentive to obtaining a patent given the expense?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. They must have had some reason for pursuing this. Again, I don't know what that would be. I have not evaluated this patent until just now.

(WHEREUPON, a certain document was marked McDuff Deposition Exhibit No. 3, for identification, as of 4/6/18.)

BY MR. DELAFIELD:

Q. So if you could also look at Exhibit 3 which is a copy of U.S. Patent No.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

8,410,121.

Have you seen this document?

A. I don't believe so, no.

Q. You see that it's assigned to
Lexicon Pharmaceuticals, correct?

A. Yes.

Q. And the original -- strike
that.

The earliest filing date is
July 11, 2007.

Do you see that?

A. I do, yes.

Q. And it says Methods of
Treating -- strike that.

If you look at the abstract on
the first page, it says: "Methods of treating
pulmonary hypertension are disclosed.
Particular methods comprise the administration
of a tryptophan hydroxylase inhibitor and a
prostacyclin."

Do you see that?

A. Yes.

Q. And if you turn to the claims
on the last page, for example, claim 12 it

1 DEFOREST MCDUFF, Ph.D.

2 says: "A method of treating pulmonary
3 hypertension, which comprises administering to
4 a patient in need thereof therapeutically
5 effective amounts of a prostacyclin and" -- I
6 won't read that long word -- "or a
7 pharmaceutically acceptable salt thereof."

8 And then in claim 3 -- 13, it
9 says: "The method of claim 12, wherein the
10 prostacyclin is epoprostenol, iloprost or
11 treprostinil."

12 Do you see that?

13 A. Yes.

14 Q. So this patent is claiming the
15 use of treprostinil with another agent,
16 correct?

17 MR. MATHAS: Object to the form.

18 BY THE WITNESS:

19 A. I wouldn't purport to provide
20 a technical interpretation of this, but I see
21 what you are referring to here in claims 12 and
22 13. It appears to indicate a prostacyclin and
23 another agent.

24 BY MR. DELAFIELD:

25 Q. And so claim 13 includes the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

use of treprostinil in this combination
therapy, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. You know understanding that I
am an economist just reading this, I mean, I
see treprostinil here in claim 13 as one
potential option.

BY MR. DELAFIELD:

Q. And that includes the use of
treprostinil for the treatment of pulmonary
hypertension, correct?

MR. MATHAS: Same objection.

BY THE WITNESS:

A. Just reading this as an
economist, I see that, yes.

BY MR. DELAFIELD:

Q. And so Lexicon Pharmaceuticals
was able to file and obtain a patent starting
in 2007 on a way of using treprostinil to treat
pulmonary hypertension, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. Well, this is some sort of

1 DEFOREST MCDUFF, Ph.D.

2 combination of compounds. I would want to give
3 this some more thought. This is the first time
4 I have seen this patent.

5 BY MR. DELAFIELD:

6 Q. But given that the patent
7 issued and the claims do specify the use of
8 treprostinil for treatment of pulmonary
9 hypertension, you would agree that at least
10 Lexicon Pharmaceuticals was not blocked by any
11 of the patents you have referenced in your
12 declaration, correct?

13 MR. MATHAS: Object to the form.

14 BY THE WITNESS:

15 A. Well, as we have discussed
16 earlier, safe harbor provisions allow for
17 scientific research to occur. You are not
18 blocking them performing research. It's about
19 commercialization that provides disincentives
20 for development. So any alleged commercial
21 success is less informative on market-wide
22 incentives because of the presence of blocking
23 patents.

24 BY MR. DELAFIELD:

25 Q. But you would agree that

1 DEFOREST MCDUFF, Ph.D.

2 obtaining a patent in general has some economic
3 incentive to it, correct?

4 MR. MATHAS: Object to the form.

5 BY THE WITNESS:

6 A. Sometimes, yes; sometimes, no.
7 There are reasons for developing it. Some of
8 which can be to commercialize a product.

9 BY MR. DELAFIELD:

10 Q. So assuming the '121 patent
11 and '716 patent inventors wanted to use their
12 invention, why would they file a patent and
13 have it issued knowing that they can't even use
14 their own patent if it was blocked by other
15 patents?

16 MR. MATHAS: Object to the form.

17 BY THE WITNESS:

18 A. I don't know the specific
19 motivations of these companies. I haven't
20 analyzed them as part of my declaration in this
21 case.

22 MR. DELAFIELD: Can we take a short
23 break?

24 MR. MATHAS: Sure.

25 THE VIDEOGRAPHER: The time is

1 DEFOREST MCDUFF, Ph.D.

2 4:01. We are off the record.

3 (WHEREUPON, a recess was had at
4 4:01 p.m. until 4:10 p.m.)

5 THE VIDEOGRAPHER: The time is now
6 4:10. We are back on the record.

7 MR. DELAFIELD: Welcome back. I
8 have no further questions.

9 EXAMINATION

10 BY MR. MATHAS:

11 Q. Dr. McDuff, I have a couple of
12 questions for you.

13 First of all, in performing
14 your analysis in this case, did you have access
15 to any internal United Therapeutics' financial
16 information?

17 A. I did not, no.

18 Q. And you have had access to
19 such information in connection with your work
20 on the district court proceeding between the
21 parties; is that correct?

22 A. Yes, that's right.

23 Q. And for purposes of your
24 opinions in this case, you did not access any
25 of that information in forming your opinions

1 DEFOREST MCDUFF, Ph.D.

2 for the declarations in the IPR cases, correct?

3 A. Yes, that's correct.

4 Q. All right. Now, there was a
5 question or some questions at the start of the
6 deposition about the contents of your
7 respective declarations, and so if you have
8 those with you, they were Exhibit 1055 which
9 was your declaration in the 1622 case and
10 Exhibit 1055 which was your exhibit in the 1621
11 case.

12 Now, I believe there was some
13 testimony about some omissions in the 1621 case
14 from your declaration. Can you tell us what
15 the omissions were?

16 A. Yes. As submitted and in the
17 version in front of me, there was a chart on
18 page 9 that appears to have been omitted for a
19 printing issue and the attachments from page 26
20 to page 45 which are present in Exhibit 1055 in
21 the 1622 case are not present in my declaration
22 in Exhibit 1055 in the 1621 case. Yet the
23 attachments are identical to those in the 1622
24 case.

25 Q. Okay. So the 1622 case at the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

end of paragraph 15 has a chart in it; is that right?

A. Yes.

Q. And that chart is omitted in the 1621 case?

A. In the declaration there, yes.

Q. But it should have been the identical chart is that correct?

A. Yes.

MR. DELAFIELD: Objection.

BY MR. MATHAS:

Q. All right. What chart should have been there?

MR. DELAFIELD: Same objection.

BY THE WITNESS:

A. The same chart that is in the 1622 declaration as well as in the underlying materials cited in footnote 6 in the 1621 declaration.

BY MR. MATHAS:

Q. All right. And the exhibits that were omitted in the 1621 case, how, if at all, were they different from the exhibits submitted in the 1622 case?

1 DEFOREST MCDUFF, Ph.D.

2 A. They were identical.

3 MR. MATHAS: All right. Can we
4 mark this as Exhibit 3, please -- or 4 for the
5 record, please.

6 MR. DELAFIELD: I am going to
7 object to this exhibit.

8 MR. MATHAS: Fine, I am making a
9 record.

10 (WHEREUPON, a certain document
11 was marked McDuff Deposition
12 Exhibit No. 4, for
13 identification, as of 4/6/18.)

14 BY MR. MATHAS:

15 Q. Dr. McDuff, the court reporter
16 has handed you what's been marked for
17 identification purposes as McDuff Exhibit 4
18 which I will represent to you is a corrected
19 version of Exhibit 1055 that was sent to
20 counsel for the patent owner last evening.
21 This has not been filed in the IPR proceeding
22 as of today.

23 Would you turn with me,
24 please, to page 9 the end of paragraph 15.
25 Does paragraph 15 in Exhibit 4 that I just

1 DEFOREST MCDUFF, Ph.D.

2 handed you correctly show the chart that was
3 omitted from your original Exhibit 1055 and
4 1621?

5 A. Yes.

6 Q. And if you will turn with me
7 to page 26 through 45 of this Exhibit 4 that I
8 have handed you, do pages 26 through 45 of
9 Exhibit 4 correctly reflect the omitted exhibit
10 from the original Exhibit 1055?

11 A. Yes.

12 Q. Are you aware of any other
13 differences between the document I have handed
14 you as Exhibit 4 and the document that was
15 filed as Exhibit 1055 in IPR 1621?

16 A. No, I am not.

17 MR. MATHAS: I have no further
18 questions.

19 FURTHER EXAMINATION

20 BY MR. DELAFIELD:

21 Q. I have a couple of questions.

22 So this new declaration that
23 we received yesterday, do you see at the bottom
24 it says page 1 of 25?

25 A. I do.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

Q. But there's 45 pages, correct?

A. Yes, there are 45 pages in the declaration including the declaration and the attachments.

Q. So the page numbering is off for the first 25 pages with respect to how many total pages, correct?

A. Yes, I suppose that could say page 1 of 45, and it would say 45 consistently throughout as it does in the attachments.

Q. Did you --

A. Either way I think it represents the full declaration.

Q. Did you yourself prepare this replacement declaration?

A. I did not do so personally. I did so through discussion and assistance from counsel.

Q. And you said you first noticed the missing exhibits and graph yesterday as well?

A. Yes.

MR. DELAFIELD: Okay. I have no further questions.

1 DEFOREST MCDUFF, Ph.D.

2 MR. MATHAS: One follow up.

3 FURTHER EXAMINATION

4 BY MR. MATHAS:

5 Q. Dr. McDuff, do the -- does the
6 additional information in Exhibit 4 or the
7 absence of the information in Exhibit 4 change
8 your opinions with respect to the '240 patent
9 in case 1621?

10 A. No, they are all the same
11 either way regardless of whether it's the full
12 document with all of the attachments and chart
13 or the abridged document that omits those.

14 MR. MATHAS: Thank you. I have no
15 further questions.

16 FURTHER EXAMINATION

17 BY MR. DELAFIELD:

18 Q. One question. You were asked
19 if the information in Exhibit 4 or the absence
20 of information of Exhibit 4 would change your
21 opinions with respect to the '240 patent,
22 correct?

23 A. More or less.

24 Q. So if your declaration did not
25 have any of the exhibits or the chart, then you

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

couldn't rely on those in your declaration or cite them, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. I don't agree with that. The most relevant charts from my attachments are in both copies of the declaration. The charts themselves are in line in paragraphs 24 and 25 -- sorry -- 23 and 24, and the attachments simply provide the supporting calculations underlying those charts, but the fundamental opinions are the same.

BY MR. DELAFIELD:

Q. And so without the attachments, there would be no supporting calculations for the '240 declaration, correct?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. There would be no details underlying how the calculations were performed. However, they are described in the declaration itself.

MR. DELAFIELD: Okay. I have no further questions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DEFOREST MCDUFF, Ph.D.

MR. MATHAS: Thank you, Dr. McDuff.

THE VIDEOGRAPHER: The time is now
4:18 p.m. This is the end of media 4. This
concludes this deposition. We are off the
record.

(WHEREUPON, the deposition was
concluded at 4:18 p.m.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

STATE OF _____)
) : ss
COUNTY OF _____)

I, DEFOREST MCDUFF, the witness
herein, having read the foregoing
testimony of the pages of this deposition,
do hereby certify it to be a true and
correct transcript, subject to the
corrections, if any, shown on the attached
page.

DEFOREST MCDUFF

Sworn and subscribed to before me,
this _____ day of _____, 2018.

Notary Public

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

CERTIFICATE
OF
CERTIFIED SHORTHAND REPORTER

I, ANDREA L. KIM, a State of Illinois
Licensed Certified Shorthand Reporter, License
number 84-3722, do hereby certify:

That previous to the
commencement of the examination of the
aforesaid witness, the witness was duly sworn
or affirmed to testify the whole truth
concerning the matters herein;

That the foregoing deposition
transcript was reported stenographically by me,
was thereafter reduced to typewriting under my
personal direction and constitutes a true and
accurate record of the testimony given and the
proceedings had at the aforesaid deposition;

That the said deposition was
taken before me at the time and place
specified;

That I am not a relative or
employee or attorney or counsel for any of the
parties herein, nor a relative or employee of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

such attorney or counsel for any of the parties
hereto, nor am I interested directly or
indirectly in the outcome of this action.

IN WITNESS WHEREOF, I do
hereunto set my hand and affix my seal of
office at Chicago, Illinois, this 9th day of
April, 2018.



ANDREA L. KIM, CSR

License No. 84-3722.

INSTRUCTIONS TO WITNESS

1
2
3 Please read your deposition over carefully
4 and make any necessary corrections. You should state
5 the reason in the appropriate space on the errata
6 sheet for any corrections that are made.

7 After doing so, please sign the errata sheet
8 and date it.

9 You are signing same subject to the changes
10 you have noted on the errata sheet, which will be
11 attached to your deposition.

12 It is imperative that you return the original
13 errata sheet to the deposing attorney within thirty
14 (30) days of receipt of the deposition transcript by
15 you. If you fail to do so, the deposition transcript
16 may be deemed to be accurate and may be used in court.

17
18
19
20
21
22
23
24
25

E R R A T A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

I wish to make the following changes,
for the following reasons:

PAGE LINE

____ CHANGE: _____

REASON: _____

____ CHANGE: _____

REASON: _____

____ CHANGE: _____

REASON: _____

____ CHANGE: _____

REASON: _____

____ CHANGE: _____

REASON: _____

____ CHANGE: _____

REASON: _____

WITNESS' SIGNATURE

DATE

&	1055 23:8,14 27:12 36:3 37:12,23 39:3 71:2 83:20 112:11 125:25 129:11 241:8,10 241:20,22 243:19 244:3,10,15	242:2 243:24,25 152 149:21 16 77:19 81:17 82:16 83:6 87:8 98:22 112:11,12 116:7 156:21 158:13,23 162:10 172:24	1994 162:2,16 163:11,25 164:7 174:23 1999 212:16,17,20 232:23 1:26 129:3,5
& 2:4,11,19 5:16 5:19,22	1057 205:19 229:11,12 10:52 64:4,7 11 113:5,24 138:2 162:9 175:2 187:17 235:11 1113 161:14,17 172:13,17,25 1140 103:15,16,21 103:22,24 104:5 1160 103:21 104:4 104:19,21 120:7 123:19	1621 37:25 241:10 241:13,22 242:6 242:19,23 244:4 244:15 246:9 1622 37:24 39:14 40:8 83:20 110:25 241:9,21,23,25 242:18,25 16a 116:8 17 158:13 163:7,8 172:18 18 43:9 67:2 68:24 70:19 73:24 74:17 78:3 81:22 83:16 83:23,25 85:9,11 86:19 87:21 88:2 88:11 98:14 99:5 100:8	2
0	1162 64:18 65:11 66:6,11 67:10,18 74:25 77:10 82:12 110:24 111:13,19 1163 64:23 65:15 77:9,11,20 80:3 81:16 82:16 111:6 111:25 119 72:10 11:03 64:7,9 12 159:25 160:3 161:22 235:25 236:9,21 121 239:10 12:35 128:23 129:3 13 83:20 132:25 236:8,22,25 237:8 15 18:6 40:3,8 41:3 77:25 81:21 83:14 85:8 160:4	19 66:10 67:18 70:19 83:23 89:15 190 4:14 1970s 162:13 1980 211:2 217:17 218:19 1980s 162:14 1990 162:2,15 163:11,25 164:7 174:23 175:14 1990s 161:16 162:14 211:6 227:13 1991 220:16	2 4:16 64:9 128:23 163:10 172:13 231:8,12 2.5 152:15 153:14 153:24 154:7,21 160:18 2.515 36:25 152:25 20 20:3,5 73:24 74:3,18 75:2 83:23 86:19,20 88:5 95:3 99:14 99:18,19 118:16 118:17 119:9,16 160:4,4 163:15 176:11 184:15 200,000 146:19 147:4,8,11,20 149:14 152:14 153:8,11 2000 162:5 175:9 176:22 211:6 20007 2:21 2000s 162:14 2001 175:10,15 177:10 217:15 219:15 2002 161:6 163:19 176:19 217:13,15 218:20 2004 120:4,8 2006 211:8,11,12 211:14 212:5,5,8 212:14 213:4,5,6 227:13,14
1	1 4:14 39:4 49:21 50:3 51:12 64:4 67:18 149:16 190:14,18 244:24 245:10 1.111 64:25 65:17 1.114 64:20 65:13 1.132 66:14 1.3 159:10,19 10 114:10 117:15 118:13 119:9 129:17 191:20 196:23 100 119:10 1001 42:2 45:6 1018 205:14,14 228:6 1019 205:2,4 206:5 1025 205:8 219:22		

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>2007 235:11 237:21 2009 26:9,16 27:15 73:7 116:20,25 120:2,11 152:24 160:19 183:13 224:20 2010 116:9,21,22 120:2 176:3 224:20 231:25 2010s 224:21 2013 27:21 28:3 72:7 2014 27:21 28:3 73:7 2015 142:11 184:21 2016 142:12,12 152:25 160:19 184:21 2017 19:23 24:7 25:16 34:4 39:6 39:21 40:21 142:12 184:22 2017-01621 1:6 18:25 23:15 39:4 45:6 65:11,15 2017-01622 1:7 18:24 23:9 42:2 64:19,23 2017-10621 37:12 2018 1:20 5:7 34:2 249:21 251:10 21 24:6 39:20 83:23 87:21 89:18 212 226:11 228:2 228:11 22 66:9 67:2 68:22 217:17 222 89:17 204:7 218:15 220:15,24</p>	<p>221:5 223:5 224:16,19 225:20 226:10 227:2,6,18 228:2 232:25 233:5 23 74:25 77:9,11 149:20 151:22 152:10 161:3 247:10 234 4:17 24 43:9 45:16 142:6 151:24 152:7 158:20 160:2 247:9,10 240 4:6 36:18 37:13,18 39:17 40:16 41:4,6 45:19 47:22 48:9 48:14 49:3,16 50:9,18 51:24 53:2 54:2,14 55:10 58:9,12 59:14 65:14,18 210:21 211:7,22 212:18,25 213:9 214:4 227:19 246:8,21 247:17 243 4:18 244 4:7 246 4:8,9 25 4:24 24:3 39:4 39:16 244:24 245:7 247:10 26 25:10 66:19 77:20 81:16 84:4 87:21 241:19 244:7,8 27 89:22 210:2 28 89:24 210:24</p>	<p>3 3 4:17 129:5 138:24 191:6 193:19 194:3 204:15 234:21,25 236:8 243:4 3.5 159:11 3.565 158:24 30 176:11 252:14 3000 2:20 31 90:3 32 27:20 325 149:10 33 146:14 333 226:11 34 27:11,19 35 1:18 2:5 90:8 99:14 100:23 218:8 36 99:15 37 64:20,25 65:13 65:17 66:13 84:4 87:21 90:9 99:15 106:5,6 38 36:2 152:22 3:03 204:15,18 3:13 204:18,20</p>	<p>40 8:2 439 72:11 45 152:22 241:20 244:7,8 245:2,3,10 245:10 470 149:21 4800 1:18 4:01 240:2,4 4:10 240:4,6 4:18 248:4,8</p>
			<p>5 5 80:2 137:8 138:3 141:12 5,153,222 205:9 219:23 50 7:25 8:12 16:13 507 23:17 36:3,18 41:5 44:4,7 45:15 45:23 47:21 48:9 48:14 49:3,17 50:9,17 51:24 52:25 54:2,15 55:11 58:9,13 59:14 64:21,25 71:2 125:25 129:12 210:22 211:7,21 212:18 212:25 213:9 214:4 227:18 540 45:21</p>
		<p>4 4 4:1,18 36:4 71:3 71:15 73:2,6 141:22 152:21 204:20 243:4,12 243:17,25 244:7,9 244:14 246:6,7,19 246:20 248:4 4,306,075 205:3 4/6/18 190:15 231:9 234:22 243:13</p>	<p>6 6 4:5 5:7 40:14 242:19 6,521,212 205:15 228:6 6,756,033 205:21 229:11 600 2:20 60606 2:6</p>

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

6th 1:19	a.m. 1:20 5:8 64:4 64:7,7,9	acoustical 50:4 51:12,15	administering 62:19 236:3
7	ability 137:11	action 107:3 138:18 139:13,14 251:5	administration 55:16 105:24 108:11 110:7 235:19
7 163:8 172:17	able 127:13 134:25 221:14 237:20	active 137:20 220:12	advanced 28:17 134:3,10
70 117:17 118:21 119:9	abridged 246:13	activities 208:21	advantage 120:18 120:23 121:24 122:10
716 232:9 239:11	absence 41:2 246:7,19	actual 155:9 161:9 162:4,9,20,22 163:22 164:6,15 175:6,8 186:17 187:11,22	advantages 81:4 95:6 98:15 120:25 121:3,4
75 16:16	abstract 194:8 232:4 235:16	adcirca 126:13 137:4,8,15	adverse 80:6
78746-5546 2:14	academic 8:23 178:9,11,11	add 117:25 119:2	affect 7:20 55:20 144:8,25 197:15
8	acceptable 236:7	addition 22:10 83:24	affirmed 250:12
8 41:12 66:18 119:25 126:3 129:12 132:24 134:8 135:13 136:21 137:3,4	accepting 178:2	additional 8:3 89:4 121:17 159:12 246:6	affix 251:8
8,410,121 4:17 235:2	accepts 179:11	address 84:24 85:18 86:25 87:15 88:9,15,16 99:8 100:9 101:9	afforesaid 250:11 250:19
80 8:12 20:4,5 72:9,12 157:8	access 240:14,18 240:24	addresses 43:14 98:23 101:11 178:12	agent 236:15,23
84-3722 1:18 3:22 250:8 251:14	account 127:5 131:8 137:14 140:3 152:9 189:11	addressed 44:10 44:18 84:21 152:6	ago 38:11 162:10 176:11
9	accounting 189:21 192:3 193:11	addressing 87:22 124:21	agree 12:5 14:19 33:4 34:14 41:20 44:12 46:5,11,14 48:12 49:2 57:13 58:22 60:2 68:4 68:17 73:6,14 75:9 76:16 83:9 85:4,23 86:6,14 87:13 92:14 94:18 98:6,12 99:3,13 104:16,18 105:10 110:9 111:18 112:8 119:16 121:19 122:25 123:5 131:12 133:15 140:22 141:10 142:5
9 41:12 241:18 243:24	accumulated 26:25	adempas 129:18 130:9,23 132:16 133:3,5	
9,339,507 42:6	accurate 23:24 25:15 37:18 105:21 162:12 250:18 252:16	administer 53:24 55:9,24 56:10 228:14 229:15,23	
9,358,240 45:7	accurately 156:4	administered 61:21 75:5 101:19 106:21	
9,550,716 231:13	accused 9:7		
9,550.716..231 4:16	achieve 127:13 157:2,8		
90 77:25 81:21 83:14 85:8 118:2 119:3,13 156:25	achieved 13:17 33:15 142:10 187:16		
900 2:12	achieving 13:21 117:18 118:22		
90s 227:10	acknowledges 110:3,5		
9:35 5:8			
9:37 1:20			
9th 251:9			
a			
a.d. 1:20			

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

149:12 150:25 151:21 154:13,19 164:5,13,25 165:4 169:14 180:10 181:25 186:16 187:9 189:17 190:2,4,7 191:15 192:7,22 193:21 194:9,21 197:9 201:9 207:24 208:15,25 211:20 212:3,4 213:14,22 217:9 219:16 222:12,22 223:13 238:9,25 247:6 agreement 75:11 agrees 178:20 ahead 22:4 allege 38:14 alleged 49:12 55:15 74:17 78:19 80:23 83:21 84:3 98:2,14 99:22 100:3,20,25 238:20 alleviate 134:20 allow 158:17 238:16 allows 29:8 110:6 223:25 alternative 56:17 57:11 70:23 72:19 amendment 64:24 65:16 amount 158:5 183:18 222:7 amounts 236:5 analog 105:4 analogs 102:5 105:8	analyses 48:4 158:8 analysis 10:9,9 11:3,5 26:23 33:9 34:4,5,5 42:14 43:13,14 44:16,20 45:16,24 46:8 47:9 48:10 71:10 71:19,21,22 81:4 96:24,25 97:12 101:21 113:25 131:10 139:22 140:15 141:7 142:2 143:24 144:3,6 145:24 151:15 152:9 153:17 156:2,13 157:16 159:19 161:4,7,8 166:16 166:24 168:17 169:2 173:23 177:13 178:21 179:6 183:3 187:4 191:17 192:17,24 193:5 197:25 198:5,24 200:9 201:22 203:14,20 207:16 214:17 225:14,15 230:18 240:14 analyze 43:12 150:2,4 161:2 170:10 172:2 184:10 189:25 195:3 196:2 analyzed 31:6 33:22 36:21 153:20 154:16 155:18 159:21 167:9,14,15 172:5 176:7 198:3	199:22 239:20 analyzes 161:25 analyzing 30:15 140:4 160:23 166:10 169:5,16 193:22 andrea 1:16 3:21 5:11 250:6 251:13 annual 142:25 145:14 149:20 158:23 161:4 answer 6:25 7:9 19:9,14,14,18 29:13 52:5 79:8,9 100:15 137:17 153:18 154:3 181:12 answered 87:17 94:20 97:3,19 108:4 213:12 answers 7:16 9:5 19:11 66:4 155:16 antagonist 138:13 anticoagulants 113:9 anybody 212:22 apologies 144:21 apologize 91:3 apparently 218:19 appeal 1:3 appear 66:24 70:6 72:6 77:15 79:22 81:6 82:13 95:7 106:3 175:12 appeared 2:2,10 appears 23:22 24:2 40:3 42:8 69:7 76:16 80:14 82:10 104:24 105:21 116:19 118:8 119:19	134:8 158:14 236:22 241:18 apples 35:18,18,21 35:21 applicability 127:11 applicable 19:19 34:5 114:3 176:4 application 101:5 218:12 applications 213:4 applied 28:21 applies 46:8,12 186:22 224:4 apply 30:4 153:19 186:21 200:18 201:6 apportionment 10:7,10,24,25 11:2 11:15,19 appropriate 10:13 128:12 140:6,19 140:23 141:4 165:2 166:14 171:2 174:2 252:5 appropriately 48:10 approval 120:8 147:25 approved 80:9 105:12 114:5 116:4 120:4,10 134:8 138:4 157:2 157:8 approximately 5:7 7:22 19:24 21:13 147:14 149:10 april 1:20 5:7 251:10 area 31:19 34:24 109:3
--	--	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>arterial 36:12 105:17 114:5,14 114:20,22 115:4,7 123:13,24,25 126:25 128:9 130:3 134:19 135:18 137:10 139:7 157:22 158:4,10 159:22 177:9,15 232:20</p> <p>article 4:14 161:6 161:14 172:13 193:19</p> <p>articles 10:21 25:4 25:7</p> <p>articulated 85:16 178:8</p> <p>arts 25:24</p> <p>asked 13:5 45:15 87:17 90:17 94:20 97:3,19 104:9 108:4 113:19 203:24 209:12 213:12 246:18</p> <p>asking 33:19 69:14 90:12 96:7 100:5,18 108:23 113:23 134:18 139:9 143:9 182:11 215:12</p> <p>aspect 9:22 26:22 57:24,25 95:20</p> <p>aspects 26:24 31:6 42:20 47:5,24 78:20 80:23 84:20 87:25 88:7,18 89:7,16 90:19,20 90:24 91:2,5,8 92:25 93:4,12,18 93:22,24 94:3 97:9 99:22 100:3</p>	<p>100:21 102:18 108:7,22 111:21 227:21 230:10</p> <p>aspire 80:5</p> <p>asserted 226:14</p> <p>assessment 84:12 144:20</p> <p>assigned 235:5</p> <p>assignee 206:13 231:21</p> <p>assignees 220:25</p> <p>assist 21:12 42:19</p> <p>assistance 245:18</p> <p>assistant 24:10</p> <p>assisted 20:20 24:18</p> <p>associated 43:7 115:11 121:2 124:2,10 189:22 192:3 193:11 196:25 230:9</p> <p>assume 66:4 91:21 91:21 122:17</p> <p>assuming 58:8 212:17 225:20 239:10</p> <p>assumption 225:25</p> <p>attached 68:4 126:2 249:12 252:11</p> <p>attachment 36:4 37:7,22 38:3 71:3 71:15 73:2,5 126:3 129:12 134:8 135:13 137:3 141:12,18 141:21,22 152:21</p> <p>attachments 38:5 39:12,24 40:17,22 41:3 241:19,23</p>	<p>245:5,11 246:12 247:7,10,16</p> <p>attempt 135:7 152:3 155:20 166:22</p> <p>attend 29:2</p> <p>attorney 32:3 250:24 251:2 252:13</p> <p>attributable 57:16 58:12 76:18 86:22</p> <p>attributes 81:8 128:6 203:4 230:10</p> <p>austin 2:14</p> <p>author 190:23</p> <p>authors 175:24,25 176:18 190:25 191:5</p> <p>availability 201:22 202:9,11 202:22,24 203:6</p> <p>available 53:9 56:8,10 61:10 155:3,7,12,17,19 158:2 160:11,15 160:21 161:2 166:18 170:11 177:9 188:18,20 188:23 196:13,14 197:8 198:19,20 198:21 199:21,24 200:3 203:8,11 206:18 217:10 218:20 227:8</p> <p>average 34:14,19 35:2 149:22 156:20 158:25 159:16,18 161:6 173:3 174:13,16</p>	<p>averages 150:6 159:7</p> <p>aware 40:24 41:7 49:14 50:7 52:23 53:22,24 54:8 59:12 61:8,18,24 62:8,18 63:6 103:4 109:24 122:7 124:12 133:17 135:11,13 140:2 155:3,7,19 157:25 160:10,15 166:18 169:23,25 170:7 176:20,24 177:20,23 179:17 188:15 196:6 201:18 223:18,20 231:4 244:12</p>
b			
<p>b 2:22 36:4 71:3 71:15 73:2,6 126:3 129:12 131:24 132:24 134:8 135:13 136:21 137:3 141:12,22 152:21</p> <p>bachelor 25:25 26:2 67:20</p> <p>bachelor's 21:22 25:19,20,24</p> <p>back 34:6,7 43:8 61:7 64:10,12 75:23 101:21 106:5 112:10 113:4 115:13 116:7 129:6,8 137:25 147:12,17 149:8 155:23 161:3 172:12 184:25 195:16 204:21 214:8</p>			

<p>240:6,7 background 21:21 25:18 52:22 bad 146:7 ballpark 8:12,15 20:7 bargaining 10:16 10:16 base 172:21 based 10:10 19:10 57:17 58:4,5 60:9 63:10 68:19 70:22 70:24 72:16,19 74:3 76:16 79:23 80:14 82:21,25 83:22 88:21 107:2 107:3 114:4,4 140:18,21,25 142:3,12 143:20 143:24 145:10 146:7 147:7 162:12 163:22 164:12 175:6,11 181:9 184:14 186:25 187:21 188:4 199:4 215:23 216:10,20 217:3,7 220:7 227:19,22 basically 121:7 basis 79:3 80:16 135:5,16 143:6 157:16 168:17,17 169:21 170:24 176:9 197:7 bdelafield 2:16 becoming 145:17 began 212:25 beginning 64:9 129:5 204:20</p>	<p>behalf 2:2,10 5:19 5:22 18:22 believe 19:22 22:14 24:12,24 29:22 30:10,17 35:24 37:8 44:9 44:14 49:8 54:5 54:19,25 62:4 67:8 70:20 94:9 97:17 116:24 147:16,21 148:5,7 148:14 155:6 162:11 170:3,13 171:8 177:3 178:6 180:20 186:2 211:5 212:16 215:10,25 217:6 217:12 225:24 231:15 235:4 241:12 benchmark 173:9 173:13,19 174:2,7 174:20 benchmarks 155:25 156:6 benefit 74:14 101:4 122:2 218:10 benefits 43:7 56:16 57:4,11 73:20 74:18,23 85:13,17,19 88:3,6 200:11,24 best 7:16 19:12,18 73:17 102:2 149:7 187:23 217:20 218:8 224:22 better 94:10 123:6 139:11 beyond 175:3,4 185:10</p>	<p>big 222:23 billion 36:25 152:15,25 153:14 153:24 154:8,22 158:24 159:10,11 159:20 160:18 billions 150:20 biochemical 138:5 140:12 bit 118:17 block 210:8 221:4 221:7 226:15 blockbuster 151:3 blocked 210:4 221:18,25 223:5 225:2 226:20 230:16,24 232:9 238:10 239:14 blockers 113:10 blocking 89:23,24 93:20 204:8 207:12,15,21 208:2,4,7,15,20,25 209:13,15,21,23 210:13,21 211:11 211:13,15,16,23 212:4 213:8,18,23 214:3,13,14,18 215:2,6 216:6 219:8,10,17,19 221:7 225:7,7,15 226:3 227:18,25 230:13 232:16 238:18,22 blocks 207:17 208:8,20 209:2 blood 107:3 bloodstream 107:17 board 1:3</p>	<p>bobby 2:15 5:15 38:7 body 108:9,12 book 36:19 48:23 49:10 55:13 176:2 220:11 224:20 226:12 228:4 boston 40:19 bottom 244:23 brand 16:21 144:15 branded 32:21 break 7:12,14 63:25 128:16,21 152:19 174:13 204:12 239:23 breakdown 43:16 44:20 168:3 breaths 78:3 81:23 83:16 85:9 87:9 87:16 88:10 99:7 99:9,20,25 100:10 101:12,19 111:7 brennan 20:16,19 21:15 24:18 25:9 brennan's 21:20 brief 232:18 briefly 25:17 66:17 bring 191:12 195:7 bringing 210:8 221:10 broader 70:12 127:12 128:7 222:24 broadly 102:19 brought 194:5 221:25 bullet 129:19</p>
---	---	--	--

burroughs 221:4 221:14,25 223:14	11:6,8 13:12,25 14:10 15:15 19:4 20:22 22:13,16,18 27:5,10,13 28:2 31:7 33:10 35:16 44:4,23 45:19 59:15 67:11 76:6 83:20 90:19 94:4 95:21 108:14 110:24 122:5,5 135:4,4 143:7,21 153:17,17,25 154:9 157:16,16 170:24,24 172:3,3 183:9 186:5 195:25 196:17 197:14 201:16 204:9 239:21 240:14,24 241:9 241:11,13,21,22 241:24,25 242:6 242:23,25 246:9	135:2,3 136:14,14 190:12 224:2,4 230:9,10 231:6 234:19 243:10 certainly 27:5 28:16 29:6 30:2 69:22 167:13 185:13,16 196:21 226:10 227:9 certificate 250:2 certified 1:17 250:4,7 certify 249:10 250:8 cfr 64:25 65:17 challenge 121:21 224:13 challenged 9:20 10:19 change 47:8 109:6 109:20 110:12 187:18,25 199:19 246:7,20 253:9,11 253:13,15,17,19 changed 175:14 176:11 177:4 changes 252:9 253:5 channel 113:10 chapter 176:3 characterization 207:25 characterize 182:16 chart 40:4,7,10 98:8 156:21 158:22 164:6 241:17 242:2,5,9 242:13,17 244:2 246:12,25	charts 247:7,8,12 cheating 8:23 9:8 check 147:12 188:17 checked 71:9 checking 188:22 chemical 58:3 chemist 215:17 chemistry 215:19 220:3 chicago 1:19 2:6 40:19 251:9 choice 135:21 chose 162:20 chronic 129:20 130:10,21 132:21 cimas 2:13 circulating 107:2 circulatory 106:14 108:3 circumstance 166:5 189:10 190:11 193:25 197:13 226:25 circumstances 136:15 143:18 166:5 185:22 201:12 207:10 citations 87:20 180:6 cite 25:4 43:6 139:3 161:22 163:7 172:9 179:13,14,19,23 191:21 192:15,18 247:3 cited 40:13 164:18 175:25 176:15 179:21 180:4 182:9 203:21 220:19 242:19
c			
c 83:21 90:10 c.f.r. 64:20 65:13 66:13 calcium 113:9 calculate 37:4 70:23 calculated 34:23 35:24 69:10 158:3 173:24 calculation 72:8 calculations 21:10 21:14,16,18 37:23 38:3 172:15,22 247:11,17,21 calibration 10:15 california 67:21 call 116:9 121:16 122:15 called 1:12 6:6 10:9 67:3 cancer 150:18,20 capable 207:2,4 capacity 129:22 130:4 capital 2:12 189:21 192:2 193:10 capitalization 183:8,12,16,22,23 184:5 captures 156:5 car 59:24 60:4,9 60:12,14,16,17,24 care 67:24 148:15 career 171:5 carefully 252:3 case 4:19 8:18 9:2 9:17,25 10:12	cases 8:3,7,10,13 8:14 12:12 14:20 15:6 16:3,14,20 17:6,16,17 18:22 19:11,15,19,21,25 20:12 21:4 27:18 27:23 29:9 30:5 33:12 66:6 67:12 103:17 104:21 161:17 168:16 185:18 205:4,9,14 205:20 228:8 229:12 241:2 ceo 116:8 certain 11:17 12:4 13:9 14:17 20:25 49:21 50:4 51:11 86:9,11 87:25 121:24 126:18,21		

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>cites 41:4 civil 1:14 claim 31:20 43:16 43:19 44:16 46:7 47:7 50:3 51:12 63:15 69:7 70:8 82:11 83:13 84:9 84:12,25 86:9,11 87:2,25 101:10 228:14 229:14 235:25 236:8,9,25 237:8 claimed 42:13,23 43:7 49:16 52:20 55:7,10 73:25 81:9 82:4 84:6 85:13,16,19 87:23 88:3,7,18 90:7 91:6,13 94:6 207:19 208:10 209:5 230:21 claiming 215:14 216:5 236:14 claims 43:9,12,15 44:3,6,10,13,19,21 44:21,23 45:18,24 46:5,8,9,12,16,18 47:21,22 48:13 49:3,21 51:10 54:14 55:17,20 61:21 62:15 63:11 63:20 77:24 81:20 84:20 86:4 87:8 90:14 95:13 98:3 227:6 235:24 236:21 238:7 clarify 33:18 44:22 72:21 93:23 101:23 169:4 171:15</p>	<p>class 30:6 105:19 115:10 123:23 124:7,16,24 125:5 125:6,12 126:7,11 126:14 129:23 130:5 133:9 136:22 138:16 classes 124:13 125:17 134:9 137:21 139:17 clear 38:19 52:7 69:18 77:22 81:18 152:12 226:13 clearly 95:10 clinical 31:5,23 51:17 57:4,25 63:23 68:13 73:19 74:14,23 75:16 76:22 81:4,11 87:25 88:3,6 92:20,21 95:6 97:9 98:14 100:23 100:24 101:3,17 102:18 103:5 107:7 108:18,22 130:5 139:10,11 148:2,18 218:10 224:8 clinically 69:2 81:3 clinician 50:11 96:14 102:7,12,14 138:15 clinicians 102:21 closer 159:16 collection 211:15 collectively 43:15 44:11,19 46:6 college 25:21 colleges 29:2</p>	<p>column 43:9 135:12 combination 162:22 164:16 237:2 238:2 combined 162:16 come 17:9 117:17 118:13,18,21 145:4 comes 27:19 30:7 31:18 41:15 59:2 101:4 121:17 144:16,17 145:7 218:10 coming 145:16 commencement 250:10 commercial 4:15 12:16,21,25 13:15 13:17,21,25 14:6 14:15,22 15:3,9,16 15:19 16:4 17:12 17:14,19,21 30:15 33:5,9,15,23 34:16 35:5,11 47:4 53:10 55:21 56:9 58:7,11 59:9,24 67:3 68:23 76:24 77:21,22 78:22 80:22 81:6,18 82:6 83:21 84:3,5 84:19 85:20 86:12 86:21 87:3,10,23 88:12,19 89:8 90:21 91:14,16 92:12,16 93:4,13 95:12 98:3 111:22 127:3 143:14 145:25 146:18 147:7 148:8,16,25 152:16 153:15,21</p>	<p>153:25 154:6,9,17 156:2 157:2,9,13 157:18 160:24 164:24 165:6,15 166:2 169:6,17 170:18 171:6,17 172:2 174:2,12,20 180:14 181:3,8,17 183:24 184:7 185:19 186:8,24 189:7,18 190:9,20 191:8,17,24 192:13,17,23 193:4,7,23 194:13 194:22 195:10,13 195:15,22 197:10 197:16,21,25 199:17 200:8,10 201:10 202:12,20 203:18,25 217:24 218:21 219:3,7 234:2,7,11 238:20 commercialization 189:23 192:4 193:12 208:21 238:19 commercialize 225:13 239:8 commercialized 217:18 commercializing 225:10 commercially 13:6 13:10 14:11,14 60:16 61:10 173:10,13,19 174:15 177:8 217:10 218:20 219:12 common 51:6 165:16</p>
---	--	--	---

<p>commonly 102:25 117:20 118:23</p> <p>companies 73:4 90:6 166:19 223:25 230:20 239:19</p> <p>company 30:20 32:8,20,25 181:5,6 181:9 182:3 206:12 224:8,25</p> <p>compare 127:18 132:2 151:12,22 151:24 152:3 156:15 220:23</p> <p>compared 35:25 44:21 137:16 156:10,25 157:7 161:5 167:24 181:15 199:9,12 201:22</p> <p>compares 140:11 158:23</p> <p>comparing 80:5 98:8 101:22 143:23 158:12 169:20 187:5</p> <p>comparison 35:18 35:22 58:6 127:13 141:14 142:16 162:23 173:6</p> <p>comparisons 166:11 173:2</p> <p>compete 61:19 112:24 113:20 115:23 130:22 132:18,23 135:17 136:8,16 139:25</p> <p>competes 112:21</p> <p>competing 53:18 54:9 61:17 70:12 112:16 126:3</p>	<p>128:5 152:7</p> <p>competition 53:10 53:16 112:15 113:14 116:2,14 121:5,6,12,17 128:3,8 140:8 145:11,13,21 185:11</p> <p>competitive 145:22</p> <p>competitor 199:8</p> <p>competitors 70:13 114:9</p> <p>complete 23:23 175:21</p> <p>completed 67:22</p> <p>compliance 75:6</p> <p>component 60:3</p> <p>composition 227:24</p> <p>compound 57:16 58:3 101:5,6 215:4,21 217:18 217:23 218:3,11 218:12 232:23</p> <p>compounds 74:6 74:10 76:18 95:8 110:5 238:2</p> <p>comprise 235:19</p> <p>comprises 236:3</p> <p>comprising 114:8</p> <p>concept 148:4</p> <p>conceptually 194:25</p> <p>concerning 250:13</p> <p>conclude 59:8 60:12 80:17</p> <p>concluded 248:8</p> <p>concludes 248:5</p> <p>conclusion 43:23 49:19 50:12 52:6</p>	<p>58:23 63:2 92:19 97:7 111:18,19,24 112:7 165:12 166:4 169:19 170:23 184:11 186:21 188:2 229:19,25</p> <p>conclusions 41:20 97:6,9 141:24 167:2 168:5,8,14 168:18,24 169:3 171:2 172:4,6 181:8 186:14 199:4 200:5 203:20,23</p> <p>condition 130:23</p> <p>conditions 131:24 132:2</p> <p>confidential 197:5 197:7</p> <p>confirm 62:5 147:18 149:8</p> <p>confirmation 109:5</p> <p>confirmed 178:17 228:2</p> <p>confusing 209:19</p> <p>connect 80:22</p> <p>connection 32:8 58:5 60:13,21 92:23 93:3 98:2 111:20 240:19</p> <p>connective 124:2</p> <p>consider 26:17,19 27:4 32:4 34:15 35:5 74:21 78:7 141:6 143:2 148:22 155:24 160:22 183:15,24 184:7 189:7 193:22 194:13,22</p>	<p>200:9,10 201:21 202:15 214:18,25</p> <p>consideration 14:6 14:22 15:4,8,8,20 15:22 16:4 17:15 17:22 186:25 190:6 203:17</p> <p>considerations 203:22,23</p> <p>considered 28:8 156:23 189:18 190:9 191:23 201:25</p> <p>considering 32:17 34:18,21 35:9,23 38:16 59:24 181:21 196:8 199:20 210:6</p> <p>consistent 85:15 95:4 107:19 125:2 128:12 140:6 160:5 171:23,24 194:11 218:25</p> <p>consistently 245:10</p> <p>constitutes 250:17</p> <p>consultant 27:3,23 30:23</p> <p>consultation 32:15</p> <p>consulted 32:7,24</p> <p>consulting 17:16 28:6 80:3</p> <p>contain 40:17</p> <p>contemplating 212:9</p> <p>content 10:9</p> <p>contents 241:6</p> <p>context 10:12 11:20 28:16 30:10 30:12 33:7 74:19 103:2 107:24</p>
---	--	--	---

108:3 132:8,8,9 149:23 151:16,18 166:12 174:11,11 180:11,16 195:5 continue 142:21 continued 176:14 continuing 142:14 contrast 101:3 contribute 30:3 86:10 203:6 contributed 180:24 contributing 82:5 contribution 11:21,25 12:3 180:18 181:14 contributions 100:24,25 101:17 191:4 conversations 155:10 copies 38:7 247:8 copy 4:16,17 23:20,24 25:15 37:18 39:5 103:15 103:20,21,21 104:20 205:9,15 205:21 228:6 231:12 234:25 corp 1:8 corporation 5:6 correct 9:9 12:4 12:12 14:2 17:24 18:22,25 24:11 25:5,12 28:10 29:11,20 30:21,25 31:4,10,15 32:2 35:6 36:15,16,19 36:20,22 37:2,3,5 39:6,24 40:4 42:7 44:8,17 45:25	46:13,16,18,25 48:5,15,24 50:18 51:24 54:10,12,16 54:24 56:22 57:22 58:14 60:4 61:11 61:25 62:21 63:9 63:21 66:23 68:6 68:20 69:25 70:19 71:6,10,14,18,24 73:3,7,11,16 74:15 75:19 76:20 77:3 78:16 79:14,21 80:13 82:7 84:13 84:25 85:20 88:12 88:22 89:2 90:24 91:17,21 92:9,12 92:17 94:4 95:13 95:25 96:15,20,24 96:25 97:2 98:9 98:19 99:10,25 100:2,11 101:12 101:25 105:9,12 105:20 106:2 107:13,18 108:20 109:2,5 110:17 111:8,25 112:22 113:15 115:15,19 115:24 117:2,9 118:4,14,19,24,25 119:5,14,18,22 120:5,11,15 122:13,15,22,25 123:7,14 125:7 126:11,14,22 127:23 129:15 130:11,17,23 131:11 132:11,19 133:10,23 135:22 139:4,5,25 140:12 140:16,21,22 141:2,3,9,16,20	144:9 145:2,11,17 146:3,9 147:4,20 148:13 149:5,17 150:5 151:19 152:4 153:2,8 154:9,22,25 155:2 155:15 156:8,17 157:14,19 158:6 158:11,24 159:5 160:9 161:7 162:2 162:6,10,23 163:20 164:7,12 165:3,8 166:8,16 167:5,18,25 168:20 169:8 171:18 172:10,15 173:3,7,8,23 174:10,23 175:5,9 177:10,16 178:23 179:15,25 180:19 183:8 184:17,18 185:6 186:19 187:8,12,20 188:8 188:9,13 189:4,5,8 189:12 192:18 194:19 196:3 197:22 198:6,7,24 200:12 201:2 202:9,17,24 203:18,19 204:2,3 204:9 206:19 207:3,7,13,19,23 209:5,17 210:14 211:2,8,9,11,24 212:19,21 213:11 213:18 214:4 217:5,6,11,12,14 217:19 219:12 220:9,25 221:5,16 221:20 222:8,21 224:3,10,14 225:3	225:23 226:3,18 226:23 227:6,21 228:15,22 229:16 229:23 231:22 232:6,11 233:2,7 233:19 234:3 235:6 236:16 237:3,13,22 238:12 239:3 240:21 241:2,3 242:9 245:2,8 246:22 247:3,17 249:11 corrected 26:2 243:18 corrections 249:12 252:4,6 correctly 244:2,9 correctness 178:18 correspondence 23:2 corresponding 40:7 cost 196:2 costs 189:3,6,22 192:3 193:11 196:25 counsel 5:12 7:10 18:9 20:10 24:25 39:9 42:24 96:4,7 155:8,10 217:8 243:20 245:19 250:24 251:2 count 12:17,22 18:4 147:10 countries 165:6 169:16 170:3,11 171:7 county 249:4
---	---	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>couple 16:25 17:4 124:5 240:11 244:21</p> <p>course 27:22 28:5 30:2,7,16 34:10 113:3,22 121:16 171:11 195:2</p> <p>courses 29:24</p> <p>court 5:11,13 6:18 10:11,19 240:20 243:15 252:16</p> <p>courts 1:15 10:20</p> <p>cover 49:12 55:13 55:15 228:21 230:3</p> <p>coverage 106:22 128:6 200:23</p> <p>covered 47:8 48:23 59:20,21,25 200:25 230:7,7</p> <p>covering 89:16 228:19</p> <p>covers 215:4,20 216:24 220:4 233:12</p> <p>create 71:14 140:17,20,24 162:23</p> <p>credible 94:24</p> <p>credit 78:10</p> <p>crestor 17:9</p> <p>criteria 190:8</p> <p>critical 67:24</p> <p>criticisms 177:21 177:23 178:5,13 178:19</p> <p>critiques 178:7</p> <p>csr 1:17 3:22 251:13</p> <p>cteph 129:21 132:11</p>	<p>current 147:10</p> <p>customer 120:24 121:5</p> <p>cutoff 159:8,9</p> <p>cutoffs 158:17</p> <p>cv 25:12,15,23 26:11 27:12 68:4 68:9,20 79:17 103:9</p> <p>cycle 187:23</p> <p style="text-align: center;">d</p> <p>d 4:1,12</p> <p>d.c. 2:21</p> <p>data 70:7,18,21,24 71:15 72:16 127:10,15 131:14 131:18 136:17 137:19,23 140:4 142:13 162:10,15 162:16,20 163:23 164:6,9 168:6,8,13 175:7,8,12 177:17 177:19 178:7 198:12,17 199:2 200:6 202:2</p> <p>date 5:6 19:23 184:16 214:2 227:15 231:25 235:10 252:8 253:23</p> <p>dates 34:8 175:11</p> <p>david 5:10 191:22</p> <p>day 1:19 249:21 251:9</p> <p>days 252:14</p> <p>decade 179:18</p> <p>decide 94:23</p> <p>decile 150:5,8,17 156:16,19,19,20 156:25 157:7,13 157:19,22 158:6</p>	<p>158:11,14,15,16 158:24 159:2,7,8,9 159:10,14,14,15 159:17,19 160:3,4 161:5 167:17 173:2</p> <p>deciles 150:23 151:2 155:24,25 156:8,12,14,22 159:23 187:5,7</p> <p>decision 32:9 199:17</p> <p>decisions 28:25,25</p> <p>declaration 4:18 21:6 22:20,20 23:21,24 24:4,10 24:15,19,21,23 25:2,5,11 26:10 35:20 37:9,18,24 37:25 38:11,17,20 39:11,12,13,17 40:9,11,16,23 41:4 42:25 43:6 44:7 56:14 57:14,18,21 65:8,23 66:13,18 68:3,10,20 70:4,17 70:19 71:2,13 72:3,20 73:24 77:7,17 79:17 83:5,12,19 86:17 87:22 88:23 89:3 89:10 90:10,23 95:3 98:9 99:10 106:5 110:3,15,23 111:23 112:11 124:22 125:10,25 129:11 138:2 144:5 146:14 158:13 166:17 168:3,22 172:10 173:25 179:16,24</p>	<p>186:15 189:15 198:6 203:21 204:4 206:2 209:7 215:24 216:23 220:8 225:20 228:12 238:12 239:20 241:9,14 241:21 242:7,18 242:20 244:22 245:4,4,14,16 246:24 247:2,8,17 247:22</p> <p>declarations 20:21 20:24 21:11 35:15 36:22 38:10 41:7 41:9,11,17,21 48:7 56:25 57:3,11 66:22 67:7 77:12 82:18 112:5 241:2 241:7</p> <p>declare 67:19</p> <p>decline 119:25 145:3 184:19,23 185:9</p> <p>declined 184:21</p> <p>declining 142:11</p> <p>decrease 70:10</p> <p>decreased 69:25</p> <p>decreasing 143:6</p> <p>deemed 252:16</p> <p>defer 39:9 47:17 50:11 95:16 102:12 103:9 106:18 108:6 228:17 229:2</p> <p>define 140:4</p> <p>defines 180:12</p> <p>definitely 26:24</p> <p>definition 70:16 122:15 123:12 147:5 208:8</p>
---	---	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

deforest 1:11 4:4 4:18 5:1,4,24 6:1 6:5,15 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 15:1 16:1 17:1 18:1 19:1 20:1 21:1 22:1 23:1 24:1 25:1 26:1 27:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1 53:1 54:1 55:1 56:1 57:1 58:1 59:1 60:1 61:1 62:1 63:1 64:1 65:1 66:1 67:1 68:1 69:1 70:1 71:1 72:1 73:1 74:1 75:1 76:1 77:1 78:1 79:1 80:1 81:1 82:1 83:1 84:1 85:1 86:1 87:1 88:1 89:1 90:1 91:1 92:1 93:1 94:1 95:1 96:1 97:1 98:1 99:1 100:1 101:1 102:1 103:1 104:1 105:1 106:1 107:1 108:1 109:1 110:1 111:1 112:1 113:1 114:1 115:1 116:1 117:1 118:1 119:1 120:1 121:1 122:1 123:1	124:1 125:1 126:1 127:1 128:1 129:1 130:1 131:1 132:1 133:1 134:1 135:1 136:1 137:1 138:1 139:1 140:1 141:1 142:1 143:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1 168:1 169:1 170:1 171:1 172:1 173:1 174:1 175:1 176:1 177:1 178:1 179:1 180:1 181:1 182:1 183:1 184:1 185:1 186:1 187:1 188:1 189:1 190:1 191:1 192:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1 201:1 202:1 203:1 204:1 205:1 206:1 207:1 208:1 209:1 210:1 211:1 212:1 213:1 214:1 215:1 216:1 217:1 218:1 219:1 220:1 221:1 222:1 223:1 224:1 225:1 226:1 227:1 228:1 229:1 230:1 231:1 232:1 233:1 234:1 235:1 236:1 237:1 238:1 239:1 240:1 241:1 242:1 243:1 244:1 245:1 246:1	247:1 248:1 249:7 249:16 degree 21:22,23 25:20 28:17 51:6 52:7 113:2,22 119:24 120:2 degrees 25:20 delafield 2:15 4:5 4:7,9 5:15,15 6:10 13:23 14:8 16:12 22:11 23:6,12 38:9,18 39:2,15 41:24 44:2 45:4 46:10,23 47:6 48:2,20 49:13 51:20 52:11 53:20 54:7,22 56:20 58:24 60:22 61:6 61:23 62:7,17 63:4 64:2,11,16 79:10 82:14 83:3 83:10 84:23 85:5 86:2 87:5,14 88:20 91:24 92:7 94:2,17 95:9,18 96:9,13 97:13,23 98:16 99:4,16 100:17 101:20 103:13 106:23 107:10 108:13 109:15 110:14 111:4 112:9 117:14 118:11 119:11 127:24 128:17,20 129:7 130:15 131:7 132:15 133:16 134:12 135:6 144:2,14 149:2 151:9 161:12 163:5 165:17	169:13 170:9 171:4 172:7 179:4 181:24 182:10,20 183:5 189:16 190:16 193:20 195:24 200:20 201:8 203:9 204:13,24 206:24 208:24 210:19 212:6 213:16 214:16 215:22 218:16 219:5,20 222:5,10,11,18 229:3,9 231:10 232:24 233:15,24 234:9,23 236:24 237:10,18 238:5 238:24 239:9,22 240:7 242:11,15 243:6 244:20 245:24 246:17 247:14,24 delay 130:5 deliver 49:23 delivered 50:3,7 51:16 54:9 106:11 delivering 51:7 61:8 delivers 53:19 delivery 31:4,9 56:17 57:12 74:2 230:9 demand 60:17,24 demonstrate 153:21 154:6,16 demonstrates 83:5 depend 26:22 110:13 166:4 depending 129:14 depends 28:15 33:6,16 34:17
---	---	---	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>35:7,7,12 121:22 122:3 132:5 134:16 153:16 157:15 159:8 160:25 172:3 176:23 184:9 185:21 189:9 190:10 193:24 194:15 195:5 197:12 201:11 213:19 226:24 231:4 deposed 6:16 8:2,5 deposing 252:13 deposited 107:4 107:18 deposition 1:11 5:4 18:10,17,21 19:3 20:11,20 40:20 190:13 231:7 234:20 241:6 243:11 248:5,7 249:9 250:14,19,20 252:3,11,14,15 depositions 1:16 derived 88:7 derives 78:17 describe 9:13 13:12,22 14:5,12 33:24 46:4 51:7,8 52:13 92:4,5 93:7 93:10 98:7,14 102:19 151:20 157:4 163:3 166:9 178:18 186:20 193:18 described 24:16 44:18 48:13 49:16 50:8,17 51:23 52:3,17,21,25 54:2</p>	<p>54:14 58:9 98:13 114:24 145:18 146:12 164:17 216:14 247:22 describes 55:3 120:24 230:8 describing 41:13 118:8 192:24 description 93:6 106:19 124:10 design 56:3,7 59:6 designated 207:12 designates 148:12 designation 146:17 designed 133:10 136:22 233:18 desired 117:19 118:23 despite 224:24 detail 84:10 100:20 details 247:20 determinant 35:22 determination 34:6 158:18 determine 166:22 180:4 determined 12:2 determines 145:22 determining 11:20 11:24 develop 210:3 227:4 developed 29:7 212:11 213:25 developing 210:7 221:4 232:10 239:7 development 21:23 30:9 148:9</p>	<p>161:15 164:20 189:23 192:4 193:12 208:22 209:25 219:4 238:20 device 100:25 101:17 228:14 devices 96:20 diagnosed 113:5 differ 105:25 difference 41:15 47:13 58:2 60:16 72:21 81:8 86:21 95:7 110:4 114:15 114:16,19 115:4 125:16 differences 41:8 44:13 47:19 57:14 74:2,4,5 75:3 76:15 78:16,18 97:10 106:10 131:9,13 133:14 135:14 137:15 140:3 244:13 different 11:9,10 14:18 19:11,14 41:5,6 47:11 48:4 51:10,14 55:25 60:15 70:16,24 71:21 72:13 74:7 74:10,10 76:18 82:22 86:4 97:25 109:25 115:11,14 115:17,18 118:3 123:13 125:12,13 128:6,6,7 129:13 129:14 131:10,21 133:9 135:8,11 136:12,13 137:20 137:20,22 139:8 139:13,13,17,18</p>	<p>139:21 142:7,8 145:10 170:2 171:7 181:7 220:24,25 242:24 differentiate 135:8 139:23 differentiation 43:16 197:19 differently 96:12 125:6,13 differs 19:9 digoxin 113:9 115:24 116:3 dimasi 177:21 178:13,17,21 179:7 184:13 187:6,15 direct 44:20 107:3 directed 102:7 direction 20:15 21:6,16 250:17 directly 21:18 107:12 132:18 171:17 251:4 disadvantage 122:11 disagree 69:4,5,13 69:15 70:17 75:14 82:16 92:8,10 94:19 95:10 179:6 179:8 disagreement 75:12 82:20 disagrees 79:2 disclose 144:6 224:24 disclosed 216:9 221:20 232:5 235:18 discloses 215:9,14 216:6 217:3,5</p>
---	---	--	---

<p>220:7,9 233:6 disclosing 155:9 disclosure 67:14 215:13 discredited 178:9 178:10 discuss 29:16,18 29:20 57:14 69:11 69:12 85:7 89:16 89:18 100:23 110:17 111:9 discussed 20:19 30:8 42:23 56:14 71:13 73:23 75:17 81:17 99:6,14 123:12 175:4 187:10 221:6,23 225:6 230:4 232:14 238:15 discusses 83:12 111:11 discussing 111:7 129:13 discussion 68:23 111:14 217:7 227:20 245:18 discussions 22:23 disease 124:11,19 124:24 139:20 diseases 124:2 disincentive 211:17 225:8,12 disincentives 210:3 222:7 238:19 disincentivize 209:24 disincentivizes 208:22 dispute 8:22 76:12 78:13 81:13 94:23</p>	<p>dissertation 28:20 29:10,15,19 distinction 125:17 154:11 distinctions 46:6 140:5 distribution 175:22 district 1:15 240:20 diuretics 113:9 doctor 67:20 79:14 doctors 102:22 document 23:4,10 23:18 37:15 41:22 42:4,10 45:2,9,12 83:25 103:19 104:7,23 161:10 161:19,21 190:12 205:5,11,13,17,23 228:10 231:6 234:19 235:3 243:10 244:13,14 246:12,13 documents 40:13 43:5 64:14 65:5,7 65:20,23 103:11 104:2 161:24 179:14 182:9 204:22 205:2 206:2 doing 34:3 116:6 168:15,16 172:11 187:22 222:3 223:6 225:3 234:6 252:7 donovan 22:21 23:2 41:7 42:25 57:25 74:4,20 75:21 76:4,13,14</p>	<p>78:14,16 79:2,4,12 80:17 81:13,14 82:21 88:22 89:9 91:7,10,11,20 94:4 94:9,19,24 95:16 96:23 97:6,25 103:4,10 106:7,18 107:23 108:6 109:7,17 110:2,9 139:3 216:11,25 217:4 donovan's 57:18 57:21 76:9,22 78:11 81:10 89:2 89:10 90:23 92:15 95:24 215:24 220:8 227:20 dosage 105:23 dosages 105:25 dose 51:9 dosing 74:2 77:25 81:21 83:14 85:7 85:12 87:9,16 88:9 99:7,8,20,25 100:10 101:2,11 101:15 111:7 double 15:23 doubled 183:13 doubling 183:17 doubt 71:22 176:5 dozen 32:16 179:17 dr 5:4,24 6:11 22:21 23:2 38:23 41:7 42:25 56:25 57:18,21,25 66:14 67:19 68:18 71:10 74:4,20,22 75:18 75:21 76:4,9,9,12 76:13,14,16,22 77:2 78:11,11,14</p>	<p>78:16,25 79:2,4,4 79:12,18 80:17,19 80:25 81:10,13,13 81:14 82:21 84:11 84:17 85:16 87:8 88:22 89:2,9,10 90:15,23 91:7,10 91:11,15,20,22 92:9,10,15 94:4,9 94:12,19,19,24 95:5,16,24 96:23 96:25 97:6,14,25 98:4,18 101:10,22 103:4,10 106:7,18 107:23 108:6 109:7,17 110:2,2,9 110:9,16,21 139:3 182:17 215:24 216:11,25 217:4 220:8 227:20 240:11 243:15 246:5 248:2 draft 21:6 24:22 24:25 drafted 20:25 21:4 drafting 24:18 dramatically 176:22,24 draw 41:20 52:10 92:22 111:17,24 122:23 168:4,7,14 168:23 169:2,3 181:7 186:14 203:22 drawing 97:6 112:7 167:2 168:24 199:4 drawn 171:3 172:6 186:15 200:5 229:18,25</p>
--	---	---	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>drive 1:19 2:5 88:18</p> <p>driving 97:10 114:15</p> <p>drug 30:25 31:4,9 32:10 36:7,17,21 82:5 86:22 108:8 119:5 121:11 126:6 127:16 128:10 131:14,15 131:16,21,23,24 133:8 137:16 140:21 141:15,19 142:4,22 144:9,16 145:6,8 146:18,25 147:6,23 148:7,12 148:13,23,23 151:18,18,22 152:13 153:7,15 153:19,24 154:7 157:12 161:16 163:12,25 167:16 167:17,24 173:20 174:15,18 175:22 176:7,21 200:23 202:2,3,6,9 218:22 224:9,10,13</p> <p>drugs 17:8 36:23 53:17 72:10 107:12 114:3,4 123:10 126:17,20 127:6,18 129:13 131:9 132:3 135:8 136:21 137:15,20 138:17 140:11 141:16 142:8,14 142:17,20 144:7 145:16,17 150:5,8 150:9,11,16,19,19 150:23,25 151:3 151:12,24 152:4,6</p>	<p>152:7 156:25 157:2,7,8,19,22 158:4,9,24 159:2 159:21 160:2 161:6,25 162:15 164:7 166:23 174:13,22 176:21 177:2,14 181:15 185:8 198:24 199:12,16 200:25 201:23 203:7,10 203:12</p> <p>dual 117:20 118:23</p> <p>due 177:4 202:10 218:21</p> <p>duly 6:2,7 250:11</p> <p style="text-align: center;">e</p> <p>e 4:1,12 84:2 89:22 253:1</p> <p>earlier 87:20 104:9 111:12 113:19 123:12 149:6 152:20 179:9 209:12 213:15 221:6,23 238:16</p> <p>earliest 231:24 235:10</p> <p>early 19:22 224:21</p> <p>earn 189:20 191:25 193:9</p> <p>earned 189:19 191:25 193:9</p> <p>earning 27:17</p> <p>earnings 116:9</p> <p>easier 202:3</p> <p>easily 59:7</p> <p>economic 26:23 31:7,19 32:5,22 42:18 47:20 49:11</p>	<p>57:24 58:4 76:21 78:15,21 81:15 84:2 89:25 91:13 92:22,23 94:25 97:12 127:15 131:17 136:17 137:23 139:22 146:20 148:6 165:14 171:22 189:3,6 191:10 193:2 195:6 210:10 221:9 222:6,20 225:8,11 239:2</p> <p>economically 4:15 173:18 174:18 176:18 190:19</p> <p>economics 21:23 22:7 25:22,24,25 26:5,6,17,20 28:9 28:13,22,22 30:8 179:21</p> <p>economist 17:16 30:4 31:13,24 42:16 48:8 51:19 52:20 76:15 96:17 102:8 109:3 138:14 139:21 229:8 237:7,17</p> <p>economists 179:6 191:15 192:21 193:17</p> <p>edit 21:7</p> <p>education 29:7,23</p> <p>educational 21:21 25:18</p> <p>effect 106:25 142:2</p> <p>effective 108:9,12 125:16 131:15 136:14 203:7</p>	<p>236:5</p> <p>effectively 207:17 209:2</p> <p>effectiveness 123:21 126:6 128:7 131:20 135:2 137:22</p> <p>either 20:12 117:19 118:23 140:21 158:14 167:22 179:24 212:18 245:13 246:11</p> <p>electronics 9:17</p> <p>element 195:3</p> <p>elements 84:9,12 86:5,9,11 87:2 101:10 146:2</p> <p>emails 22:25</p> <p>embody 46:16,17</p> <p>employee 30:22 250:24,25</p> <p>employer 22:9,13</p> <p>enabled 225:22</p> <p>endnote 191:20</p> <p>endothelin 138:13 138:16,19</p> <p>england 170:16,17 170:19</p> <p>enter 107:17</p> <p>entered 68:25 69:16</p> <p>entire 90:17</p> <p>entitics 210:2</p> <p>entitled 65:12,16 161:15 190:19</p> <p>entity 210:6</p> <p>entrant 121:20 122:12,16,21</p> <p>entry 36:15 123:2</p>
--	--	---	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

eon 231:21 232:8 233:25	94:16 97:12 171:13 174:7 197:20	example 32:12,20 35:16 50:2,5 51:13 55:23 59:2 59:23 60:7,23 72:7 86:20 93:19 100:22 101:7 116:15 123:19 125:4 126:5 130:9 131:20 135:25 136:11 144:15 146:17 165:18 173:19 175:24 181:4 199:7,10 200:21 207:6 224:7,11 226:16 230:19 235:25	81:16 82:12,16 83:20 103:15,16 104:5,20 110:24 111:6 112:11 113:24 120:6 123:19 125:25 129:11 141:12 161:14,16 163:8 172:13,17,25 190:14,18 205:2,4 205:7,7,8,13,19,20 206:5 219:22 228:5,7 229:10,12 231:8,12 234:21 234:25 241:8,10 241:10,20,22 243:4,7,12,17,19 243:25 244:3,7,9,9 244:10,14,15 246:6,7,19,20
epoprostenol 236:10	evening 243:20	examples 17:3,5,9 32:16 185:8	exhibits 64:18 65:10 66:11 81:5 105:14 126:2 242:22,24 245:21 246:25
equal 203:7	event 77:24 78:2 81:20,22 83:14,16 85:9	exceptional 149:22	expect 213:2 232:15
equally 135:17	events 80:7	excerpt 101:16 117:12 182:8 193:16	expected 189:20 191:25 193:9
equipment 48:13 50:16 59:13 62:21	everybody 69:20	exchange 22:25	expense 234:12
errata 252:5,7,10 252:13	evidence 15:2,11 15:13 49:14 50:14 51:22 52:9 56:15 57:10 61:25 62:9 63:6,14 83:5 89:18 116:2,13 125:18,22 131:3,5 132:20 140:7,7 141:4 143:20 168:20 179:24 180:13 186:8 191:9 227:7 232:17	exclude 114:18 233:23	expenses 189:12
esq 2:7,15,22	evolve 32:18	excluded 9:11,22 12:8	expensive 199:3 200:3,22 222:17
essence 191:16 192:16,22	exact 19:23 20:2 67:13 145:9 224:18 228:17	exclusive 227:10	experience 26:25 27:3 29:8 76:5 79:13 94:10 103:5 125:3 155:13 168:15 188:21 227:23
established 121:25	exactly 21:3 158:16	exclusively 93:18	expert 7:23 8:2,5 17:17 22:16,18
establishing 123:21	exam 4:5,6,7,8,9	exercise 129:22 130:4 137:11	
estate 28:24	examination 1:13 6:9 240:9 244:19 246:3,16 250:10	exert 106:25	
estimate 20:2	examine 33:14 90:3,5 93:19,20,21 136:17 192:12 196:22	exhibit 4:13,14,16 4:17,18 23:8,14 27:11 36:3 37:12 37:23 39:3 42:2 45:6 64:18,22,23 65:11,15 66:6,19 67:10,17 71:2 77:9,11,20 80:3	
etiologies 123:23	examined 6:7 90:13 137:24 199:5		
evaluate 31:18 53:4,6,16 55:18 59:18 62:13 63:2 63:6,14 135:4 160:21 165:16 170:24 179:18 180:7	examining 34:10		
evaluated 33:11 46:5 53:17 72:4 125:9,22 131:6 171:6 178:8,16 194:11 229:8 234:17			
evaluating 13:11 26:23 32:20 38:21 59:20 125:18 164:24 165:15 170:25 172:2 174:20 186:24 192:13 227:23			
evaluation 15:12 57:23 80:21 83:22			

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

26:17,20 27:4,6,6 27:9,14 28:2,4,8 28:14 29:8 30:24 31:3,10,11,14,21 31:25 50:12 63:17 69:11 95:21 96:19 97:16 139:12 expertise 28:6,18 29:6 30:3 31:17 31:20 102:20 103:3 109:4 experts 34:23 47:18 78:13 171:25 expiration 184:16 185:20 186:5 213:21,23 214:2 214:15 219:19 expired 211:4,10 211:21 212:15,17 212:20 213:10,17 214:12 219:7,18 221:12,14 224:17 232:23,25 233:5 explain 70:3 74:3 81:10,14 88:5 89:23,25 108:2 138:12 144:13 174:11 210:2 explained 82:17 115:7 193:16 200:2 213:15 explaining 69:13 78:15 88:17 94:25 explains 74:19 76:14 explanation 69:6 76:14 215:19 extent 79:24 external 60:9 144:24 145:15,19	146:9 extremely 142:23 eyeballing 72:5 f face 121:21 226:6 fact 8:17,21 81:8 82:21 97:24 122:20 127:5 145:10 174:16,21 177:5 186:2 200:9 202:15 216:9 217:4 224:24 factor 14:16 33:5 34:15 35:5 143:2 148:21 160:23 184:7 189:7,24 190:5 193:22 194:13,22 195:14 197:20,22 201:24 202:4 factors 11:22 88:17 144:7,24 145:15,19,20,20 145:21,22 146:7,9 facts 71:23 factual 9:5 fail 252:15 fair 13:3,12,14 15:5,25 19:7,16 41:18 77:14 91:25 93:6 127:17 132:2 132:7,8 144:20 159:20 178:20 179:5 180:15 182:15 223:8 fall 49:24 55:19 falls 55:16 226:7 familiar 43:24 56:4,6 65:19 68:18 79:20 104:6 104:22 124:20	133:19 148:4 201:20 205:16,22 223:21 228:9 far 19:25 36:24 49:8 149:16 159:4 fast 182:3 favor 15:13,17,22 16:5 favorable 142:17 142:18 avored 14:23 15:9 favoring 15:20 favors 15:11 fda 31:15 49:10 55:13 59:3,5,10,12 80:8 147:24 148:11,15 220:11 223:22 224:19 226:12 228:3 features 77:23 81:19 82:4 95:13 202:8,21 federal 1:13 feldman 5:10 fellowship 67:23 felt 27:7 fewer 127:2 146:19 147:3,8,19 199:8 field 28:21 fifth 2:13 figure 41:3 149:9 163:10 172:13 figures 72:5,15 172:14,21 file 237:20 239:12 filed 211:2,8,22 212:19 213:11 217:17 220:16 233:2,4 243:21	244:15 filing 213:3 235:10 filings 166:20 finally 205:19 financial 28:22,24 240:15 find 12:14 13:5 35:14,21 155:4,20 finding 17:21 93:11 fine 7:11 243:8 finish 6:23,24 first 6:6 10:6 19:20 23:16 25:11 27:13,18,25 64:18 105:24 107:17 117:24 119:4,24 120:18,23,25 121:8,10,16 124:6 126:5 129:19 137:4 141:19 144:18 149:20 150:3 156:19 158:14,24,25 159:7,9,14 160:3 161:5 173:2 191:7 194:3 205:2 217:10 219:11 220:14 235:17 238:3 240:13 245:7,20 five 9:19 flat 70:11 73:12 flawed 83:22 flaws 69:12 floor 2:13 flying 40:19 focus 90:4 123:2 focused 125:19 198:7 202:5
---	--	---	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>focuses 75:18 foley 2:19 5:19 foley.com 2:23 follow 34:9 108:24 118:7 135:23 246:2 followed 145:8 175:19 following 27:16 69:8 116:20 216:19 253:5,6 follows 6:8 footnote 40:14 138:24 161:22 242:19 forces 191:11 212:11 foregoing 249:8 250:14 forget 37:11 forgotten 37:6 form 13:18 14:3 22:3 25:20 39:7 43:20 46:2,19 47:2,15 48:16 49:5,23 50:8,16,19 51:8,23 52:16 53:14,19,25 54:3 54:10,17 55:25 56:11,17 57:12 58:15 60:5 61:2 62:2,10,22 63:8 71:25 73:21 79:5 82:8,23 83:7 84:14 85:2,11,21 87:4,11 88:13 89:12 91:23 93:15 94:13 95:14 96:3 98:10,13,24 99:11 100:12 101:13 102:23 103:6</p>	<p>106:16 107:5 109:10,22 110:18 112:2 114:9 117:10 118:5 119:6 127:20 130:12,24 132:12 132:17 133:11 134:5,23 135:12 135:20 136:2 140:21 143:15 144:10 148:19 151:5 162:24 165:9 169:9 170:5 170:20 171:19 178:24 181:18 182:5,15 189:13 193:13 201:3 202:25 206:20 208:17 210:15 211:25 214:5 215:15 217:10 218:5,23 219:13 221:21 222:9 228:23 229:5 231:2 232:12 233:8,20 234:4,13 236:17 237:4,23 238:13 239:4,16 247:4,18 forming 78:8 240:25 forms 135:8,12,17 136:13 formulary 200:23 formulation 30:25 formulations 134:15 forth 17:20 27:6 85:14 98:15 forward 88:2,4 95:5 227:11</p>	<p>found 12:20,24 13:15,16 14:21 15:7 16:3 25:7 154:5 foundational 179:20 four 9:18 18:19 22:9 64:17 66:2 124:13 204:25 freely 198:21 200:3 frequent 106:7 108:11 109:9,18 110:6 frequently 10:11 31:17 32:4 75:5 106:22 133:14 143:7 145:5 146:10 front 38:2 39:25 241:17 full 6:14 30:20 109:4 117:2 119:10 149:14 162:18 187:23 191:7 192:21 204:4 212:17 245:14 246:11 fully 166:14 functional 105:19 123:22 124:7 129:22 130:5 133:9 fundamental 191:16 192:16,23 193:4,7 247:12 fundamentally 195:6 further 228:2 240:8 244:17,19 245:25 246:3,15</p>	<p>246:16 247:25 future 142:18 186:7,13 187:2</p> <p style="text-align: center;">g</p> <p>gain 121:21 gears 204:12 general 42:15 59:19 139:6 181:20 227:9 228:18 229:19 230:8 239:2 generally 12:5 105:16 109:16 120:20 143:19 146:4 151:8 206:25 223:24 generate 164:10 generic 32:17,18 144:17,25 224:7 genericized 145:17 generics 145:4 223:25 226:16 genre 176:15 getting 207:9 give 6:21 100:22 108:23 109:4,13 153:17 238:2 given 35:16 62:14 97:15 145:2 159:15,18 171:9 178:19 186:8 199:3 200:4 211:20 213:9 234:12 238:6 250:18 giving 7:16 11:16 global 49:20 58:23 153:18 166:4,7 169:18 170:22 186:21 200:17</p>
--	--	--	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>201:6</p> <p>go 6:17 22:4 25:17 29:7 49:7 66:3 75:23 83:24 89:11 89:24 93:22 110:21 111:2 147:12,17 149:8 150:2,4 164:11 184:24 224:9 226:14</p> <p>goes 11:22 111:20 163:15 191:14</p> <p>going 22:2 61:7 67:10 96:2 101:21 104:3 126:16 128:15 155:23 161:3 182:14 210:9 243:6</p> <p>gold 179:11,14</p> <p>good 5:2,21 6:11 6:12 35:17 63:25 117:4 121:5 142:23 143:10,22 146:7 222:7</p> <p>goodrich 2:11 5:16</p> <p>government 200:10,22</p> <p>grabowski 161:7 172:13 177:14,21 178:13,16,21 179:7 187:15</p> <p>graduate 30:7</p> <p>graduated 26:12</p> <p>graduation 27:16 28:13</p> <p>granted 147:7</p> <p>granting 148:6</p> <p>graph 69:8,9,23 70:2,5,21 71:15 72:6,12 245:21</p>	<p>graphs 158:12</p> <p>greater 20:3 72:12 121:21 123:8 167:13 185:13 197:17</p> <p>gross 154:25 155:15 188:12,13</p> <p>ground 6:17</p> <p>group 114:23 115:9</p> <p>groups 115:11,12 123:15 177:24</p> <p>grow 185:9</p> <p>growing 182:3</p> <p>guess 115:13 117:4 135:15,19 178:14 186:12 224:22</p> <p>guidance 171:23 172:8,9</p> <p style="text-align:center">h</p> <p>half 8:15 32:16 74:7,11 76:17 106:9,14,20 107:23 108:3,9 109:8 110:4,6,17</p> <p>hand 65:25 103:20 251:8</p> <p>handed 23:7,13 41:25 45:5 64:17 64:23 65:11 103:14,25 161:13 190:17 204:25 231:11 243:16 244:2,8,13</p> <p>happen 144:22</p> <p>happens 145:5</p> <p>happy 79:8 82:18</p> <p>harbor 223:22 225:5 232:15 238:16</p>	<p>hard 13:7 35:21</p> <p>harder 202:2,6</p> <p>head 6:21 89:14</p> <p>header 84:2</p> <p>health 30:8 115:10 199:2 200:6</p> <p>hear 146:10</p> <p>heard 120:18,19 148:3</p> <p>heavily 187:14</p> <p>held 227:12</p> <p>help 24:22,25 134:20</p> <p>helped 24:10,14</p> <p>helpful 89:12</p> <p>herceptin 17:8</p> <p>hereto 251:4</p> <p>hereunto 251:8</p> <p>heritable 123:24</p> <p>high 18:7 47:19 142:23 160:18 194:7</p> <p>higher 75:6 159:2 199:7</p> <p>highest 176:15</p> <p>highway 2:12 60:10</p> <p>historical 163:22</p> <p>histories 41:5</p> <p>history 56:22 64:21 65:2,14,18 90:4 196:22,24</p> <p>hit 142:15</p> <p>holder 38:4 40:12</p> <p>holds 170:2</p> <p>hours 18:19 19:24 20:3,5</p> <p>housing 28:24</p> <p>huh 6:22</p> <p>hundreds 147:16 149:5</p>	<p>hydroxylase 235:20</p> <p>hypertension 31:22 36:12 57:5 68:5,14,19 73:16 75:19 76:6 79:13 79:19 80:9 94:11 96:19 101:24 105:17,20 107:2 112:25 113:6,8,21 114:6,13,14,20,21 114:23,24 115:2,5 115:5,8,9,12,15,19 115:22 116:4 118:4 119:5 120:15 122:13,19 123:10,14,25,25 124:18 126:25 127:6 128:10 129:20 130:3,11 130:21 132:17,22 134:3,4,19,22 135:18,22 137:10 139:7 147:15 149:4,15 150:14 157:23 158:5,10 159:22 177:10,15 220:5 221:16 232:20 235:18 236:3 237:13,22 238:9</p> <p>hypothetical 10:17</p> <p>hypothetically 143:10</p> <p style="text-align:center">i</p> <p>i.e. 191:10</p> <p>idea 80:22 212:10 233:19</p> <p>ideas 194:4</p>
--	--	---	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>identical 67:6 105:13,15 126:24 136:25 181:6,10 241:23 242:9 243:2</p> <p>identification 190:15 231:9 234:22 243:13,17</p> <p>identified 9:4 114:9 216:2 230:25</p> <p>identify 5:12 215:13</p> <p>identifying 95:20</p> <p>idiopathic 123:24</p> <p>ii 126:7,14 134:9</p> <p>iii 105:19 123:23 126:11,14</p> <p>illinois 1:19 2:6 3:22 250:6 251:9</p> <p>illustrates 136:11</p> <p>iloprost 75:3 78:19 106:9,24 236:10</p> <p>immediately 27:16</p> <p>impact 142:7 180:7</p> <p>impactful 123:4 133:6 187:25</p> <p>imperative 252:12</p> <p>implementing 210:5</p> <p>implication 76:22 78:15 81:15</p> <p>implications 94:25</p> <p>importance 194:19</p> <p>important 35:5 42:12,17 160:23 189:7 193:22 194:12,22 200:9</p>	<p>200:11</p> <p>improve 129:22 130:4,4 137:10</p> <p>improving 139:19</p> <p>ims 198:12 199:2 200:6</p> <p>inapplicable 175:18 177:7</p> <p>incentive 195:7 210:10 222:21,23 225:12 234:2,7,11 239:3</p> <p>incentives 93:21 148:9 191:10 193:2 219:3 221:9 222:25 238:22</p> <p>incentivized 191:11</p> <p>incidence 80:6</p> <p>incident 9:6</p> <p>include 37:22 86:4 113:8,14,23</p> <p>included 40:10 123:11,21 174:4 200:22</p> <p>includes 209:14 236:25 237:11</p> <p>including 39:11 77:24 81:20 89:17 113:7 245:4</p> <p>incorrect 71:23 76:20 83:6 91:22 97:18 98:5 109:7 109:17 110:13 128:2</p> <p>increase 124:24 142:14,21</p> <p>increased 69:24 73:7 176:22,25</p> <p>increasing 143:5</p>	<p>independent 31:20 52:5 57:20 152:11 220:2</p> <p>indicate 142:7 230:24 236:22</p> <p>indicated 22:19 44:10 111:17 130:3,18 131:21 131:24,25 137:9 149:6 163:23 173:15 179:9</p> <p>indicates 68:12 116:13 146:20 174:16</p> <p>indication 105:12 105:15 127:12 129:18 130:14 131:15 132:10 133:8 136:20 137:7 141:2 145:7 145:9 150:15</p> <p>indications 104:11 105:3,22 123:20 126:23 129:14 131:9,13,20 136:24 150:21</p> <p>indicative 143:13 199:11</p> <p>indicator 197:10 197:18</p> <p>indirectly 137:18 251:5</p> <p>individual 44:20 46:9</p> <p>individually 44:11 45:25</p> <p>industry 27:2 151:16,23 160:5</p> <p>influence 199:16</p> <p>influenced 187:14</p>	<p>inform 191:8</p> <p>information 9:6 38:16,19 80:15 89:5,9 90:4,5,9,11 91:6 92:20 93:19 93:20,21 95:5 96:10 97:11 102:18 110:21 111:20 151:14 155:3,5,9,12,17,21 157:25 159:12 160:11,15,21 175:22 184:10,11 188:15 196:5,7,11 196:18,19 197:4,6 198:10,16 200:4 201:13 216:11 240:16,19,25 246:6,7,19,20</p> <p>informative 238:21</p> <p>ingredient 220:13</p> <p>ingredients 137:21 137:21</p> <p>inhalable 31:4,9</p> <p>inhalation 56:2 61:9 62:20 78:2 83:16 85:9 106:11 107:4 229:21</p> <p>inhale 53:8 55:3</p> <p>inhaled 49:23 50:8 50:15 51:8,23 52:16 53:19,25 54:10 55:25 57:5 61:19 63:8 69:10 72:22 73:15 90:7 96:20 101:24 107:12 108:15 112:13 116:14 120:14 122:12,18 123:11 134:14</p>
--	---	--	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>228:20 inhaler 51:9 inhaling 52:24 inherently 152:6 186:7 201:25 inhibitor 137:9 235:20 initial 120:8 innovative 78:19 80:23 88:18 99:22 100:3,20 inoperable 129:21 input 95:19 inputs 131:17 insight 22:7,10 instance 8:19 9:15 instances 9:12,14 9:19 185:22 instructions 252:1 instructs 7:10 insurer 200:21 integrity 8:23 intention 177:18 interest 177:24 interested 90:6 227:4 251:4 interestingly 68:25 internal 163:8 172:18 240:15 international 170:8 interpretation 220:2 233:12 236:20 interpreted 180:13 interpreting 35:13 intership 67:22 introductions 161:16 163:12,25</p>	<p>invalid 226:3,5,9 invention 34:7 43:7,19 88:8 91:6 189:18 190:8 191:12,23 207:19 208:10 209:4,15 209:23 212:10 213:25 239:12 inventions 42:24 87:23 91:13 224:3 inventors 220:25 223:4 232:8 239:11 invested 189:21 192:2 193:10 investigate 53:12 183:4 investigation 230:12 investigator 80:5 involved 14:21 31:8 68:13 80:12 182:18 involving 68:13 ipr 1:6,7 18:24,25 23:8,14 37:12 39:4 42:2 45:6 64:18,23 65:11,15 196:5 241:2 243:21 244:15 ipr2017-01621 4:19 iprs 155:13 188:20 irvine 67:22 issue 10:14,24 13:13 34:9 40:6 41:13 44:4,23 45:19 59:9 60:21 61:22 76:25 78:20 78:23 80:24 81:7 133:2,6 165:12</p>	<p>169:19 227:16 228:17 229:2,18 241:19 issued 222:8,13 238:7 239:13 issues 9:20 10:4,5 13:11 32:4 216:22 230:6 item 88:23 89:3 114:15 iv 2:13 123:23 125:6 126:7 133:22 134:9</p> <p style="text-align: center;">j</p> <p>japan 169:8 jesse 191:22 job 30:20 july 116:25 117:4 117:6 235:11 june 24:6 25:16 39:5,20 40:21 117:5 justify 200:12</p> <p style="text-align: center;">k</p> <p>k 2:20 keep 90:12 keeping 106:4 kim 1:16 3:21 5:11 250:6 251:13 kind 23:2 32:14 51:14 60:8,9,15 66:6 155:12 175:22 197:4 kit 49:16 52:25 54:13 55:3,6,9 58:8 228:22,22 229:14,15,22 kits 47:21 230:8 kmathas 2:8</p>	<p>know 6:16 12:19 13:7,12 16:18,23 19:17 21:13 27:3 28:15 30:9 44:3 44:22 45:18 49:7 52:15 53:3 63:19 70:5,22 72:13,15 76:4 79:18,23 94:9 96:23 100:14 102:9 108:14,20 108:21 109:12 110:11 111:10 112:4 114:4 115:3 121:11 125:11 140:10 142:9 147:13 150:7,10 150:11,22 151:7 151:11 153:9 157:21 159:13 160:20 167:3,6,8 167:21,23 168:13 173:21 180:3 182:7 183:11 185:4 186:10,18 196:15 197:3 202:18 206:7,10 206:17,22 211:4 212:24 214:20 216:13,18 224:16 226:8 229:4 232:20 234:7,16 237:6 239:18 knowing 239:13 knowledge 148:11 175:17 177:18 213:7 known 56:2 114:23 218:19 knows 121:8 ks 114:10 196:23</p>
--	---	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

kurt 2:7 5:21	left 105:2 120:7 129:10	list 36:14 43:9 113:23 114:4 133:4 166:23 203:12	123:18 126:2 129:17 142:16 147:18 151:13 160:13 163:6 165:2 168:12 172:24 176:6 180:21 196:10,16 196:24 197:4 198:9,22 201:15 203:10 214:22 219:21 220:14 225:15 228:5 229:10 230:13 232:18 234:24 235:16
l	legal 32:5 43:23 165:12,13	listed 27:19 36:18 48:23 49:10 50:2 55:13 114:7 117:25 126:10 127:7 136:21 140:25 210:24 220:11 224:19 226:12 228:3	looked 79:23 111:12 112:6 152:20 168:5,8 181:22 182:12 184:10 196:17
l 1:16 3:21 250:6 251:13	length 175:11	lists 36:7 126:6 138:6 180:5,9 220:20	looking 16:14 27:11 51:5 67:17 73:5 74:25 77:4,6 104:19 105:22 113:4 132:24 158:19 172:12 194:17 215:11
label 54:23 103:16 104:20,25 120:7 123:19 127:2	lengths 142:8	literature 156:18 156:22 164:19 173:16 175:19 176:14 177:25 178:2,9,11,12 179:10	looks 72:8 133:2 201:25
labeled 205:14	letairis 158:15	litigation 223:18 224:14	lose 173:17
labor 28:25	level 47:20 137:22 229:19 230:8	litigations 171:10 171:13	lot 165:23 222:13
laboratories 1:5 5:5,23	lexicon 235:6 237:19 238:10	little 118:17	low 84:2 142:24 143:12 146:18 147:7
labs 231:21 232:8 233:25	license 206:8 207:5 227:8,10,12 250:7 251:14	llp 2:19	lower 159:3 160:6 167:8,15,18,22,23 202:10
lack 13:15 15:19 92:15 148:24 202:11 219:3	licensed 206:19 207:2,7,10 227:3 250:7	long 7:13 18:16 21:24 27:8 116:17 141:7 142:19 226:17 236:6	lunch 128:16,17
language 105:15	life 76:17 106:9,14 106:20 107:23 108:3,9 109:8 110:4,6,17 187:23	longer 106:8,21 108:8,10 110:5 162:17 214:13	lungs 107:3,12,17
lardner 2:19 5:19	lifes 74:7,11	look 35:3 40:2 66:5,18,20,25 70:9 77:8 79:17 80:2 103:9 105:23 109:25 112:10 116:3 117:15 120:6 122:4	
large 83:18 117:17 181:6	light 141:4 159:25 185:11 202:15		
largely 47:23 57:15 86:22	likewise 91:21 167:16		
largest 151:12	limit 156:13		
las 2:13	limitations 49:21 51:11 56:16,18 83:13 84:25 87:25 230:10		
late 211:6	limited 91:2 93:18 93:24 101:2 127:3 146:20 148:8 157:18 196:5 219:2		
launch 32:9,17,19 32:20,22 37:5 116:17 144:25 164:7 175:11 182:4,13 183:8,24	limiting 167:19 219:15		
launched 116:20 116:25 122:7 141:19 142:4 162:2,15 174:24 175:14 217:13	line 22:3 72:6,17 162:13 247:9 253:8		
launching 189:4			
law 32:2,4			
lawsuit 226:6			
leading 75:5 211:14 213:3,6			

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>m</p> <p>m.d. 75:18,21 76:3 79:19,22</p> <p>maebius 2:22 5:18 5:18</p> <p>magnitude 150:12 153:20 166:13</p> <p>main 10:3 91:7</p> <p>major 138:5</p> <p>majority 9:21 13:3 14:19 21:16 101:3 117:16,17 150:22 159:21,24 179:10 187:6 218:9</p> <p>making 82:11 152:15 207:17 208:9 209:3,8 210:13 216:14 221:19 226:16 230:15,22 232:11 233:18 243:8</p> <p>manifested 127:14</p> <p>manifests 137:19</p> <p>margin 160:18,22 188:12,13</p> <p>margins 155:15</p> <p>marion 191:22</p> <p>mark 243:4</p> <p>marked 4:13 23:14 42:2 45:6 103:15 161:14 190:13,18 231:7 231:12 234:20 243:11,16</p> <p>market 28:25 32:18,22 53:9 68:25 69:9,17,24 70:5,6,14,16 71:9 72:23 89:21 93:21 98:8 101:25 112:13,14,16,21</p>	<p>113:14,24 114:7,8 119:21 120:25 121:6,8,11,15,18 121:20,20,21 122:11,15,16,19 122:21,22,24 123:2,11 125:19 128:8 130:22 136:15,19 137:2 141:8 142:8,20 144:16,18 145:4,7 145:16 180:12,12 182:12 183:7,12 183:16,22,23 184:5 185:11 191:11,12 194:5,6 194:25 195:7 210:9 212:11 219:2 221:10 222:2,24 226:14 238:21</p> <p>marketing 89:19</p> <p>marketplace 210:5</p> <p>markets 28:24</p> <p>marking 93:19</p> <p>maryland 25:21 26:3</p> <p>master's 21:23 26:4</p> <p>material 191:10 192:25</p> <p>materials 242:19</p> <p>mathas 2:7 4:6,8 5:21,22 13:18 14:3 18:13,18 22:2 38:6,14,22 39:7 43:20 46:2 46:19 47:2,15 48:16 49:5 50:19 51:25 53:14 54:3</p>	<p>54:17 56:11 58:15 60:5 61:2 62:2,10 62:22 71:25 73:21 79:5 82:8,23 83:7 84:14 85:2,21 87:4,11,17 88:13 91:23 92:2 93:15 94:13,20 95:14 96:2,11 97:3,19 98:10,24 99:11 100:12 101:13 102:23 103:6 106:16 107:5 108:4 109:10,22 110:18 112:2 117:10 118:5 119:6 127:20 128:19 130:12,24 132:12 133:11 134:5,23 143:15 144:10 148:19 151:5 162:24 165:9 169:9 170:5 170:20 171:19 178:24 181:18 182:5,14 189:13 193:13 201:3 202:25 206:20 208:17 210:15 211:25 213:12 214:5 215:15 218:5,23 219:13 221:21 222:9,14 228:23 229:5 231:2 232:12 233:8,20 234:4,13 236:17 237:4,14 237:23 238:13 239:4,16,24 240:10 242:12,21 243:3,8,14 244:17</p>	<p>246:2,4,14 247:4 247:18 248:2</p> <p>mathematics 25:22 26:3</p> <p>matter 5:4 42:13 42:15 82:12 84:7 106:15 113:2,22 134:21 181:20 212:7 228:18</p> <p>matters 107:24 108:3 180:16 250:13</p> <p>mcduff 1:12 4:4 4:19 5:1,4,24 6:1 6:5,11,15 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 15:1 16:1 17:1 18:1 19:1 20:1 21:1 22:1 23:1 24:1 25:1 26:1 27:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1,23,23 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1 53:1 54:1 55:1 56:1 57:1 58:1 59:1 60:1 61:1 62:1 63:1 64:1 65:1 66:1 67:1 68:1 69:1 70:1 71:1 72:1 73:1 74:1 75:1 76:1 77:1 78:1 79:1 80:1 81:1 82:1 83:1 84:1 85:1 86:1</p>
--	---	--	--

87:1 88:1 89:1 90:1 91:1 92:1 93:1 94:1 95:1 96:1 97:1 98:1 99:1 100:1 101:1 102:1 103:1 104:1 105:1 106:1 107:1 108:1 109:1 110:1 111:1 112:1 113:1 114:1 115:1 116:1 117:1 118:1 119:1 120:1 121:1 122:1 123:1 124:1 125:1 126:1 127:1 128:1 129:1 130:1 131:1 132:1 133:1 134:1 135:1 136:1 137:1 138:1 139:1 140:1 141:1 142:1 143:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1 168:1 169:1 170:1 171:1 172:1 173:1 174:1 175:1 176:1 177:1 178:1 179:1 180:1 181:1 182:1 182:17 183:1 184:1 185:1 186:1 187:1 188:1 189:1 190:1,13,18 191:1 192:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1 201:1 202:1 203:1 204:1 205:1 206:1	207:1 208:1 209:1 210:1 211:1 212:1 213:1 214:1 215:1 216:1 217:1 218:1 219:1 220:1 221:1 222:1 223:1 224:1 225:1 226:1 227:1 228:1 229:1 230:1 231:1,7 232:1 233:1 234:1,20 235:1 236:1 237:1 238:1 239:1 240:1 240:11 241:1 242:1 243:1,11,15 243:17 244:1 245:1 246:1,5 247:1 248:1,2 249:7,16 mean 16:11 17:2 33:16 34:17 55:12 60:20 69:19 84:16 85:10 86:15 93:23 102:15 103:20 122:6,8 123:16 132:6 138:11 140:13 143:12 173:3 174:4 176:23 194:15 199:13 202:18 206:14,22 207:4 208:6 209:9,11 210:18 214:20 216:4,16 223:11 223:19 225:18 233:10 237:7 meaning 153:7 means 69:19 93:3 162:8 166:14 212:12 meant 11:15 107:23 118:12	119:13 mechanism 110:7 138:17 139:13 mechanisms 139:14,18 media 64:4,9 128:23 129:5 204:15,20 248:4 median 173:6,12 173:16,22 174:18 medical 102:22 medication 7:19 medications 112:25 113:7,20 118:9 125:13 135:3 medicine 67:21,24 118:4 meet 18:9,12,14 18:16 159:22 meets 190:8 member 20:14 memory 75:24 mention 88:11 mentioned 9:25 12:10 24:9 28:7 86:19 172:8 222:6 223:3 233:16 mentioning 99:6 merely 194:6 met 18:13,18 147:9 metered 51:8 method 55:7 59:6 59:14 61:8 220:4 227:24 229:14 236:2,9 methodological 178:7 methodologies 178:16	methodology 10:7 10:12,15,18 164:17 methods 47:23 48:13 49:16 50:17 52:25 54:13 55:9 58:9 61:9 228:19 229:20 230:8 235:14,17,19 metric 35:14 200:7 micro 28:22 micrograms 77:25 77:25 81:21,21 83:14,15 85:8,8 mid 227:10,13 million 119:25 149:11,21,21 millions 151:3 mind 16:6 17:10 27:19 30:7 33:17 41:15 50:21 59:3 67:9 90:12 144:13 182:22 minor 41:10 mischaracterizat... 192:20 misrepresents 70:4,13 misses 225:6 missing 40:3 119:8 154:10 245:21 model 176:11,16 models 10:16 money 173:17 222:7,13 morning 5:2,21 6:11,12 40:25 motivations 239:19
---	--	---	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>move 96:11 mover 120:18,23 121:17,23 moving 123:9 multiple 59:20 97:22 136:16</p>	<p>never 8:5 30:19 new 117:8 161:16 163:11,25 244:22 nexus 59:8 60:13 60:20 76:23 77:3 77:22 78:21 80:18 80:20,22 81:18 82:6,11 83:13,22 84:5,13,18 85:19 86:12 87:2,9,16,22 88:12,25 89:8 90:14,20 91:13,16 92:11,16,20,23 93:2,3,10,23 95:11 95:17 96:24 97:2 97:7,8,8,12,15 98:5,23 99:9 100:9 109:21 110:17,22,23 111:2,6,9,14,18,21 111:25 112:8 146:2,5</p>	<p>noxafil 17:8 nuance 110:12 nuances 125:14 number 4:13 12:11 16:24 27:19 27:22 32:15 53:17 74:8 87:16 88:10 99:7,8,20,25 100:10 101:11,19 111:7 128:4 147:24 148:24 150:10,18 159:5 176:21,21 178:15 198:5 205:8,20 219:22 228:7 250:8 numbering 245:6 numbers 71:8 166:8 174:22 nyha 105:19 123:22 124:7</p>	<p>112:2 117:10 118:5 119:6 127:20 130:12,24 132:12 133:11 134:5,23 143:15 144:10 148:19 151:5 162:24 165:9 169:9 170:5 170:20 171:19 178:24 181:18 182:5,14 189:13 193:13 201:3 202:25 206:20 208:17 210:15 211:25 214:5 215:15 218:5,23 219:13 221:21 222:9 228:23 229:5 231:2 232:12 233:8,20 234:4,13 236:17 237:4,23 238:13 239:4,16 243:7 247:4,18 objection 51:25 92:2 222:14 237:14 242:11,15 objectionable 96:6 objective 186:8 191:9 obligated 7:5 obtain 26:7 202:2 202:3,7 222:19 237:20 obtained 28:9 58:11 160:8 200:6 201:19 218:4 obtaining 208:15 234:11 239:2 obvious 14:23,25 191:13 212:12</p>
<p>n</p> <p>n 4:1,12 n.w. 2:20 name 5:9 6:14 16:25 20:15 narrower 126:25 127:12 near 160:3 nebulize 55:24 nebulizer 50:4 53:7 78:4 81:24 83:17 85:13 230:9 necessarily 59:8 60:12,20 115:23 201:5 208:3 209:9 222:23 necessary 54:15 167:2 168:4,23 199:2,3,22 200:6 252:4 need 7:12 75:4 79:17 120:6 136:25 186:13 236:4 needed 33:22 151:14 158:6 needs 108:11 negative 15:23 negotiate 10:17 negotiation 10:17 11:21 net 152:15 160:19 189:21 192:2 193:10 196:2</p>	<p>night 38:12,20 noah 20:16 nod 6:21 non 14:7 15:14,22 16:5 93:22 116:14 notary 249:24 note 25:23 114:11 noted 252:10 notice 164:21 231:16 noticed 26:10 40:22 245:20 noting 76:13 notion 43:24 89:23 117:13 221:7 225:6 novel 100:25 101:17</p>	<p>o</p> <p>o75 204:7 object 13:18 14:3 22:2 38:10 39:7 43:20 46:2,19 47:2,15 48:16 49:5 50:19 53:14 54:3,17 56:11 58:15 60:5 61:2 62:2,10,22 71:25 73:21 79:5 82:8 82:23 83:7 84:14 85:2,21 87:4,11 88:13 91:23 93:15 94:13 95:14 96:2 98:10,24 99:11 100:12 101:13 102:23 103:6 106:16 107:5 109:10,22 110:18</p>	

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>obviously 78:25 79:20 182:17</p> <p>obviousness 14:7 14:17 15:4,9,11,14 15:17,21,22 16:5 34:6</p> <p>occasions 32:15</p> <p>occur 108:11 186:10,10,18 221:10 238:17</p> <p>occurred 34:10 162:13 175:2,9 186:9 187:2 223:19 232:17</p> <p>occurs 10:11 110:8 143:4 171:9</p> <p>odd 122:23</p> <p>offered 185:19</p> <p>office 1:2 39:5 251:9</p> <p>okay 9:10 19:20 65:25 66:8,21 67:17 84:8 103:25 104:5 107:25 136:4 141:13 152:23 163:9 206:6 241:25 245:24 247:24</p> <p>older 162:16</p> <p>omissions 241:13 241:15</p> <p>omit 114:2</p> <p>omits 112:16 246:13</p> <p>omitted 40:25 241:18 242:5,23 244:3,9</p> <p>once 68:25 69:16 121:17</p> <p>one's 132:5</p>	<p>ones 35:14</p> <p>ongoing 176:9</p> <p>onward 219:16</p> <p>open 34:18,21 35:8,23 77:11 106:4 181:21 196:8 199:20</p> <p>opine 13:5 29:8</p> <p>opined 125:10</p> <p>opinion 13:4,9,24 14:9,25 17:12 41:19 46:12,21,24 48:3,19 49:9 50:12 51:18 52:6 52:10 54:20 55:21 57:20 58:4 63:14 63:23 75:16 76:9 76:10,12,19,22 77:6 78:11,14,23 81:11 86:9 89:2 90:17 92:19,22,24 95:24 97:14,17 98:4,5 107:8 109:6,7,14,20,25 110:11 122:20,24 127:22 131:23 135:16 139:10 149:3 152:13 153:13,23 154:20 154:24 155:14 156:5,24 157:6 160:7 169:5,19 170:23 171:16 176:13 177:22 180:18 183:6 185:19 188:11 189:3 195:9 197:15 200:18 201:6 204:6 209:20 216:25 217:2,22 218:2</p>	<p>opinions 9:21,23 12:11 28:3 41:16 47:11,18 48:8,22 56:18 74:4,13,17 74:20,22 78:8 91:12,16 92:21 95:2,17 97:25 98:8 102:12,17 109:17 122:9 168:24 169:22 195:13 199:19 203:17,25 240:24 240:25 246:8,21 247:13</p> <p>opportunity 127:4 128:9 146:19,21 147:8 148:8,16,25 165:15 194:6,19 195:2 202:12 219:2</p> <p>option 237:9</p> <p>options 113:7 125:15 136:12,13 136:17</p> <p>opto 50:4 51:12</p> <p>oral 117:9,19,20 118:23,24 119:13 136:2</p> <p>orange 36:19 48:23 49:10 55:13 220:11 224:20 226:12 228:4</p> <p>order 108:11 123:2 166:11 180:7 186:14 200:25 222:19</p> <p>orenitram 136:2</p> <p>organization 115:10</p> <p>original 206:13 235:8 244:3,10</p>	<p>252:12</p> <p>originate 118:10</p> <p>orphan 146:17,25 147:6,23 148:6,12 148:23 150:9,11 150:15,15,16,19 151:17,21 152:4,6 152:13 153:6,15 153:23 154:7</p> <p>outcome 251:5</p> <p>outside 54:11 61:21 88:7 165:13 166:10 171:16</p> <p>overall 179:22 180:11,19,25 181:15</p> <p>overlooked 196:20</p> <p>overstated 112:14</p> <p>owner 1:9 2:10 5:17,19 16:22 17:8 56:15 57:10 73:25 74:18 85:14 88:4 90:14 98:15 222:3 243:20</p>
			p
			<p>p.m. 128:23 129:3 129:3,5 204:15,18 204:18,20 240:4,4 248:4,8</p> <p>page 4:3 24:3 25:10,11 27:11,12 27:20,20 36:2 39:4,16 43:8 45:16 66:9,10,18 66:19 67:2,18 68:22 69:8 74:25 77:9,11,20 81:16 83:20,24 105:24 117:15 129:17 137:4 138:3 141:23 152:22</p>

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

156:21 158:13,13 158:23 163:7,8,8 172:16,17,18,24 191:6 193:19 194:3 220:15 235:17,25 241:18 241:19,20 243:24 244:7,24 245:6,10 249:13 253:8 pages 163:7 244:8 245:2,3,7,8 249:9 pah 36:7 53:17 79:24 90:5 101:6 114:8 115:12 116:14 126:3 128:5 134:14 138:4 141:15 147:11 151:24 152:8 153:11 218:12 228:19 229:21 paper 162:12 163:18 164:11,18 174:8,22 175:8,23 176:15,15 178:2 179:19 180:6,8 184:13 187:6,15 190:19,21,24 191:3,21 192:14 192:15 194:2,18 papers 176:7,16 179:17,21 180:7 paragraph 40:3,8 41:3 67:2,18 68:24 74:3,17,18 75:2 77:19 80:2 81:17 82:10,16 83:6 85:11 86:20 87:8 88:2,5,11 89:15,18,22,24 90:3 95:3 98:13	98:22 99:5,17,19 100:8,23 106:5,6 112:11,12 113:4 114:25 116:7 137:25 138:23 139:4 142:6 146:13 149:19 151:22,24 152:7,8 152:10 158:19 160:2 161:3 194:4 210:2,24 218:7 242:2 243:24,25 paragraphs 41:12 70:18 73:24 83:23 84:4,21 85:24 86:18,19 87:20,21 87:21 88:16 90:8 99:14,14 101:8 247:9 parenteral 118:14 park 25:21 part 20:21,23 58:11 59:21 64:20 65:13,17 71:18 83:18 92:25 97:11 130:14 161:7,8 209:15 210:12 217:24 225:15 239:20 particular 13:11 32:10 70:5 138:4 138:17 142:6 180:11 235:19 particularly 123:3 142:23 180:23 181:22 183:14 184:3 203:15 parties 10:16 227:4 240:21 250:25 251:2	parts 21:3,6 97:22 party 114:7 patent 1:2,3,9 2:10 4:16,17 5:17,19 8:6,9,14 11:6,21 12:12,15,20,25 13:9,13 14:20,23 14:25 15:6 16:2 16:20,22 17:8,13 19:5,10 23:17 27:10 28:2 29:9 30:4,12 32:2,4 36:3,18,18 37:13 37:19 38:4 39:5 40:11,16 41:6,6,14 42:6,21,22,23 43:3 43:5,19 44:4,7 45:7,15,19,23 47:21,22 48:7,9,9 48:14,14 49:3,3,17 49:17,22 50:9,9,17 50:18 51:24,24 53:2,2 54:14,15 56:15 57:10 58:13 58:13 60:2,21 64:21,25 65:14,18 71:2 73:25 74:18 78:20 82:4 84:20 85:14 88:4 89:17 89:18 90:14 93:12 93:14 98:15 125:25 129:12 146:8 164:25 165:7,24 166:2,8 169:6,17 170:18 170:19 171:18 185:20 186:4 203:5,5 204:7,7 205:3,9,15,21 206:5,8 207:5,7,13 207:15,16,19,22	207:22 208:2,3,4,5 208:7,11,13,15,16 208:20 209:2,5,13 209:15,23 210:7 210:11,13,21,21 211:2,10,12,13,15 211:17,19,21,23 212:4,5,15,19 213:3,8,8,9,17,23 214:3,4,4,12,13,14 214:18,19,23,25 215:4,7,11,14,20 216:3,6,9,14,19,20 216:24 217:3,16 218:15,15 219:6,9 219:10,17,17,19 219:22,24,25 220:4,7,10,15,20 220:24 221:3,5,7 221:11,13,15,20 222:4,8,13,20 223:5,7,14 224:6 224:13,17,19 225:7,21,21 226:2 226:8,10,12,13 227:2,3,6,8,18,18 227:19,19 228:2,3 228:3,6,11,13,19 228:21 229:11,14 231:13,14,17 232:9,10,22,25 233:4,5,17,22 234:2,11,18,25 236:14 237:20 238:4,6 239:2,10 239:11,12,14 243:20 246:8,21 patented 146:2 165:19,20,21 170:15,16 189:17 190:8 191:23
--	---	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>195:9,13 202:8,21 224:2,9 230:14 patenting 209:14 209:22 patents 10:25 11:10,12,17 12:4 13:5,15,16,21 14:2 14:7,10,13,17 26:21 27:15 29:4 29:6,11,16,18,24 29:25 30:6,10,15 34:9 41:12,13 42:13 46:11,13,18 47:14 48:5,11,22 49:10,25 51:5,7 52:7,18,20,21 54:2 55:7,11 58:6,9 59:9,14,21 60:2,13 61:22 62:15 63:12 76:25 78:23 80:24 81:7 88:4 89:7,16 89:23,25 90:19 92:16 93:20 98:19 99:23 170:2,8,10 171:6,11,12,14 176:21 177:3 184:17 204:7,8 206:25 207:12 209:21 210:22,24 211:7,16,22,23 212:25 213:10 222:17 224:23 225:7,16 226:11 227:13,16,21,23 227:24,25,25 230:3,5,13,16,20 230:25 232:21 238:11,23 239:15 path 162:18 187:22</p>	<p>pathway 140:12 pathways 138:6,6 138:10 139:7,21 139:24 140:9,18 patient 49:15 74:9 75:6 125:4,6 134:17,18 135:20 136:2,9 152:10,11 219:2 236:4 patients 68:5 69:20 80:7,13 113:5 117:8 118:2 118:9,13,17 119:3 123:22 125:11,16 126:6,11,13,18,21 127:3,7,11 130:20 133:17 134:2,14 135:3,10 136:12 136:14 139:16 146:20 147:4,8,24 148:17,24 149:4 149:15 151:4,11 152:14 153:8,11 payer 200:22 payers 200:10 paying 200:12 pde5 137:8 peak 35:16 141:8 141:15,25 142:3 142:10,15,24,25 143:12,22 144:3,6 144:18 145:9,14 158:23 161:4 184:20 185:5,9 186:3 peer 10:21 177:25 178:15 179:10 pending 7:14 77:24 81:20 84:20 people 121:11 147:13 148:2</p>	<p>149:11 178:8 199:15 230:15 percent 8:9,12,14 16:13,17 21:14 72:9,12 117:17 118:2,13,16,18,21 119:3,9,9,9,10,13 119:16 149:16 156:25 157:8 160:4,4 percentage 21:17 percentages 117:25 119:3 150:5 perform 15:12 31:12 42:14 72:7 223:10 225:8,12 performance 58:7 59:9 76:24 78:22 80:23 81:7,8 84:6 84:19 86:21 87:23 88:19 91:14,17 111:22 performed 21:14 21:15,18 32:14 34:4 71:22 101:23 123:6 158:7 167:4 203:13 225:16 247:21 performing 221:8 223:15 230:17 238:18 240:13 period 33:14,17,22 34:2,11 70:11 108:10 121:14 152:16 153:14 154:8,22 174:25 175:7 211:14 213:2,6,19 214:14 219:18 221:11</p>	<p>permitted 9:18,23 10:2,18,20 223:10 224:5 225:5 persistent 129:19 person 63:7 personal 250:17 personally 79:24 245:17 perspective 31:6,7 31:12,19,24 32:5,6 32:23 42:16,18 43:23 47:20 49:11 49:20 59:4,11 60:19 78:21 81:12 165:14,14 171:22 persuasive 180:13 pertain 19:5 pertaining 1:15 pervasive 133:2 petitioner 1:6 2:2 5:23 ph.d. 1:12 4:4,19 5:1 6:1,5 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 15:1 16:1 17:1 18:1 19:1 20:1 21:1 22:1 23:1 24:1 25:1 26:1,5,8 27:1 27:9,17 28:1,9,12 28:20,23 29:1,10 29:15,19 30:1,3 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1 53:1 54:1 55:1 56:1 57:1</p>
--	---	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

58:1 59:1 60:1 61:1 62:1 63:1 64:1 65:1 66:1 67:1 68:1 69:1 70:1 71:1 72:1 73:1 74:1 75:1 76:1 77:1 78:1 79:1 80:1 81:1 82:1 83:1 84:1 85:1 86:1 87:1 88:1 89:1 90:1 91:1 92:1 93:1 94:1 95:1 96:1 97:1 98:1 99:1 100:1 101:1 102:1 103:1 104:1 105:1 106:1 107:1 108:1 109:1 110:1 111:1 112:1 113:1 114:1 115:1 116:1 117:1 118:1 119:1 120:1 121:1 122:1 123:1 124:1 125:1 126:1 127:1 128:1 129:1 130:1 131:1 132:1 133:1 134:1 135:1 136:1 137:1 138:1 139:1 140:1 141:1 142:1 143:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1 168:1 169:1 170:1 171:1 172:1 173:1 174:1 175:1 176:1 177:1 178:1 179:1 180:1	181:1 182:1 183:1 184:1 185:1 186:1 187:1 188:1 189:1 190:1 191:1 192:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1 201:1 202:1 203:1 204:1 205:1 206:1 207:1 208:1 209:1 210:1 211:1 212:1 213:1 214:1 215:1 216:1 217:1 218:1 219:1 220:1 221:1 222:1 223:1 224:1 225:1 226:1 227:1 228:1 229:1 230:1 231:1 232:1 233:1 234:1 235:1 236:1 237:1 238:1 239:1 240:1 241:1 242:1 243:1 244:1 245:1 246:1 247:1 248:1 pharmaceutical 8:14 12:11,15,20 12:25 14:20 15:6 16:2,20 26:21,25 27:10,18,23,25 29:24,25 30:6,9,20 32:8,25 33:2,14 120:17 149:23 156:2 164:19 173:10,14,16 176:2 178:22 179:21 pharmaceutically 236:7 pharmaceuticals 27:14 29:20 138:4 143:4,19 173:7 175:13,14 235:6	237:19 238:10 pharmacies 201:19 202:16 203:11 pharmacodynamic 75:3 phosphodiesterase 137:8 physicians 69:21 135:4 pill 136:5 place 100:6 250:21 places 41:14 plagiarizing 9:4 plausible 68:8 play 8:25 please 5:12,14 6:13,23 16:7 50:22 58:18 96:12 152:18 243:4,5,24 252:3,7 plot 34:24 plus 119:9,9 point 7:13 27:4 38:5,24 40:12,15 41:10 50:13 57:20 77:5 83:11 86:16 110:10 119:8 128:15 129:19 136:11 142:6 147:22 153:11 214:24 215:8 218:7 219:23 227:11 pointing 82:3 population 149:17 152:10,11 219:3 portion 12:9 portions 21:2 position 210:20 227:17	positive 189:20 192:2 193:10 196:2 positively 122:2 possible 60:14 96:6 176:10 184:24 185:2,13 185:15,16 possibly 158:15,16 potential 84:18 237:9 potentially 9:4 152:14 212:10 practice 121:25 practicing 207:22 208:3,5 preclinical 189:12 predominantly 123:22 preferred 69:2,16 69:19,20,21,22 81:3 prejudice 38:15 premarked 23:8 premium 197:9,15 preparation 18:10 20:21 40:19 65:23 68:10 226:20,23 231:18 233:14 prepare 18:17 226:17 245:15 preparing 65:8 206:2 232:5 233:6 prescribed 130:10 130:16 131:4 132:21 150:23 199:15 prescription 198:16 200:7 prescriptions 72:17 132:23
---	--	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>198:5,23 199:10 presence 238:22 present 2:1 3:2 208:5 241:20,21 presentation 69:12 70:23 presented 15:3 21:10 70:18 71:23 98:18 presume 124:9 pretty 226:13 prevent 7:16 208:3,5 209:13,21 223:14 233:18 prevented 222:3 225:9 prevention 223:18 prevents 207:22 208:15 previous 22:8,13 27:20 37:7 52:4 82:12 84:22 90:25 92:6 100:15 114:24 141:23 154:11 158:22 163:23 192:24 250:9 price 197:17 198:3 199:7,8 prices 196:25 pricing 32:25 33:4 33:8,11 197:10,15 primarily 46:25 78:17 88:6 134:2 primary 74:16 148:6 187:13 190:23 princeton 26:5,6 principal 80:4 printing 40:6 241:19</p>	<p>prior 27:23 28:5 77:16 80:3 164:12 175:7,9 184:14 188:4 212:5,7,13 priority 34:8 227:15 231:25 privileged 96:4,10 probably 8:12 16:15 18:7 20:3 28:16 59:25 66:3 117:3 134:16 139:11 procedurally 19:18 procedure 1:14 proceeding 182:17 182:21 240:20 243:21 proceedings 182:18 250:19 process 11:24 21:5 53:8 55:3 56:2 216:13 231:17 232:5 233:6,13 processes 230:14 230:22 product 14:15 32:18,21 33:2,15 53:18 54:9 59:20 59:21 61:18 74:9 80:8 90:8 93:13 120:25 121:15 127:10 143:10 149:23 165:19,22 173:20 174:15 181:5,7 187:24 191:12 193:8 195:7,9,14,21 196:7 197:18 202:13,21 203:4 207:18 208:9,14</p>	<p>209:3,8,9 222:2 225:10 226:7,17 226:21 239:8 products 35:18 58:3 61:18 74:6 89:21 112:14,17 112:22 114:4,18 115:22 128:4 132:25 133:4 135:14 136:8,16 136:18 139:18 141:7 143:23 145:23 146:18 162:5 170:4 173:11,14,16 174:24 175:15 198:2 221:10 227:5 professional 27:2 profile 153:19 187:16 profiles 163:11,24 profit 160:8,18,22 193:21 194:5,12 194:19,21 195:2,4 196:6,18 profitability 174:14 180:19,25 181:15 182:12 profitable 173:18 174:17,19 195:10 195:14 profits 154:25 183:19 191:9 196:25 program 187:23 progresses 124:25 progressive 124:18 project 162:18 184:15 185:20</p>	<p>186:4,13 projected 162:22 164:15 184:14 186:16 187:7,12 187:20,21 188:3 projection 188:5 projections 162:21 163:20,22 164:10 175:5,6 187:14,18 187:24 prong 147:9 prongs 148:22 proprietary 197:5 prosecution 41:5 43:5 56:22 64:21 65:2,14,18 98:18 196:21,24 prostacyclin 72:23 102:5 104:12,17 105:4,8,8 235:21 236:5,10,22 prostacyclins 69:10 104:10 protected 165:5 protection 165:8 165:24 224:6 226:13 provide 11:9 13:4 17:4,12 19:11,13 29:13 35:17 38:2 43:22 44:15,19 45:16 47:18 48:4 48:21 49:19 50:12 50:14 51:14 52:5 52:9 56:16,19 57:11,23 58:4 61:19 63:2,13,22 71:5 72:18 76:11 76:19,21 79:7 83:4 84:5,10 85:19 86:12 87:2</p>
--	---	---	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

89:7 90:20 94:16 98:22 102:12,17 122:9,20 141:25 148:9 160:7 165:11 166:3,15 168:19 175:21 178:21 180:17 188:10 189:2 191:9 198:4,15 200:24 203:25 233:11 236:19 247:11 provided 8:21 9:5 12:11 13:24 27:9 28:2,5 35:15 38:4 39:13 40:11 45:24 46:21 49:9 54:20 57:4 62:21 70:22 74:13 86:8 87:19 91:15 95:23 97:25 100:16 154:24 155:14 156:20 160:11 168:2 171:23 179:7 183:6 188:15 195:8 196:19 202:16 203:16 216:25 230:5 provides 57:25 74:17 92:19,24 168:18 175:23 211:16 229:20 232:10 233:22 238:19 providing 35:19 43:15 46:6 48:18 51:17 72:22 78:24 91:12 92:20 95:2 166:7 195:12 196:6	provision 223:22 223:25 225:5 232:15 provisions 238:16 pto 171:24 172:9 public 166:20 249:24 publications 175:20,21 178:15 publicly 169:21 197:8 198:19,20 published 10:21 156:22 163:18 176:2 pulmonary 31:22 36:12 57:5 67:23 68:5,14,19 73:16 75:19 76:5 79:13 79:19 80:9 94:11 96:19 101:24 105:17,19 106:25 112:25 113:6,8,21 114:5,12,13,20,20 114:22,23 115:2,4 115:5,7,8,11,14,18 115:22 116:4 118:3 119:4 120:15 122:12,18 123:10,13,24,25 124:18 126:24 127:6 128:9 129:20 130:3,11 130:21 132:17,22 134:3,4,19,22 135:18,21 137:10 139:7 147:14 149:4,15 150:13 157:22 158:4,10 159:22 177:9,15 220:4 221:16 232:19 235:18	236:2 237:12,22 238:8 pulsed 78:3 81:23 83:17 85:12 purchase 198:18 purely 162:20 purport 43:22 63:22 215:18 236:19 purported 112:12 purportedly 209:4 purports 70:3 purpose 111:2 130:17 132:5 191:16 192:16,23 193:4,7 225:22 purposes 51:3 216:22 225:19 240:23 243:17 pursuant 1:13 pursue 210:9 pursuing 90:5,7,7 210:11 234:16 put 14:18 17:20 26:11,14 27:5 86:3 87:6 88:2,4 98:15 138:24 157:10 166:11 169:11 186:11 207:21 224:8 puts 95:5 putting 151:15,17	quantification 11:24 quantifies 10:10 quantifying 11:23 quarter 117:5 question 6:20,24 6:25 7:13 16:7 19:5 29:13 50:22 52:4 58:17 61:13 62:24 84:8 91:2 96:5 97:21 102:7 103:10 107:8 108:18,18,20 122:17 135:19,24 139:10 152:17 154:3,4,11,12 164:3 182:16,23 183:21 194:20 200:13 209:18 214:7 216:12 229:13 241:5 246:18 questioning 22:3 questions 7:6,9,17 45:14 67:12 108:21 240:8,12 241:5 244:18,21 245:25 246:15 247:25 quickly 145:8 quote 100:24 101:6 116:8 191:22 192:18 218:9,13
		q	r
		q2 116:22 qualifications 79:16 qualified 27:7 102:17 qualify 148:17,23 150:21	r 253:1,1 r&d 176:2 range 13:10 20:4,9 27:21 28:3 85:7 151:23 222:16

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

ranging 149:21 rank 180:5 rate 12:3 rationale 46:15 148:6 reach 158:6 185:9 reached 169:22 184:20 185:5,10 186:3 reaching 141:8 172:4 read 16:8 42:22 50:23 58:17,19 61:12,14 101:16 182:24 195:16,18 200:14 214:7,9 236:6 249:8 252:3 readily 166:18 reading 16:6 50:21 52:6 63:11 76:15 182:8 237:7 237:16 real 28:24 realize 40:15 realized 72:22 really 13:20 117:18 118:22 143:10,13 146:6,7 reason 7:15,15 26:13 69:3,15 71:22 75:13 82:15 94:8 96:23 97:16 109:8 143:11 144:16 176:5 186:4,6,7,12 216:12 234:6,15 252:5 253:10,12 253:14,16,18,20 reasonable 9:16 9:24 11:3,4,19 12:3	reasonably 189:20 191:25 193:9 reasoning 109:18 reasons 71:12 239:7 253:6 rebut 87:7 90:13 98:17 204:5 rebuttal 98:22 recall 9:25 11:11 21:8 27:8 30:11 30:14,18 32:12 35:19 43:15 44:5 44:24 45:20 48:18 53:18 55:2,5 56:24 57:8 59:16 68:16 75:24 76:7 79:12,15 90:25 92:18 97:5 103:8 111:15,16 116:5 124:21 129:16 134:9 138:21 147:9,10 149:8 155:11,17,22 157:25 172:11 178:4 188:19,24 191:2 195:11,12 196:12 198:11 201:17 224:18 230:17 receipt 252:14 receive 38:12 received 67:20 244:23 receiving 27:9 receptor 138:13 138:20 receptors 138:16 recess 64:6 129:2 204:17 240:3 recognition 28:17 120:24 121:5	recognize 23:18 37:14 42:3 45:8 65:4 103:18 161:18 190:21 205:5,10 recognized 182:2 recollection 20:8 24:17 73:18 102:3 149:7 217:21 record 5:3,13 6:14 16:8 38:6,9 50:23 58:19 61:14 64:5 64:10 128:24 129:6 182:24 195:18 200:14 204:16,21 214:9 240:2,6 243:5,9 248:6 250:18 recurrent 129:19 reduced 250:16 reduces 221:9 refer 67:10 103:2 reference 41:11,14 57:21 67:12 85:10 85:11 86:20 referenced 37:8 84:22 88:16 101:8 228:12 238:11 references 220:19 referred 123:16 referring 36:11 102:16 110:16,24 113:17 117:23 236:21 reflect 244:9 reflected 127:9 131:13,17 refresh 75:24 regard 81:11 91:4 regarding 80:18 80:20 91:16 92:11	92:15 97:15 98:2 98:5 109:8,18 141:25 154:25 155:15 180:18 183:7 188:11 189:3 197:16 regardless 110:7 246:11 regimen 74:2 85:12 101:2,15 registry 80:5 regular 143:6 regulation 59:4 60:10,10,11 regulations 31:15 regulatory 60:19 relate 17:7 27:13 47:21,22 74:5 95:7 105:16 126:24 203:4,5 related 8:22 10:6,7 10:8,15 11:2 17:18 28:23 29:3 29:11,25 89:19 93:8,17 101:18 114:12 146:8 182:18 210:12 232:21,22 relates 14:7,16 106:8 114:25 218:15 relating 9:16 relation 144:7 202:21 relationship 93:11 188:11 relative 11:22 56:16 57:7 89:21 106:9 151:16 250:23,25
--	--	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>released 177:12</p> <p>relevance 84:3 89:25</p> <p>relevant 33:5,13 33:17 34:2,11,15 35:11 53:10 56:8 56:13 89:24 91:12 112:16 114:18 122:25 125:18 136:25 143:2 145:19,20,23 151:10 155:25 156:6 165:7,13,25 169:7,15 170:17 171:12,17 173:9 174:7,12,19 180:23 181:14,16 181:23 183:15,24 184:3,7 187:3 189:22 192:3 193:11 197:20 199:6,11 201:10 201:13 203:15 213:24 247:7</p> <p>reliance 88:22 164:14</p> <p>relied 177:22</p> <p>rely 79:4 81:14 88:24,25 89:4,4,9 90:9,22 91:5,6,8,9 91:20 92:21 94:4 95:24 97:7,8 161:6 162:20 247:2</p> <p>relying 76:8 78:14 94:24 162:19</p> <p>remains 108:9</p> <p>remember 21:2 24:20 27:13 30:13 188:22</p>	<p>reminder 6:18</p> <p>remodulin 126:6 133:20,22 134:2 217:11</p> <p>repeat 152:17 167:10 200:13</p> <p>repeating 182:22</p> <p>rephrase 96:5 164:4</p> <p>replacement 245:16</p> <p>reply 64:24 65:16</p> <p>report 8:5 27:7 35:15 69:11 85:7 85:24 116:8 156:18,19 166:19 167:9 172:25 173:2,5 175:12 176:3 218:8</p> <p>reported 3:21 73:4 142:13 158:5 169:21 250:15</p> <p>reporter 1:17 5:11 5:14 6:18 16:9 50:24 58:20 61:15 182:25 195:19 200:15 214:10 243:15 250:4,7</p> <p>reports 8:2 114:7 174:8</p> <p>represent 76:2 181:10 243:18</p> <p>representatives 89:20</p> <p>represents 164:6 202:12 245:14</p> <p>required 48:15 49:4,8 58:10,14 59:3,5,10 60:3,8 60:18 148:18</p>	<p>requires 147:24</p> <p>requiring 59:13</p> <p>research 25:8 28:23 30:9 114:7 161:15 162:13 164:19 176:2,4 179:11 212:24 221:8,24 223:4,6 223:10,15 224:5 225:4,8,11,12 226:20,22 232:16 233:17 238:17,18</p> <p>researchers 223:2</p> <p>reserved 134:2,10 146:18</p> <p>residency 67:23</p> <p>resolve 78:12 81:12 94:22</p> <p>respect 26:20 27:15 28:8 30:5 32:25 41:16 43:6 48:9 55:6 58:2 74:13,19,22 80:17 84:13 87:24 88:11 89:6 90:13,18,24 92:22 94:10 96:19 97:6 99:9 100:9 109:20 110:16 111:18 121:4 125:15 128:11 136:8 169:5,16 170:11 178:22 210:25 213:8 215:2 245:7 246:8 246:21</p> <p>respective 41:12 241:7</p> <p>respiratory 80:6</p> <p>response 6:21 7:5 7:17 37:7 52:4 84:22 163:23</p>	<p>212:11</p> <p>responses 92:6 100:15</p> <p>responsible 217:23 218:3</p> <p>rest 74:21 132:24</p> <p>result 32:19,21 137:23 145:15 187:25</p> <p>resulted 225:10</p> <p>results 72:14 117:19 118:22 175:18 177:7 187:13,18</p> <p>retained 8:4 16:21 17:7,23 18:3 19:21 20:13 22:18</p> <p>return 189:21 192:2 193:10 196:2 252:12</p> <p>returns 161:15</p> <p>revenue 37:5 131:11 152:25 158:4</p> <p>revenues 36:7 71:5 72:17,19 141:15 183:17,18 198:8</p> <p>review 21:7 22:20 57:17 65:7,22 68:9 77:16 110:2</p> <p>reviewed 10:21 42:9,24 43:4 45:11 54:23 56:21 81:5 91:18 128:13 141:5 143:20,21 177:25 178:15 179:10 205:25</p> <p>right 19:2 28:5 36:24 44:13 47:9 57:6,12 62:9</p>
--	--	--	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

63:17 67:7 71:11 75:22 80:17 83:6 87:3,10 92:13 96:16 97:18 102:5 102:10,22 115:25 116:22 121:12 124:14 130:19 136:23 142:4 146:25 148:18 153:3 156:16 162:7 163:16,25 164:15,22 168:9 172:23 173:4 174:5,9,25 177:11 190:24 194:14 196:16 199:25 209:10 211:18 230:3 233:23 240:22 241:4 242:3,13,22 243:3 robert 6:15 roham 66:14 67:19 role 8:23,25 229:8 rosati 2:11 5:16 roughly 73:10,12 77:12 117:25 royalty 9:16,24 11:3,4,20 12:3 rules 1:14 6:18	127:14 128:5 131:11,14,16 132:3,3,16,18 137:19,24 140:4 141:9,15,25 142:3 142:10,10,15,21 142:24,24 143:2,4 143:7,12,13,21,22 144:6,8,18,25 145:3,14 146:6 149:20,23 150:8 150:11,19 151:2 151:12,15,18,18 151:23 152:3,15 153:14,21,24 154:5,8,15,18,21 156:3,18 158:23 159:11 160:19 161:4,9 162:5,18 162:22,22 163:6 163:11,22,24 164:6,11,12,15,22 165:2,12,16,23,24 165:25 166:8,10 166:12,13,16,19 166:21,23 167:4,6 167:7,8,9,12,14,15 167:19,25 169:2,6 169:7,14,15,20 170:17,25 171:16 172:5 173:6,22 174:5,22,25 175:15,22 176:7 178:22 184:5,14 184:14,16,21,24 185:5,9,20 186:3,4 186:7,14,17,17,25 187:2,3,6,7,11,11 187:16,20,22 188:4,4 191:9 194:6 199:9,12	202:2,4,7,10,23 208:21 salt 231:17 232:6 232:11 233:7,13 236:7 satisfied 216:8 saw 200:4 saying 50:6 60:24 61:5 119:20 146:11 157:17 165:25 192:11 193:18 223:13 says 25:24 55:6 67:18 68:24 77:3 80:3 81:2 104:12 105:3 117:7 118:13 120:8 123:20 129:19 137:7 146:16 163:24 164:21 232:4 235:14,17 236:2,9 244:24 scholars 191:15 192:22 science 25:25 26:2 67:20 scientific 221:8,24 223:2,4 224:5 225:4 232:16 233:16 238:17 scope 29:5 49:24 55:16,20 204:4 226:8 228:18 scot 3:3 5:9 seal 251:8 second 10:14 30:7 32:19 36:15 64:22 66:20 77:12 115:14 117:5 121:19,23 122:11 122:16,21 146:16	156:20 157:13 158:15,15 159:7 159:10,14,15,16 159:19 160:3 161:5 173:2 secondary 14:6,22 15:3,7,8,20,21 16:4 17:15,22 186:24 203:17,22 203:23 section 64:20 65:13 66:13 67:3 67:6 83:21 84:2,2 89:22 90:2,10 see 36:5,9 40:7 43:9,10 47:10 66:12,15 67:4,25 68:7 69:6 70:2 71:9 72:24 75:7 77:5 78:5 80:10 80:24 81:25 83:21 83:25 84:4 104:5 104:14 105:5,14 106:12 111:13 112:7,18 113:11 116:3,10 117:12 117:13,21 120:9 122:4 124:3 126:8 126:15 129:24 130:7 133:2 134:7 135:12 137:5,12 138:7,25 141:22 146:11,22 149:24 163:13 184:2 187:15 188:17,23 191:18 192:5 196:18 201:12 220:15,17,21 221:2 230:13,15 231:19,23 232:2 232:17 233:10
s			
safe 223:21 225:5 232:15 238:16 sale 144:3 145:9 sales 34:10,13,14 34:19,25,25 35:2,4 35:10,16,20,23 70:9 72:10 73:3,6 73:10 89:19 119:24 120:18 123:7,8 127:10,13			

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>235:5,12,22 236:12,20 237:8 237:17 244:23 seek 63:5 seeking 76:11,19 78:12 81:12 90:13 94:22 96:10 114:2 114:17 165:11 seen 37:23 40:12 56:14 57:9 111:19 115:25 131:3,4 132:20 140:7,8 178:11 180:5 185:8 227:7 231:14 235:3 238:4 segment 121:20 segments 128:10 sell 167:24 224:2 224:10,12 226:7 226:17 selling 207:17 208:9 209:3,9 226:21 seminar 8:24 sense 34:3 51:6 142:19 194:8 sensible 51:15 62:14 63:12 159:25 sent 243:19 sentence 69:7 114:12 123:20 138:2 146:16 191:7 192:21,25 194:3 209:6 separate 44:16 48:6 133:7 separately 130:2 set 51:4 52:5,9 53:4,5 55:17</p>	<p>59:17 62:13 70:12 85:13 127:11 139:14,16 145:21 145:22 177:17,19 251:8 seven 152:16 153:14,24 154:8 154:22 162:9 175:2 187:17 212:18 severe 134:21 share 69:9,24 70:7 71:10 72:9,23 89:19 98:9 112:13 119:21 121:21 180:12,12 181:9 182:12 shared 222:24 shares 194:7 sheet 252:6,7,10 252:13 shifting 204:12 short 239:22 shorthand 1:17 250:4,7 show 34:25 63:7 70:3 85:6 202:4 244:2 showing 69:9 141:15 shown 180:8 189:19 191:24 226:5,5 249:12 shows 39:3 69:23 137:23 158:23 163:10 side 16:22 66:7,7 sign 226:13 252:7 signature 24:4 39:18 253:23</p>	<p>signed 24:6 39:20 significant 181:2 183:18 significantly 176:12 180:25 signing 252:9 similar 47:23 48:10 66:2,5,23 90:9 106:22 139:14,16 143:5 155:16 168:18 169:3 209:22 similarly 40:2 145:6 simply 21:8 34:24 76:13,21 78:13 94:24 97:8 147:25 247:11 single 77:24 78:2 81:20,22 83:14,15 85:8 sir 90:16 sitting 11:13 12:18 23:25 33:25 44:5 44:24 45:20 47:10 53:21,23 59:16 62:12 75:15,24 79:11,16 96:22 97:16 103:8 107:9 108:17 109:14 110:3 134:11 138:22 149:9 157:24 178:6 184:2,12 199:18 223:20 224:22 232:17 situation 93:11 121:23 122:3 143:3,17 160:25 172:3 186:22,23 200:19 201:7</p>	<p>size 152:10,11 skimming 23:25 slight 133:14 slightly 131:14 133:8 160:6 smaebius 2:23 small 120:2 181:5 219:2 smaller 202:12 sold 165:19 181:5 181:6 199:8 219:12 sole 190:5 solely 215:23 217:3 sonsini 2:11 5:16 sooner 212:11,12 213:25 sorry 12:23 61:12 66:10 119:12,12 167:10 183:20 247:10 sort 40:6 60:19 222:20 237:25 sought 62:5,25 63:13 72:18 94:15 168:22 206:7 229:25 sounds 124:14,20 154:2,12 162:7 201:20 219:16 sources 91:8 south 2:12 space 252:5 speaking 84:18 223:24 special 177:24 specialty 201:19 202:16 203:11 specific 16:24 18:4 19:4,4 20:8 24:17</p>
--	---	---	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>29:5 31:16 44:16 56:15 57:10 59:13 60:8,9 79:16 84:12 86:16 92:19 97:5 100:19 101:10,11 108:7 113:17 114:3,12 121:13 127:17 133:3 135:20 147:23 149:9 168:3 203:14 232:19 239:18</p> <p>specifically 11:11 24:21 27:17 29:17 29:21 30:5 51:4 52:9 55:5 59:17 62:5 66:25 69:14 72:4 77:2 82:4 83:12 84:9 87:10 87:24 88:10 90:18 98:21,23 99:8,24 100:6,10,18 101:16 111:24 114:6,13 116:5 124:21 125:9 130:10 131:5 136:9,21 138:21 151:25 152:5 160:14 168:22 170:14 171:14 178:3,12 179:19 195:4 196:4 198:11 214:25 218:21</p> <p>specifics 60:11 207:8</p> <p>specified 250:22</p> <p>specify 19:4 44:6 136:21 141:19 156:8 229:22 238:7</p>	<p>speculation 52:12</p> <p>spent 19:25</p> <p>spoke 20:14</p> <p>spoken 20:11</p> <p>ss 249:3</p> <p>stable 102:5</p> <p>staff 20:15</p> <p>stage 134:4,10</p> <p>stages 123:13</p> <p>standard 179:11 179:14</p> <p>start 22:12 65:2 66:12 99:17 206:4 241:5</p> <p>started 142:11 177:12 184:19</p> <p>starting 67:2 77:9 117:16 138:3 237:20</p> <p>starts 68:23</p> <p>state 1:17 6:13 106:6 112:12 249:2 250:6 252:4</p> <p>stated 120:13 218:8</p> <p>statement 69:4 75:10 80:18,19 87:7 92:11,15 116:13,18,21 117:7 118:13 119:18,20 154:14 180:16 190:3 191:21 192:8</p> <p>states 1:2,14 75:2 77:21 81:17 138:3 165:20,22,23 220:8</p> <p>statistic 143:23</p> <p>status 147:6,23 148:7,24</p>	<p>stayed 73:10</p> <p>stenographically 250:15</p> <p>step 115:13</p> <p>stephen 2:22 5:18</p> <p>steve 222:10</p> <p>stewart 191:22</p> <p>strawn 2:4 5:22</p> <p>street 2:20</p> <p>strike 11:5 22:16 45:17,21 46:17 53:22 55:21 59:22 86:10 92:9 93:2 100:6 107:15 108:17 121:9 124:16 126:19 131:22 133:18 144:4 150:3,24 165:20 167:22 169:24 185:24 199:9 212:23 217:25 219:9 230:11 235:8,15</p> <p>strikes 29:12 75:15 107:7 228:16,25 229:17</p> <p>strong 210:3</p> <p>structure 176:17 216:3</p> <p>student 8:22 9:3 30:3</p> <p>students 29:2</p> <p>studies 123:21 177:21</p> <p>study 161:25 162:8,21</p> <p>subcutaneous 133:23</p> <p>subgroups 140:16</p> <p>subject 28:19,23 42:13 82:11 84:6</p>	<p>249:11 252:9</p> <p>submarkets 128:10 140:5,17 140:21,25</p> <p>submission 64:19 65:12</p> <p>submit 8:4</p> <p>submitted 7:25 27:6 37:21 38:11 39:5,10 48:6 212:13 241:16 242:25</p> <p>subscribed 249:20</p> <p>subsequent 10:20</p> <p>subset 114:25 115:8</p> <p>substance 82:5 86:22 117:13</p> <p>substantial 116:13 194:7 200:24</p> <p>substantive 64:19 65:12</p> <p>success 4:15 12:16 12:21,25 13:15,17 13:21,25 14:6,15 14:22 15:3,9,16,19 16:5 17:12,15,19 17:21 30:15 33:5 33:9,15,23 34:16 35:6,11 47:4 53:10 55:21 56:9 58:11,12 59:24 67:3 68:23 77:21 77:22 81:19 82:6 83:22 84:3 85:20 86:12 87:3,10 88:12 89:8 90:21 92:12,17 93:5,13 95:12 98:3 143:14 145:25 152:16 153:15,22,25</p>
---	--	--	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>154:6,9,17 156:2 157:3,9,14,18 160:24 164:25 165:6 166:2 169:6 169:17 170:18 171:6,17 172:2 174:3,12,20 180:14 181:3,8,17 183:25 184:8 185:19 186:8,24 189:8,19 190:9,20 191:8,17,24 192:13,17,23 193:4,7,23 194:13 194:23 195:10,13 195:15,23 197:11 197:16,21,25 199:17 200:8 201:10 202:20 203:18,25 217:24 218:4,21 238:21 successful 13:6,10 14:11,14 136:18 173:10,13,20 174:15 202:13 sued 222:3 suffered 38:15 sufficient 169:22 171:2 172:5 suit 88:4 99:23 184:17 230:3,5 suite 1:18 2:20 summarize 13:8 82:19 93:8 summary 10:22 35:14 41:19 52:22 85:11 89:12 90:17 98:13 100:20 143:23 154:19 230:5</p>	<p>supplement 64:24 65:16 supplier 32:17 support 15:4 17:21 25:9 63:14 70:7 116:12 204:5 supported 69:8 supporting 70:21 247:11,16 supports 140:8 suppose 110:13 201:12 245:9 supposed 110:21 sure 38:24 55:17 64:2 83:18 84:16 86:15 108:25,25 113:17 118:7 122:6 135:23 140:13 144:12 149:7 158:16 159:17 164:2 181:11 185:4 199:13 204:13 207:9,24 208:6 210:17 223:11 225:18 239:24 surgery 113:7 surgical 129:21 surprise 183:11 surprised 160:17 swear 5:14 switched 117:8 118:2 119:4,17 sworn 6:3,7 249:20 250:11 symptoms 105:19 123:23 124:8,10 124:13,16,24 125:5,7,12 126:7 126:11,14,19,21 127:8,17,19</p>	<p>128:11 129:15 133:9 134:9,20,21 136:22 139:15,17 139:19 140:25 synthetic 105:4 system 63:9</p> <hr/> <p style="text-align: center;">t</p> <hr/> <p>t 66:14 67:19 253:1 take 6:22 7:12,14 29:24 63:7 66:20 128:20 135:25 136:6 204:12 239:22 taken 1:13,16 133:22 232:18 250:21 takes 74:9 136:2 152:9 222:7,12 226:23 talk 20:17 22:15 22:17 99:20 100:19 talked 110:22 174:21 talking 11:16 67:13 99:21 103:23 122:18 129:11 131:19 194:18 211:18 213:20 target 138:5 targets 138:16 task 6:19 technical 31:11 42:20 47:17,18 50:11 63:16,23 77:23 81:19 89:7 90:18,20,24 91:2,4 91:8 92:25 93:4 93:12,18,22,24</p>	<p>94:3 95:12,20 96:18 97:16 102:11,18,20 103:3 106:19 108:7,18,19,22 115:3 139:11 216:22 227:20 228:16,25 229:17 230:6 233:11 236:20 technologies 208:23 209:25 technology 10:8 11:13 14:16 31:8 31:10 50:8 55:10 94:6 208:16 209:22 210:4,7,8 210:12 229:23 234:3 tell 7:5 120:21 241:14 tells 128:8 ten 18:6 tend 143:4 144:22 173:16,17 174:13 tendered 23:5,11 41:23 45:3 64:15 103:12 161:11 204:23 tends 174:18 term 56:5,6 102:19 120:19,24 146:11 terminology 102:11 terms 31:16 39:10 56:9 61:17 71:23 76:17 87:15 95:20 102:11 120:17 123:7 126:18 135:9 137:16</p>
---	--	---	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>139:24 150:8 167:4 174:14 186:23 203:19 223:9 testified 6:7 27:14 testify 18:22 38:24 250:12 testifying 17:17 28:4 testimony 7:20 8:21 9:10,17,19 10:2 11:9,16 12:7 17:18 24:13 27:10 54:6 111:17 241:13 249:9 250:18 testing 148:18 teva 27:20 texas 2:12,14 text 37:9 thank 64:13 129:9 246:14 248:2 theoretical 143:17 therapeutically 236:4 therapeutics 1:8 5:6,17,20 80:4,8 170:2 182:2,13 183:7,12 184:4 188:12 206:9 230:21 240:15 therapies 80:9 101:25 108:15 116:15 117:9,20 118:14,24 119:14 120:14 126:3 therapy 117:18 118:18,22 121:25 135:20,22 237:3 thereof 236:4,7</p>	<p>thing 59:4 121:6 192:12 things 42:17 81:9 124:5 131:22 156:9 think 13:20 14:13 15:10,18,19,24 17:2,14 31:2 33:25 34:12 39:11 46:7 49:18 51:5 51:15 52:6 70:4 70:13 89:13 101:18 122:24 123:15 128:3 129:10 136:10 140:18 142:25 150:14 156:4,5 159:25 160:5 166:3,14 168:4,25 169:18,19 170:24 171:8 175:10 177:11 180:15,16 180:22 181:2,7,13 181:16 182:15 184:6,15 185:12 186:13,22,23 187:2 188:14 189:24 192:10,12 192:19 193:3,6,17 194:10,24 195:21 196:20 197:17,19 200:17 202:11 203:13 206:23 208:19 209:16 218:8,25 245:13 thinking 4:14 37:9 142:19 174:14 176:17 190:19 194:25 195:6 213:24</p>	<p>third 114:7 156:16 186:12 205:13 thirty 252:13 thought 109:13 212:23 238:3 thousands 59:25 147:17 149:5 three 17:11 18:19 22:9 131:21,24,25 132:25 138:5,6 139:6,23 190:25 thromboembolic 129:20 130:11,21 132:22 tie 81:6 time 5:7 7:13 8:11 13:4 20:12 27:2,7 27:24 28:9,13 30:20 33:13,17,22 34:2,7,11,11,13,15 34:25 35:2,20 63:25 64:3,8 66:3 69:25 70:10 73:9 108:10 111:5,10 121:14 123:6 128:22 129:4 142:9 147:22 153:12 164:11 175:7,11,16,19 176:12 177:12 182:3 183:17 204:14,19 211:14 213:4,19 219:11 219:18 221:11 226:9 227:9 238:3 239:25 240:5 248:3 250:21 timeframe 162:18 times 7:23 8:3 12:19 18:5,6 32:16 74:9 99:6</p>	<p>timing 145:11 tire 60:15 tissue 124:2 title 231:16 233:11 233:13 titled 4:14 today 7:13,17,20 18:10 33:25 38:25 53:21,23 79:11 96:22 97:17 112:6 153:10 176:4 243:22 today's 5:6 told 95:24 96:3,8 top 89:14 104:12 105:2 150:4,8,16 150:23 151:2 155:23,24 156:8 156:11,14,25 157:7,18,21 158:6 158:11 159:23 163:10 167:17 180:8 187:5 191:7 topic 177:25 179:12,18 topics 10:22 total 20:6 35:4,10 35:19,23 36:25 37:4 117:24 132:3 152:14 158:3 202:23 245:8 totaled 152:25 tracked 180:7 tracker 10:8 tracleer 158:14 159:4,6,11,13 tract 80:6 trademark 1:2 transcript 249:11 250:15 252:14,15</p>
---	---	---	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>transportation 60:11 treat 94:11 105:18 112:25 113:20 115:22 127:17,18 129:15 131:21,24 131:25 132:10,17 133:10 136:22 139:7,14 157:22 158:4,10 177:15 237:21 treated 68:5 80:7 80:13 125:5,12 150:16 treating 68:19 101:6 128:9 139:19 218:12 220:4 221:15 228:19 229:21 232:19 235:15,17 236:2 treatment 31:22 75:19 105:16 106:7 108:12 109:9,19 113:6 121:13 122:12 125:15 129:21 135:18 137:9 138:3 147:11 227:24 237:12 238:8 treatments 57:5 73:15 76:5 90:5 113:8,24 115:18 122:19 152:8 177:9 treats 79:19,24 trends 177:4 178:22 treprostinil 49:23 50:7,15 51:7,22</p>	<p>52:16,24 53:8,19 53:25 54:9 55:4 55:24 56:10 57:16 61:9,20 62:19 63:8,20 75:4 78:2 78:18 81:22 83:15 86:23 90:8 101:4 106:25 136:3 170:4 215:4,9,13 215:21 216:3,7,8 216:14,20,24 217:3,5,11,18 218:3,11,18 219:8 219:11,23 220:5,7 220:9,12 221:15 221:19 223:6,16 224:25 225:2 227:5 228:14,20 229:15 230:14,15 230:22,23 231:17 232:6,11,22 233:7 233:13 236:11,15 237:2,8,12,21 238:8 treprostinil's 106:8 trial 1:3 trials 68:13 148:2 224:9 tries 226:7,14 trigger 51:13,14 51:15 triggers 50:5 truc 16:15 25:14 37:17 47:12 61:22 61:25 62:9,14 68:8,15 102:3,6 119:23 120:3 121:22 125:8 133:5 143:18,19 143:20 151:8</p>	<p>153:9 180:2 188:14 217:21 249:10 250:17 truth 7:5 250:12 try 35:13 71:14 79:8 82:18 89:11 155:4 trying 11:14 33:17 79:3 103:2 107:21 135:15 tryptophan 235:20 turn 24:3 25:10 36:2 37:12 39:16 43:8 45:15 66:9 66:10 70:25 77:9 77:19 83:19 106:5 125:24 137:3,25 141:11 146:13 149:19 152:21 191:6 235:24 243:23 244:6 turning 23:16 68:22 116:7 tutor 9:3 two 10:3 13:25 14:7 17:15 18:22 19:10,21,25 25:20 32:16 41:8,11 47:14 48:4,11,22 52:17 58:2 65:3 65:10,20,22 66:3 67:7 72:10 73:15 74:6 78:13 101:24 103:25 105:14 110:4 112:5,13 120:14 132:25 136:7 148:22 150:5,23 151:2 155:23,24 156:8 156:11,14 157:7</p>	<p>157:18 159:23 160:2 187:5 type 10:8 32:19 55:25 59:13 121:24 137:16 168:16 198:17 types 32:16 115:14 115:18 126:18,21 135:3 224:4 typewriting 250:16 typical 21:4 143:3 typically 14:24 21:2 34:22 35:13 102:21 123:16 146:12 151:2 155:12 160:16 166:20 168:16 188:20 196:13 197:5 198:15 226:23 typo 25:23 tyvaso 15:16 36:14 37:3 41:17 46:16 46:17,25 47:5,8 48:15,22,24 49:4 49:12,15 53:17 54:11,15,24 55:10 55:14,15,16 57:4 57:15 58:7,10,11 61:7,10,19,20 62:21 63:9 67:3 68:18,24,25 69:15 69:24 70:6,12 71:6 72:10,11,13 73:6,14,20 74:14 74:23 75:4 77:23 78:17,22 79:21 80:8,13 81:2,19 82:6 84:6,19 86:13 87:24 88:19</p>
---	---	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

89:17,20 92:12,17 94:11 95:6,12 97:10 100:11 101:4,22,23 102:4 103:16 104:10,12 104:16 105:7,11 105:25 106:8,10 109:19 110:6 111:21 112:21 113:15 115:23 116:14,18,20,24 117:8 118:2,3,9,14 119:3,5,17,21 120:10 122:8,11 122:16,20 123:2,5 126:10,25 130:16 130:22 131:4,10 132:10,18,21 134:20 135:17 136:6 137:16 139:25 140:11 142:9,18 146:24 147:9 151:15,21 152:3,24 153:2,6 153:20 154:5,15 154:25 155:15 160:8,19 161:5,9 166:12,13 167:4 169:20 170:3,12 170:15,16,25 173:6,22 174:16 180:24 182:19 184:5,15 186:3 187:5 188:8 189:4 189:12 196:2,7 197:2,14 198:23 199:16 200:11 201:16,18,22 203:12 215:2 217:25 218:4,10 220:11 224:20	228:4 tyvaso's 91:14 146:17 149:20 180:18 181:14 182:4,13 183:8,17 183:23 188:12 197:16 199:7 u u.s. 4:16,17 42:6 45:7 69:10 72:22 120:8 146:19 147:4,14 149:11 149:16 153:11 164:25 165:2,13 166:8,11,16,21,23 167:4,6,12,15,19 167:24 168:5,8,12 168:17 169:2,6,7 169:15,17 170:16 170:18 171:10,11 171:14,16,18,23 172:9 205:3,9,15 205:21 228:6 229:11 231:13 234:25 ucb 27:20 uh 6:22 ultrasonic 78:4 81:23 83:17 85:12 unavailable 227:11,12 underlying 40:13 70:21 242:18 247:12,21 underrepresentat... 112:15 understand 7:2,4 7:8 11:14 18:21 19:5 23:17 37:20 38:3 42:12,18 43:3,18 49:9,11,20	51:9 55:12 62:24 67:11,15 70:15 71:20 73:25 79:3 85:14 100:4 106:6 107:11,22,22 110:20 133:25 135:16 138:9 146:24 164:2 166:13 171:22 181:11 216:24 222:16 228:18 understanding 33:21 40:5,9 42:20 47:19 48:25 50:10 51:18 52:8 52:19 55:8,14 62:15 63:11 68:21 75:20 84:17 86:7 88:5 91:5 94:6 106:20 107:20 108:8,16,23,24 109:2 110:25 115:6 120:16,22 124:7,15,17,23 132:14 135:5 138:15 139:12,20 162:17 196:13 215:3,20 216:10 216:23 217:7 218:14,18 220:3,6 221:17 223:17 226:19 229:20 233:3 237:6 unique 144:8 united 1:2,8,14 5:5 5:17,20 80:4,7 165:20,22,23 169:25 181:25 182:13 183:7,12 184:4 188:12 206:8 230:21	240:15 units 72:16 199:8 universities 29:2 university 25:21 26:3,5,6 67:21 unprofitable 195:22 upcoming 20:20 updated 40:10 upjohn 206:12 upper 120:7 usage 104:11 105:3 123:20 use 38:8,10 48:15 49:4,15 52:24 54:15 55:10 58:10 62:20 68:18 79:20 94:10 97:11 102:5 110:23 116:4 134:14,20 135:20 135:21 162:14 207:18 208:10 209:4 219:7 221:15 224:2,8 228:22 230:22 236:15 237:2,11 238:7 239:11,13 useful 127:2 user 200:25 uses 111:6 126:18 162:4 174:22 208:16 209:22 210:12 utc 114:9 142:13 160:8,12,17 169:23 181:13,16 188:16 196:6,19 197:5 227:9,12 utc's 90:4 116:8 180:19,25 183:18 183:23
---	--	---	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

utilizing 210:5	versus 5:5 27:20 41:6 43:17 46:7 181:6	51:16 52:14,17 53:24 54:20 62:6 63:2 86:3 87:6 92:5 93:8 96:5 102:25 106:10 107:16 128:3 134:13 146:12 151:21 153:18 157:5,10 163:4 166:10 169:11 175:18 176:17 177:6 188:24 194:4 206:10 207:21 226:6 227:9 232:10 237:21 245:13 246:11	wish 253:5 witness 1:12 4:3 5:14,24 6:2,6 7:23 8:18,22 13:19 14:4 16:10 22:5 23:5,11 39:8 41:23 43:21 45:3 46:3,20 47:3,16 48:17 49:6 50:20 51:2 52:2 53:15 54:4,18 56:12 58:16,21 60:6 61:3,16 62:3,11,23 63:24 64:15 72:2 73:22 79:6 82:9 82:24 83:8 84:15 85:3,22 87:12,18 88:14 92:3 93:16 94:14,21 95:15 97:4,20 98:11 99:2,12 100:13 101:14 102:24 103:7,12 106:17 107:6 108:5 109:11,23 110:19 112:3 117:11 118:6 119:7 127:21 128:14 130:13 131:2 132:13 133:12 134:6,24 143:16 144:11 148:20 151:6 161:11 163:2 165:10 169:10 170:6,21 171:20 179:2 181:19 182:6 183:2 189:14 193:14 195:20 200:16 201:4 203:2 204:11,23
v	viable 60:16 video 5:3 videographer 3:3 5:2,10 6:4 64:3,8 128:22 129:4 204:14,19 239:25 240:5 248:3 videotaped 1:11 view 14:24 71:13 95:2 122:14 123:3 133:5 140:6 141:3 166:25 168:4,23 173:9,25 180:23 181:22 185:17 198:25 199:22 200:5 203:14 viewed 10:11 48:10 174:6 vs 1:7	ways 49:22 139:8 181:10 weighing 14:25 weighs 195:22 weight 186:11,17 welcome 38:7,22 64:12 129:8 240:7 wellcome 221:4,14 221:25 223:15 went 184:5,6 west 1:18 2:5 wheel 60:8 wheels 60:3,25 whereof 251:7 wide 238:21 widely 164:18 175:25 177:25 179:20 wider 127:7,11 wildly 143:7 wilson 2:11 5:16 winston 2:4 5:22 winston.com 2:8	
valid 30:12 225:17 225:21 validity 176:5 192:11 193:17 valuable 182:2 valuation 84:5 value 10:25 11:16 values 11:9 varies 8:11 variety 9:20 127:7 various 125:16 144:7 150:20 203:3 vary 143:7 varying 135:2 vasodilator 104:13 vast 101:3 159:20 218:9 vehicle 10:8 venativs 57:7,15 69:2,16,25 70:7,9 71:6 72:11 73:10 73:15,20 74:14 75:5 78:17 81:3 89:20 95:6 97:11 101:22,23 102:4 104:20,25 105:3,7 105:11,25 106:10 112:22 118:18 119:13,17,22,24 120:4,7 122:7 123:3,6,18 ventavis 104:10 verbal 6:21 version 37:21,22 38:4 39:23 40:10 241:17 243:19 versions 77:11	w wacker 1:18 2:5 wade 215:18 230:6 waded 216:21 wait 6:23,24 want 6:17 224:12 230:6 238:2 wanted 51:13 65:25 71:14 227:4 239:11 wanting 148:8 wants 208:13 washington 2:21 watson 1:5 5:5,23 17:24 18:3 22:18 206:7,15 way 13:8,13,22 14:13,18 15:10,18 35:17 46:5 48:19		

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>206:21 208:18 210:16 212:2 213:13 214:6,11 215:16 218:6,24 219:14 221:22 222:15 228:24 229:6 231:3 232:13 233:9,21 234:5,14 236:18 237:5,15,24 238:14 239:5,17 242:16 247:5,19 249:7 250:11,11 251:7 252:1 253:23 wondering 216:7 word 6:23 110:23 111:6 112:8 236:6 words 6:19 74:8 127:2 167:12 184:20 192:9,10 192:15,25 202:13 work 20:22 21:4 22:12 24:19 30:2 31:12,18 63:20 136:5,7 139:21 171:9,25 240:19 worked 7:23 17:7 21:24 22:6,8 27:22 30:19 59:7 171:10 214:19 225:22 working 20:15 21:5,18 34:24 works 19:17 145:13 216:15,17 world 73:3 115:9 115:10 179:3 worldwide 163:11 164:22 165:16 166:19 167:7,13</p>	<p>167:25 168:17 169:21 171:12 172:4 worsening 130:6 write 20:23 24:10 24:14 218:9 writing 76:17 191:2 written 192:20 wrong 80:19 84:11 116:25 212:16 wsgr.com 2:16</p>	<p style="text-align: center;">z</p> <p>zamanian 56:25 66:14 67:19 68:18 71:10 75:18 76:12 76:16 77:2,6 78:11,25 79:4,18 80:19,25 81:13 84:11,17 85:16 87:8 90:15 91:15 91:22 92:9,10 94:12,19 95:5 96:25 98:18 101:10,22 110:9 110:16,21 zamanian's 70:19 74:22 76:9 97:14 98:4 110:2 ziarko 3:3 5:9</p>
	x	
	x 4:1,12	
	y	
	<p>yeah 103:23 104:3 128:20 year 22:7,10 26:7 26:11,14 30:7 34:20,25 35:17 36:8 38:11 71:5 116:20 117:2,3,6 117:24 119:4,24 142:2,3,23,24 143:5,5,8,11,13 144:17,19 145:2,9 152:16 153:14 154:8,22 224:18 year's 144:8 years 22:9 141:15 143:22 153:5,24 162:9,10 163:15 163:19,21 175:2 176:11 184:15 187:17,19 211:21 212:18 213:10 217:17 226:23 yesterday 40:18 40:25 244:23 245:21</p>	

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

Federal Rules of Civil Procedure

Rule 30

(e) Review By the Witness; Changes.

(1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:

(A) to review the transcript or recording; and
(B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.

(2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY. THE ABOVE RULES ARE CURRENT AS OF SEPTEMBER 1, 2016. PLEASE REFER TO THE APPLICABLE FEDERAL RULES OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS
COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.